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Chapter 1.  General introduction 
The research results reported in this thesis involved a study of porcine circoviruses (PCV) that 
have been recently associated with a newly described syndrome in pigs designated 
postweaning multisystemic wasting syndrome (PMWS) in North America, Europe and Asia, but 
not reported in Australia.  A review of the literature on circoviruses and their association with 
disease is provided in Chapter 2, as a basis for the studies that were undertaken and reported in 
the remainder of the thesis.    
PMWS has not been reported in Australia, and there have been no published reports of the 
occurrence of PCV in the Australian pig herd.  The first objective of this project therefore 
involved the development of techniques that could be used to detect porcine circovirus types 1 
and 2 (PCV1 and PCV2) in fresh and formaldehyde-fixed tissues from normal pigs and pigs with 
clinical signs or lesions suspicious of PMWS, and then application of these techniques to the 
detection of PCV in Australia and subsequent determination of the characteristics of the strains 
present.  The development of a polymerase chain reaction (PCR) for the detection of PCV1 and 
PCV2 DNA and the application of this assay to the detection of PCV in pig tissues from 
throughout Australia is reported in Chapter 3.  An immunofluorescence assay with the 
persistently-infected pig kidney (PK15) cell line was used to detect PCV antibody and then used 
to determine the prevalence of PCV antibody in pigs in the Western Australian pig herd, and in 
one herd with a high prevalence rate it was also used to determine when infection occurred.  
These results are also reported in Chapter 3.   
Genetic characterisation of PCV1 and PCV2 detected in pig tissues is also reported in 
Chapter 3.  
The immunofluorescence assay described in Chapter 3 was unable to differentiate antibody to 
PCV1 and PCV2 so a recombinant protein antigen was prepared by cloning the capsid-encoding 
gene of an Australian strain of PCV2 into a baculovirus vector and subsequent expression of the 
capsid protein in insect cells.  The expressed protein was purified and used to develop PCV2-
specific ELISA and Western immunoblotting procedures, which were then used to determine the 
prevalence of antibody-positive PCV2 pigs in the Australian pig herd.  The development of the 
recombinant protein antigen, the development of the serological assays and the results of the 
serological survey using this assay are reported in Chapter 4. 
Two animal experiments were conducted and are reported in Chapter 5.  In one, the known non-
pathogenic PCV1 present in persistently-infected PK15 cells was inoculated into pigs to provide 
data on the optimum tissues to use for the detection of PCV in pigs by PCR, tissues to use in an 
attempt to provide PCV-positive tissues for the development of in situ hybridisation (ISH)   9 
techniques, and a source of known PCV1-specific antibody.  In a second experiment, an attempt 
was made to infect weaner pigs with an Australian strain of PCV2 to determine its pathogenicity. 
A general discussion of the results is provided in Chapter 6.  In this discussion, particular 
emphasis was given to why, when the results indicated the widespread occurrence of PCV in 
the Australian pig herd, and when the viruses detected appeared genetically indistinguishable 
from isolates associated with PMWS, PMWS has not occurred in Australia. 
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Chapter 2.  Review of the literature 
 
In this Chapter, a review of literature relevant to the research project is presented.  The 
review encompasses background information on the taxonomy, structure and genomic 
composition of the Circoviridae and related virus families with emphasis on the circoviruses, 
in particular porcine circoviruses.   
The review contains five sections.  The first section provides an introduction and outlines the 
history of the family Circoviridae and other related virus families.  The remaining sections 
examine the physico-chemical characteristics and comparative genetics of members within 
the  Circoviridae, aspects of circovirus diseases and the current taxonomic standing of 
circoviruses. 
The nomenclature used in this thesis to name viruses follows that proposed by Pringle 
(1999b).  The naming of genes follows a convention where genes and open reading frames 
(ORFs) are written in lowercase italics and gene products (mRNA and protein) are non-
italicised and have the first letter in uppercase. 
Introduction and history 
Circoviridae 
The  Circoviridae are single stranded (ss) DNA viruses, with covalently closed, circular 
genomes (Todd et al., 1991) that have come under intense scrutiny in the past decade.   
There are two genera within the Circoviridae; Circovirus and Gyrovirus (Pringle, 1999a).  The 
only member of the genus Gyrovirus is chicken anaemia virus (CAV).  The genus Circovirus 
contains three members, beak and feather disease virus (BFDV), porcine circovirus type 2 
(PCV2) and the type species porcine circovirus type 1 (PCV1) (Pringle, 1999a).  Other novel 
circoviruses have been detected in geese (Todd et al., 2001b), pigeons (Mankertz et al., 
2000b; Smyth et al., 2001; Todd et al., 2001b) and canaries (Phenix et al., 2001).  These 
viruses are at present unassigned, but based on their similarities to BFDV and PCV, it has 
been proposed that they be assigned to the Circovirus genus (Todd et al., 2001b). 
Animal circoviruses were first encountered in 1974 as contaminants in the continuous pig 
kidney cell line, PK15 (ATCC-CCL 33) (Tischer, Rasch, and Tochtermann, 1974).  Initially 
they were described as picornavirus-like particles (Tischer, Rasch, and Tochtermann, 1974), 
however, characterisation of the nucleic acid using sedimentation analysis, nuclease 
sensitivity and electron microscopy demonstrated that they contained covalently closed, 
circular, ss DNA, measuring 1.76 kb in size (Tischer et al., 1982).  The name porcine 
circovirus (PCV) was proposed in recognition that this was the first animal virus shown to 
possess a circular ss DNA genome, and this name was adopted by the International 
Committee for the Taxonomy of Viruses (ICTV), when the Circoviridae were described as a 
separate virus family (Lukert et al., 1995).  BFDV and CAV were also classified as   11
circoviruses when biochemical characterisations revealed that these viruses also possessed 
circular ss DNA genomes contained within small, non-enveloped icosahedral capsids 
(Gelderblom et al., 1989; Ritchie et al., 1989; Todd et al., 1990).  In the 7
th report of the ICTV 
(Todd et al., 2000), a fourth circovirus, pigeon circovirus (PiCV), was added as a tentative 
member of the family on the basis of its particle size, pathological characteristics, and low-
level DNA homology with BFDV (Woods et al., 1994).   
The majority of circoviruses are associated with potentially fatal disease in their respective 
hosts, and in the cases of CAV and PCV, with diseases that are of economic importance.  
Psittacine beak and feather disease (PBFD) was first described in Australia in the 1970s 
(Pass and Perry, 1984).  PBFD manifests as a chronic disease associated with feathering 
dystrophy and loss, beak deformities and eventual death in various species of cockatoos and 
parrots (Pass and Perry, 1984).  
Infectious chicken anaemia was first described by Yuasa, Taniguchi and Yoshida (1979) as a 
disease associated with increased mortality in very young chickens, characterised by 
anaemia, lymphoid depletion, and haemorrhages.  The causal agent, originally known as 
chicken anaemia agent, was shown by filtration experiments to be a virus (Yuasa, Taniguchi, 
and Yoshida, 1979).   
The PCV derived from contaminated PK15 cells was shown to be non-pathogenic in pigs 
following experimental infection (Tischer et al., 1986; Allan et al., 1995; Krakowka et al., 
2000). However, investigations of a disease of young pigs known as post-weaning 
multisystemic wasting syndrome (PMWS), which was first recognised in 1991 (Clark, 1997), 
demonstrated the involvement of a new PCV, which was shown to differ from the PK15 
contaminant virus in several important aspects.  Since the two types of PCV were clearly 
different in terms of antigenicity and DNA sequence, the PK15 contaminant was designated 
PCV1, and the virus isolated from pigs with PMWS, PCV2 (Allan et al., 1998a; Allan et al., 
1998b; Ellis et al., 1998; Meehan et al., 1998).   
Comparison between BFDV, PCV and CAV has revealed no common antigenic determinants 
(Todd et al., 2000; Todd et al., 1991).  These viruses appear to be specific for species of 
origin but modes of transmission and possible vectors are not known.  These viruses have a 
worldwide distribution.  The species demarcation criteria are (1) differences in nucleotide and 
gene product sequences, (2) differences in host range, and (3) differences in viral antigens.  
The three species in the two genera have different host ranges.  In addition, they lack 
antigenic cross-reactivity as determined by indirect immunofluorescence (IIF) using antisera 
raised to purified virus and they lack nucleotide sequence similarity as determined by 
hybridisation techniques (Todd et al., 2000).  A low level of cross-hybridisation has been 
observed between BFDV and pigeon circovirus (Todd et al., 2000).     12
Geminiviridae 
A family of ss DNA viruses with many characteristics similar to the circoviruses, particularly 
the mode of replication, is the Geminiviridae.  Geminiviruses are a large and diverse family of 
plant viruses with ss DNA and predominantly multipartite genomes that replicate via double 
stranded (ds) DNA intermediates in the nuclei of infected plant cells (Fontes et al., 1994a; 
Orozco and Hanley-Bowdoin, 1996).  The name geminivirus is derived from the occurrence of 
the small quasi-isometric particles, approximately 18 x 30 nm, that are found predominantly in 
pairs, or twins (Rybicki et al., 2000; Stanley, 1985).   
The genome organisation and biological properties of geminiviruses allow them to be divided 
into four genera.  Those that have a monopartite genome and are transmitted by leafhopper 
insect vectors to monocotyledonous plants are members of the genus Mastrevirus, of which 
maize streak virus (MSV) is the type species.  The genus Curtovirus comprises viruses that 
have a monopartite genome and are transmitted by leafhoppers to dicotyledonous plants; 
beet curly top virus (BCTV) is the type species.  The genus Topocuvirus has only the type 
species as its member; tomato pseudo-curly top virus (TPCTV), which has a monopartite 
genome and is transmitted by tree hoppers to dicotyledonous plants.  The fourth genus, 
Begomovirus, includes viruses that are transmitted by whiteflies to dicotyledonous plants; 
bean golden yellow mosaic virus (BGMV) is the type species (Fauquet et al., 2000).  These 
viruses have bipartite genomes (A and B components), with some exceptions such as tomato 
yellow leaf curl virus, cotton leaf curl virus and tomato leaf curl virus, for which no B 
components have been found (Fauquet et al., 2000). 
Geminivirus genome segments are small, replicate to high copy number and contain a well-
defined origin of replication.  Replication is dependent on only a few viral proteins as they 
recruit the remainder of the replication machinery from the host plant (Settlage, Miller, and 
Hanley-Bowdoin, 1996) and is thought to occur through ds DNA intermediates via a rolling-
circle mechanism (Gladfelter et al., 1997).  As the replication strategy employed by the 
geminiviruses is similar to that of the Circoviridae and Nanoviridae, it has been suggested that 
geminiviruses would therefore be excellent model systems to investigate both DNA replication 
and transcription in circoviruses, due to the fact that their replication and transcription is 
dependent on host factors to mediate these processes (Fontes et al., 1994b).   
Nanoviridae 
Members of the family Nanoviridae were formerly classified as unassigned members of the 
Circoviridae and considered ‘plant circoviruses’ (Fauquet and Mayo, 2001).  The Nanoviridae 
include plant non-enveloped viruses with a genome consisting of multiple circular ss DNA 
molecules, each of approximately 1 kb size and encapsidated in an icosahedral virion, 17-20 
nm in diameter.  Six to ten DNA components, each of which appears to be encapsidated in a 
separate particle, have been isolated from virion preparations of different species and their 
isolates.  The number and type of ss DNA components constituting the integral genome parts 
have not been determined for any of the nanoviruses.     13
The ICTV has deemed that the family Nanoviridae contain two genera (Mayo, 2002).  The first 
of these is the genus Nanovirus with the type species subterranean clover stunt virus (SCSV), 
and the second genus is Babuvirus, with type species banana bunchy top virus (BBTV).   
Nanovirus DNA is structurally similar to that of the geminiviruses and at least one of the DNA 
components of each species codes for a replication associated (Rep) protein.  Therefore 
nanovirus DNA is proposed to be replicated from transcriptionally and replicationally active ds 
DNA forms via a rolling-circle type of replication mechanism (Randles et al., 2000).  Although 
they are no longer classified in the same family, it has been shown that the nanoviruses and 
circoviruses have conserved regions in their genomes which coincide with highly conserved 
functions such as replication (Bassami et al., 1998).   
Biological properties of circoviruses 
Chicken anaemia virus 
CAV causes a transient severe anaemia due to destruction of erythroblastoid cells, and 
immunodeficiency due to depletion of cortical thymocytes in young chickens, the severity of 
which is dependent on the age of the affected chicks and the presence of secondary 
infectious agents (Noteborn et al., 1994a).  The depletion of the thymocytes occurs via CAV-
induced apoptosis (Noteborn et al., 1994a).   
CAV has been found in the USA, Australia and Japan, with high strain conservation 
suggesting that only one genotype exists worldwide (Kato et al., 1995).  The domestic fowl 
appears to be the natural host of CAV, as the vast majority of CAV isolates have been 
discovered in chickens (McNulty, 1991).  Antibody to CAV was not detected using IIF in 
turkey and duck sera from the United Kingdom (Todd et al., 2001a) and turkeys have been 
shown to be resistant to experimental infection (McNulty, 1991).  Similarly, using virus 
neutralisation tests it has not been possible to demonstrate antibodies in sera from pigeons, 
ducks and crows from Japan.  However, neutralisation of CAV with sera from Japanese quail 
has been demonstrated (Todd et al., 2001a) and Noteborn et al. (1992b) have referred to a 
CAV isolate from guinea fowl (Todd et al., 2001a).  This may alter the commonly held belief 
that the chicken is the sole host for CAV.   
The growth of CAV is restricted to the T-cell lymphoblastoid cell lines MDCC-MSB1 (MSB1) 
and MDCC-JP2 established from Marek’s disease lymphomas, and the B-cell line LSCC-
1104B1, derived from a lymphoid leucosis lymphoma.  Of the susceptible cell lines, MSB1 
has been the most frequently used.  Cultures infected with CAV eventually show a cytopathic 
effect (CPE) characterised by cell death, enlarged swollen cells, alkaline medium and an 
inability to subculture.  CAV grows to moderate titres, typically 10
5 to 10
6 TCID50/0.1 mL in 
MSB1 cells (Todd et al., 2001a; Yuasa and Yoshida, 1983).  Not all sublines of MSB1 are 
susceptible to CAV infection (Todd et al., 2001a) and some sublines lose susceptibility   14
Table 2.1.  Physical and biochemical characteristics of animal circoviruses (adapted from Todd et al., 2001a). 
 CAV  PCV1  BFDV 
Particle size (nm)  19.1 - 26.5  17 - 20.7  14 - 20.7 
Buoyant density (g/mL 
in CsCl) 
1.33 - 1.37  1.36 - 1.37  1.378 
Sedimentation 
coefficient 
91S 57S - 
Genome size (kb)  2.17 - 2.3  1.76  1.7 - 2.0 
Virion proteins (kDa)  50  36  26.3, 23.7, 15.9 
 
following repeated subculture.  CAV can be isolated in MSB1 cells from tissues collected from 
infected chicks (Todd et al., 2001a).  It has also been observed that some CAV isolates fail to 
grow in selected MSB1 cell lines that are susceptible to other isolates, and have reduced 
replication rates in other MSB1 cell sublines (Todd et al., 2001a).   
The physical properties of CAV have been determined using virus purified from infected 
MSB1 cells.  Examination of the purified CAV preparations has revealed particles with 
diameters ranging from 19.1 to 26.5 nm (Todd et al., 2001a) (Table 2.1).  Particles also 
showed three-fold and five-fold axes of symmetry, and the surface detail on such particles 
was highly suggestive of a class P=3 icosahedron, with a triangulation number of three and 
possessing 32 morphological subunits, consisting of 12 apical pentons and 20 face-centred 
hexons (Gelderblom et al., 1989; McNulty et al., 1990b).   
Porcine circovirus 
PCV1 is the type species of the genus Circovirus, and was first recognised as a contaminant 
in the PK15 (ATCC-CCL3) cell line (Tischer et al., 1982; Tischer, Rasch, and Tochtermann, 
1974) and subsequently shown to grow in a range of primary and semicontinuous porcine cell 
lines (Allan et al., 1994b; Allan et al., 1994c; Tischer et al., 1982).  PCV1 has also been 
isolated in PK15 cells from the tissues of stillborn pigs (Allan et al., 1995).  Many serological 
studies have been conducted and reported with the inference that the prevalence and 
distribution of PCV1 antibody was examined; however, they would not have differentiated 
antibody to PCV1 and PCV2.  These include studies that demonstrated PCV infection is 
common in pigs in Canada (Dulac and Afshar, 1989), Germany (Tischer et al., 1995b; Tischer 
et al., 1982), the United Kingdom (Allan et al., 1994c; Edwards and Sands, 1994), and New 
Zealand (Horner, 1991), with up to 95% of sera from slaughtered pigs in Germany reported to 
contain antibodies (Tischer et al., 1986).  Sera from cattle, sheep, chickens, turkeys, goats, 
mice, rabbits and humans have been tested for the presence of antibodies to PCV (Allan et 
al., 1994c; Tischer et al., 1982) and these initially appeared to be absent.  However, in a   15
subsequent study, Tischer et al. (1995a) reported the detection of antibodies reactive with 
PCV1 using immunoblotting techniques.  The prevalence of PCV1 antibodies in sera from 
humans, mice and cattle in Germany were found to be 30.2%, 12-69% and 35%, respectively 
(Tischer et al., 1995a).   
Recently, a different type of PCV (PCV2) has been sequenced and this is thought to be 
associated with PMWS, a recently described disease of young pigs (Clark, 1997).  PCV2 has 
been isolated from pigs in North America, Europe, and South East Asia (Allan and Ellis, 2000; 
Allan et al., 1999b; Allan et al., 1998b; Choi and Chae, 1999; Mankertz et al., 2000a; Morozov 
et al., 1998; Plana-Duran et al., 1999; Segales et al., 1997), suggesting that PCV2 infection in 
pigs is widespread.  Serological surveys have shown that up to 100% of farms and up to 
100% of individual pigs sampled in parts of Europe, the United States, and Canada were 
positive for PCV2 antibodies (Allan et al., 2000c; Cottrell et al., 1999; Todd et al., 2001a; 
Walker et al., 2000).  Almost 70% of archived pig sera in Northern Ireland from 1973 had 
antibody to PCV2 (Walker et al., 2000) indicating that PCV2 infection pre-dates the initial 
isolation of the virus by several years.  The detection of PCV2 nucleic acid and antigen in 
bovine tissue has also been reported (Nayar et al., 1999) but not confirmed by others.  No 
PCV2 antibodies were detected in bovine sera collected from farms in Northern Ireland and 
France (Allan et al., 2000c).  No PCV2 antibodies were detected in 120 human sera or in 120 
sheep sera (Allan et al., 2000c), suggesting that PCV2 infection is species specific.   
PK15 cells are commonly used for isolation, propagation and assay of PCV1 and PCV2 in 
vitro; the original cell-line was persistently infected with PCV1 but PK15 cells have been 
developed that are PCV-free.  Regardless, the key features of the growth of PCV1 or PCV2 in 
this cell line are (1) accumulation of virus antigens in the nucleus and cytoplasm of the cells 
as indicated by immunostaining with hyperimmune antisera or monoclonal antibodies (MAb), 
(2) a lack of CPE in infected cultures, and (3) an increase in the number of infected cells and 
enhancement of virus titre by treatment of cell cultures with glucosamine (Allan et al., 1994a; 
Tischer et al., 1982; Tischer et al., 1987).  The original PCV1 strain from persistently-infected 
PK15 cells was shown to replicate in other cells of porcine origin, and also in Vero (African 
green monkey kidney) cells (Allan et al., 1994b; Allan et al., 1994c; Dulac and Afshar, 1989; 
Edwards and Sands, 1994).  PCV1 was also shown to infect bovine and ovine cells in vitro, 
but no infectious virus was produced and virus antigen only was observed in the cytoplasm of 
the cells (Allan et al., 1994c).  PCV1-infected cell lines, established by cloning of persistently-
infected primary pig kidney cells, exhibited properties consistent with transformation of cells, 
such as immortalisation and loss of contact inhibition (Tischer, Peters, and Pociuli, 1995).  
However, as the passage number of the cloned cells increased, the growth rate decreased 
and CPE was observed in the cultures, suggesting that the ‘transformed’ state was unstable.  
PCV1 was also shown to infect porcine macrophage/monocytes in vitro, with production of 
infectious virus (Allan et al., 1994b).  Infection of bovine mononuclear cells was also 
demonstrated but there was no evidence of growth in mononuclear cells from sheep or 
humans (Allan et al., 1994b).     16
The physical properties of PCV1 have been largely determined using PCV1 purified from 
infected PK15 cells.  PCV2 is largely uncharacterised, but based on genomic similarities, is 
assumed to behave similarly to PCV1.  Electron microscopic studies performed in a number 
of laboratories have detected particle diameters of 16.8-20.7 nm for PCV1 (Todd et al., 
2001a) (Table 2.1).  Thin section studies of PK15 cells infected with PCV1 showed 
intracytoplasmic and intranuclear inclusions, often in association with aggregates of virus-like 
particles measuring approximately 12 nm in diameter.  Large and small intracytoplasmic 
inclusions were described; the smaller inclusions were considered to be the centres of virion 
assembly, while the larger inclusions were membrane-bound structures of greater electron 
density.  The intranuclear inclusions also contained virus-like particles in irregular aggregates, 
or were seen as round or ring-shaped structures, often in association with nuclear chromatin 
(Stevenson et al., 1999b).  No detailed studies of PCV morphogenesis in vivo have been 
published; however, electron micrographs of lymphoid tissues from pigs with PMWS in which 
PCV2 antigen and/or nucleic acid was demonstrated, show large arrays of virus particles and 
electron-dense intracytoplasmic inclusion bodies (Ellis et al., 1998; Kiupel et al., 1998).   
Beak and feather disease virus 
PBFD affects both wild and captive Psittaciformes (Bassami et al., 1998).  In most species, 
the disease is characterised by chronic progressive, symmetrical feather dystrophy and 
occasional beak deformity (Bassami et al., 1998).  The causative agent of PBFD is BFDV.  
Although a feathering disease that resembled PBFD both clinically and pathologically was 
described in Senegal doves by Pass, Plant and Sexton (1994), subsequent work 
demonstrated that these non-psittacine birds were infected with a circovirus antigenically 
different from BFDV (Raidal and Riddoch, 1997).  Similarly, the circovirus detected in pigeons 
is antigenically different from BFDV, although some DNA homology was reported (Woods et 
al., 1994).  Circovirus–like particles have also been detected in finches, passerines, geese 
and southern black-backed gulls but whether these represent genuine circoviruses that are 
related to or distinct from BFDV is as yet unknown (Todd et al., 2001a).   
Virus purified from infected feather pulp has been used for the physical characterisation of 
BFDV.  Results from different electron microscopic studies performed in a number of 
laboratories indicate particle diameters of 14-20.7 nm for BFDV (Table 2.1).  Ultrastructural 
studies of tissues from birds with BFDV or PiCV infections revealed similar inclusions, 
including paracrystalline arrays of tightly packed virus particles, to those seen in cells infected 
with PCV1 and PCV2 (Latimer et al., 1991; Woods et al., 1994).  BFDV, unlike CAV or PCV 
has been reported to cause haemagglutination of erythrocytes from a variety of psittacine 
species (Raidal and Cross, 1994), with cells from galahs being commonly used.  In addition, 
erythrocytes from some geese and some guinea pigs were susceptible to haemagglutination 
by BFDV (Ritchie et al., 1991; Sexton et al., 1994).     17
Comparative physical and chemical properties of circoviruses 
In a collaborative study in which PCV1, BFDV and CAV were compared within the same 
laboratory, Todd et al. (1991) reported that PCV1 and BFDV were almost identical in size and 
some 20% smaller than CAV (Table 2.1).  When PCV1 and CAV were analysed in the same 
gradient, Allan et al. (1994c) reported that the buoyant density of CAV (1.33-1.34 g/mL) was 
less than that of PCV1 (1.36-1.38 g/mL).  Similarly, the sedimentation coefficient of CAV 
(91S) was greater than that of PCV1 (57S) and, as such, reflected the difference in particle 
diameter between these viruses.  The sizes of the circovirus genomes were firstly determined 
by electron microscopy using the circular, ss DNA genome of bacteriophage ϕX174 (5386 bp) 
as an internal standard (Table 2.1).  Accurate estimates of genome size were subsequently 
made by nucleotide sequence determination.   
The ability to propagate CAV and PCV1 in cell cultures has facilitated investigations into their 
physical and chemical stability.  As would be expected for non-enveloped, icosahedral 
viruses, the infectivity of CAV and PCV1 was unaffected by treatment with ether or 
chloroform.  Both CAV and PCV1 are also highly stable at 70°C for 15 min and after 
treatment at pH 3 (Allan et al., 1994c; Yuasa, Taniguchi, and Yoshida, 1979).  Although 
similar investigations with BFDV have not been possible, the ability of BFDV to 
haemagglutinate was unaffected by incubation at 80°C for 30 min (Raidal and Cross, 1994), 
suggesting that, like CAV and PCV1, this virus is very stable.  CAV also exhibits high degrees 
of resistance to chemical inactivation.  For example, CAV is not completely inactivated by 
fumigation with formaldehyde or ethylene oxide for 24 h, and comparatively high 
concentrations (10%) of iodine and hypochlorite are required to inactivate CAV following 
treatment at 37°C for 2 h (Yuasa, 1992).   
Genome organisation and expression of circoviruses 
The genomes of CAV, PCV1, PCV2 and BFDV have been sequenced.  PCV and BFDV have 
ambisense genomes, that is, they require proteins encoded by both the viral and 
complementary DNA strands of the replicative form (RF) for replication to occur (Niagro et al., 
1998).  Conversely, CAV does not have an ambisense genome, and only one of the two 
strands of the RF is transcribed to produce mRNA (Niagro et al., 1998).  With CAV and both 
PCV types, circular ds RF DNA can be extracted from virus-infected cells and in each case 
the cloned RF has been shown by transfection to contain all the elements necessary to 
produce infectious virus (Meehan et al., 1997a; Meehan et al., 1998; Noteborn et al., 1991).  
The inability to propagate BFDV in cell culture has hindered investigations of its molecular 
biology, although future investigations could be facilitated by the use of infectious clones.   
The genomic organisation of CAV deduced from sequence analysis and molecular biological 
studies is very different from those deduced for PCV and BFDV.  The complete genomic 
sequences of seven CAV isolates have been reported.  Three of these are variants of the   18
Cux-1 isolate, called CuxN (Noteborn et al., 1991), CuxM (Meehan et al., 1992) and Cux10 
(Meehan et al., 1997b), two are isolates from the United States, known as 26P4 (Claessens 
et al., 1991) and CIA-1 (Todd et al., 2001a), and two are Japanese isolates, CAA 82-2 (Kato 
et al., 1995) and TK-5803 (Farkas et al., 1996).  DNA from the CuxN, Cux10, and CAA 82-2 
isolates, which comprise 2319 nt, differ from CuxM, 26P4, CIA-1, and TK-5803, all of which 
comprise 2298 nt, in that they contain a distinctive 21 nt insertion.  Comparative analyses 
indicate that the level of nucleotide sequence diversity is less than 3%.  With the majority of 
these isolates, three partially overlapping ORFs, which encode potential proteins of 
approximately 52 kDa, 24 kDa, and 13.6 kDa, are located, together with appropriately 
positioned transcription initiation and termination signals, on one of the strands that comprise 
the RF (Figure 2.1).  Transcriptional analyses demonstrated that CAV utilises one major 
transcript (~2.1 kb) which encompasses the three ORFs (Noteborn et al., 1992a; Phenix et 
al., 1994).  Investigations using strand-specific probes indicated that the CAV transcript was 
complementary to the encapsidated DNA (Noteborn et al., 1992a; Phenix et al., 1994); CAV 
can therefore be regarded as having a negative sense genome.  Demonstration that protein 
products corresponding to each of the three ORFs were synthesised within infected cells 
provided confirmatory evidence that CAV uses an unspliced, polycistronic message (Douglas 
et al., 1995) and, as such, it is unique among animal DNA viruses.  Adopting the convention 
used later for PCV and BFDV, the ORFs have been labelled C1, C2 and C3 (Figure 2.1), in 
order of decreasing size, since they occur on the complementary strand.   
 
 
 
Figure 2.1.  Genome organisations of circoviruses.  (a) Chicken anaemia virus.  CAV uses a negative sense 
genome expression strategy, producing 1 polycistronic transcript encompassing 3 partially overlapping 
ORFs.  The non-transcribed region exhibits promoter/enhancer activity.  (b) Porcine circovirus type 2.  PCV2 
employs an ambisense genome expression strategy, in which at least two of the ORFs (C1 and V1) are 
functional.  A potential stem-loop with nonanucleotide motif is part of the origin of virus DNA replication.  
Evidence from PCV1 indicates that the transcript encompassing C1 is processed by splicing.  (c) Beak and 
feather disease virus.  Sequence analysis indicates that BFDV employs an ambisense genome expression 
strategy very similar to that of PCV1 and PCV2.  The number of functional ORFs is unknown. 
 
Three sequences of PCV1 isolates that were recovered from virus-contaminated PK15 cells 
have been published (Mankertz et al., 1997; Meehan et al., 1997a; Niagro et al., 1998).  The 
sequence of a fourth PCV1 virus is available in the Genbank database [Genbank Accession 
Number: AF012107].  All of these reports sized the genome at 1759 nt and minimal sequence   19
variation was detected.  Analyses of the PCV1 sequences indicated the presence of between 
four and eleven ORFs, the number identified being dependent on the size of the potential 
protein encoded.  The nucleotide numbering and ORF-labelling conventions employed for 
geminiviruses have been adopted (Meehan et al., 1997a; Niagro et al., 1998).  Thus, the 
ORFs present on the encapsidated virus strand have been labelled ‘V’, while those present in 
the complementary strand have been labelled ‘C’ (Table 2.2).   
The genome sequence of PCV2 has 76-78% overall nucleotide identity with the non-
pathogenic PCV1.  Hamel, Lin and Nayar (1998) sequenced the first isolate of PCV 
associated with PMWS and since then, more than 70 PCV2 isolates originating in North 
America, Europe and South East Asia have now been either reported (Hamel, Lin, and Nayar, 
1998; Larochelle, Magar, and D'Allaire, 2002; Mankertz et al., 2000a; Meehan et al., 1998; 
Morozov  et al., 1998) or submitted to the databases (Genbank accession numbers: 
AF147751, AF085695, AF086834, AF086835 AF086836, AF154679, AF166528).  These 
were determined using either cloned RF fragments recovered from PK15 cells infected with 
PCV (Meehan et al., 1998) or DNA amplified by polymerase chain reaction (PCR) using 
primers based on PCV1 sequences (Hamel, Lin, and Nayar, 1998; Mankertz et al., 2000a; 
Morozov et al., 1998).  A sequence comparison showed that PCV2 isolates shared >96% 
nucleotide identity and that, as a group, they shared <80% identity with one PCV1 isolate 
(Meehan et al., 1998).  The genomes of the PCV2 isolates had overall sizes of 1767 or 1768 
nt and contained small deletions and insertions at different locations throughout the genomes 
when compared to the PCV1 isolates.   
Although the occurrences of additional smaller ORFs were reported in each of the individual 
papers, four ORFs were consistently identified in the PCV2 sequence analyses conducted by 
Hamel, Lin and Nayar (1998), Meehan et al. (1998), and Morozov et al. (1998) (Figure 2.1).  
These corresponded to the V1, C1, C2 and C3 ORFs found in the PCV1 genome (Table 2.2).  
Mankertz et al. (2000a) reported that only three ORFs (V1, C1 and C2) were consistently 
detected when the genomes of seven European PCV2 isolates were analysed.  Comparison 
of 24 PCV2 and four PCV1 isolates revealed that the predicted amino acid sequences for the 
V1 and C1 ORFs exhibited identities of 82% and 62%, respectively (Mankertz et al., 2000a).  
It was also reported that the amino acid homologies shared by viruses within the respective 
PCV1 and PCV2 groups were higher.  Thus, in the V1 ORF, the group of PCV2 isolates 
exhibited 95.7% homology and the PCV1 group exhibited 99.4% homology whereas, in the 
C1 ORF, the PCV2 group exhibited about 90% homology and the PCV1 group exhibited 94% 
homology (Mankertz et al., 2000a).  These findings suggest that the protein encoded by the 
V1 ORF was more conserved than that encoded by the C1 ORF.  Also of note is the fact that 
the C2 and C3 ORFs specified by PCV2 represent truncated versions of the corresponding 
ORFs found in PCV1 sequences (Hamel, Lin, and Nayar, 1998; Meehan et al., 1998) (Table 
2.2).  Further analyses of PCV2 genome sequences reveal the presence of two non-coding 
regions, 83 and 44 nt long between the V1 and C1 ORFs (Mankertz et al., 2000a).  The 83 nt 
region separating the initiation codons of the V1 and C1 ORFs contains a distinctive potential   20
stem-loop structure encompassing a nonanucleotide motif that is thought to play a key role in 
rolling circle replication (RCR) of the virus DNA.   
There are four reported studies involving the transcriptional analyses of PCV1 and PCV2 
(Cheung, 2003a; Cheung, 2003b; Mankertz and Hillenbrand, 2002; Mankertz et al., 1998b), 
which have shown that 12 RNAs are synthesised in PCV1-persistently-infected PK15 cells 
(Cheung, 2003a; Mankertz and Hillenbrand, 2002; Mankertz et al., 1998b) and nine RNAs in 
PCV2-infected PK15 cells (Cheung, 2003b).  The 12 PCV1 RNAs detected included the viral 
capsid protein RNA (designated CR), a cluster of eight Rep-associated RNAs (designated 
Rep, Rep’, Rep3a, Rep3b, Rep3c-1, Rep3c-2, Rep3c-3 and Rep3c-4), and three non-
structural (NS) protein-associated RNAs (designated NS462, NS642 and NS0) (Cheung, 
2003a).  Members of the Rep-associated RNA cluster all shared common 5'- and 3'-
nucleotide sequences and a common 3'-nucleotide sequence with the NS-associated RNAs.  
Rep, capable of coding for the full-length replication-associated protein, appeared to be the 
primary transcript that gives rise to the other seven Rep-associated RNAs by alternate 
splicing (Cheung, 2003a).   
The nine RNAs synthesised by PCV2 have been designated CR, Rep, Rep’, Rep3a, Rep3b, 
Rep3c, NS15, NS672 and NS0 by Cheung (2003b).  Sequence alignment analysis showed 
that both the non-pathogenic PCV1 and the pathogenic PCV2 utilise comparable genetic 
elements located similarly along the genome for viral gene expression (Cheung, 2003a; 
Cheung, 2003b).  The Rep, Rep', Rep3a, Rep3b and NS0 of PCV1 and PCV2 were 
considered equivalent entities in their respective systems but quantitative and qualitative 
differences such as splice junction variation were observed in the Rep3c- and NS protein-
associated RNAs (Cheung, 2003a; Cheung, 2003b).   
The complete genome sequences of BFDV isolates have been reported (Bassami et al., 
1998; Niagro et al., 1998).  In both of these reports, sequence data were obtained by 
generating a ds DNA using a virus genomic DNA template and both reported that the genome 
contained 1993 nt.  In the sequence analysis undertaken by Bassami et al. (1998), the 
numbering scheme adopted for geminiviruses was employed and seven ORFs encoding 
potential proteins of >8.7 kDa were identified on the putative RF (Figure 2.1 and Table 2.2), 
whereas in the analysis by Niagro et al. (1998) only the larger ORFs (V1, C1 and C2) were 
identified.  The inability to propagate BFDV in cell culture has eliminated the possibility of 
conducting a comprehensive transcription analysis but, working with RNA extracted from 
feather pulp from infected birds, Niagro et al. (1998) reported that transcripts synthesised on 
both RF strands were produced, suggesting that, like PCV1 and PCV2, BFDV has an 
ambisense genome.  Indeed, there is a marked similarity between the genome organisations 
of these two circoviruses.  In each case, the largest ORFs, V1 and C1, initiate close to a small 
non-coding region containing the distinctive potential stem loop and nonanucleotide motif.  
Homology studies indicated that the V1 and C1 ORFs of BFDV corresponded to those 
occurring in the two PCV types.  Thus the V1 and C1 ORFs of BFDV and PCV1 share 45.6%   21
and 29.1% amino acid identities, respectively (Bassami et al., 1998).  It is possible that the 
transcript encompassing the BFDV V1 ORF uses one of two possible Poly(A) signals on the 
BFDV RF.  Another Poly(A) signal, which occurs on the complementary strand, may be 
involved in processing transcripts containing the BFDV C1 ORF.  Nucleotide sequencing of 
additional BFDV isolates may help to elucidate which of the remaining ORFs are conserved 
and are therefore likely to be expressed.  Ypelaar et al. (1999) have reported that in a 
comparison of ten BFDV isolates obtained from different psittacine species and collected from 
different parts of Australia, the nucleotide sequence identity of a 717 bp region within the V1 
ORF ranged from 88 to 99%.   
Virus proteins and antigens of circoviruses 
Only one protein, sized at approximately 50 kDa, detected when CAV was purified using 
sodium dodecyl sulphate (SDS) treatment, differential centrifugation, and equilibrium density 
gradient centrifugation, was analysed by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) (Todd et al., 1990).  Western immunoblot (WIB) investigations 
using a CAV-specific MAb (1H1) (McNulty et al., 1990c), in conjunction with a recombinant 
protein approach, showed that the C1 ORF encoded the 50 kDa capsid protein (Todd et al., 
2001a).  The predicted amino acid sequence at the N-terminus of the C1 ORF is very rich in 
basic amino acids and a high level of homology is shared with chicken protamines (Noteborn 
et al., 1991).  This finding is consistent with the N-terminal region having a DNA binding role 
within the virion.  Additional WIB results using the CAV MAb, 3B1 (McNulty et al., 1990c) and 
an antiserum raised to synthetic peptides specified by the C2 ORF showed that proteins 
encoded by the C2 and C3 ORFs, named VP2 and VP3, respectively, could be detected in 
CAV-infected MSB1 cells as 30 kDa and 16 kDa proteins, respectively (Douglas et al., 1995; 
Noteborn et al., 1994b; Todd et al., 2001a).  This suggested that the proteins produced from 
each ORF were full length.  In experiments performed with CAV-infected MSB1 cells, IIF 
indicated that the VP2 and VP3 proteins could be detected as early as 13 h post-infection 
(p.i.) whereas the 50 kDa capsid protein, VP1, was not detected until 30 h p.i. (Douglas et al., 
1995).  This finding suggests that translation of the polycistronic message may be regulated 
to produce early and late proteins.   
Noteborn et al. (1994a) showed that transient expression of VP3 in chicken T lymphoblastoid 
and myeloid cells caused apoptosis or programmed cell death in these cells and concluded 
that this protein alone was capable of triggering the apoptotic pathway in CAV-infected cells.  
They also showed that truncation of the basic C-terminus of the VP3 or ‘apoptin’ protein 
reduced its nuclear localisation and apoptotic activity.  The apoptin was closely associated 
with the chromatin structure and it was speculated that it may directly interact with histone or 
non-histone proteins within the chromatin to disrupt the supercoiled organisation and cause 
DNA fragmentation.  Koch et al. (1995) suggested the role of VP2 is uncertain and showed 
that there must be simultaneous co-synthesis of VP2 and VP1 by recombinant baculoviruses 
within insect cells to enable the recombinant VP1 to achieve the conformation that it requires   22
to react with a virus neutralising MAb and to induce neutralising antibodies in chickens 
following inoculation.  It is proposed that VP2 may act as a scaffold protein, on the basis that 
VP2 cannot be detected in the virus capsid (Noteborn et al., 1998; Todd et al., 2001a).   
Although antigenic differences in geographically diverse CAV isolates were revealed by 
immunofluorescence using MAbs (McNulty et al., 1990c; Todd et al., 1999), comparative 
studies have shown that CAV isolates share antigens detectable by cross-
immunofluorescence tests.  Based on cross-neutralisation tests with polyclonal antisera, all 
isolates belong to the same serotype (Connor et al., 1991; McNulty, Connor, and McNeilly, 
1989; McNulty et al., 1990a; Yuasa and Imai, 1986).  The failure of virus neutralising MAbs to 
react with VP1 in WIBs confirmed that important neutralising epitopes were conformational 
(McNulty  et al., 1990c; Todd et al., 2001a).  In this connection, Scott et al. (1999) have 
recently shown that six VP1 amino acid changes, selected by subjecting the Cux-1 isolate to 
multiple passages in MSB1 cells, appeared to alter the conformation of the protein so that its 
reactivity with neutralising MAbs was greatly reduced.  Renshaw et al. (1996) reported the 
existence of a hypervariable region within VP1 and provided evidence using chimeric virus 
constructs that amino acid changes within this region influenced the rate of virus replication in 
MSB cell cultures.  The methods currently used to serologically diagnose CAV infections, 
namely the virus neutralisation and enzyme-linked immunosorbent assay (ELISA) tests, 
probably measure levels of antibody against VP1, the major or only protein in the capsid.   
The V1 ORF of PCV1 and PCV2 has 83% nucleotide and 86% predicted amino acid identity, 
and the C1 ORF of PCV1 and PCV2 has 67% nucleotide and 65% predicted protein 
homology (Gibbs and Weiller, 1999; Meehan et al., 1998; Morozov et al., 1998).  There is C-
terminal truncation of the predicted proteins encoded by ORF3 and ORF4 of PCV2 (Meehan 
et al., 1998; Morozov et al., 1998).  A 61.5-62% predicted amino acid identity for the protein 
encoded by the C2 ORF of PCV2 and PCV1, and an 83% predicted amino acid identity for 
the protein encoded by the C3 ORF of PCV1 and PCV2 was reported (Hamel, Lin, and Nayar, 
1998; Meehan et al., 1998).  A 79% and a 67% identity between the two other ORFs of PCV2 
and PCV1 (Hamel, Lin, and Nayar, 1998) was reported.  Little is known about the significance 
of the four smaller potential ORFs.   
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Table 2.2.  Characterisation of ORFs specified by PCV2, PCV1 and BFDV.  Taken from (Todd et al., 2001a).   
 
PCV2 PCV1  BFDV 
ORF 
Position 
(nt) 
No. 
amino 
acids 
Position 
(nt) 
No. 
amino 
acids 
Amino acid 
identity 
(PCV1/PCV2)  Position 
No. 
amino 
acids 
Amino acid 
identity 
(PCV1/BFDV) 
V1 (rep)  51-995 314  47-985 312  82%  131-997  289  45.6% 
V2     1163-1450  95   543-843  106   
V3     1670-0081  56   1049-1366  101   
C1 
(capsid) 
1735-1034 233  1723-1022 233  62%  1978-1238 247  29.1% 
C2 671-357  104 658-38  206  62%  544-65  160   
C3  565-386 59  552-205 115  83%  1021-758  88   
C4     1518-1330  62   1278-1021  86   
 
PCV1 preparations, purified by differential and CsCl2 equilibrium density gradient 
centrifugation, were shown to comprise one major protein of 36 kDa (Tischer et al., 1982).  
Phenix  et al. (1994) detected only one protein of 34 kDa in purified PCV1 preparations.   
Mankertz et al. (2000a) concluded that the C1 ORF of PCV1 encoded the capsid protein after 
demonstrating that MAbs specific to the purified virus were reactive by WIB with a C1 ORF-
fusion protein produced in bacteria.  There appears to be a discrepancy between the 
predicted size of the protein encoded by the C1 ORF (27 kDa) and the higher molecular 
weight estimates (36 kDa) determined by SDS-PAGE (Tischer et al., 1982).  A report by 
Tischer et al. (1995a) of the detection of two PCV1 proteins of 33 kDa and 31 kDa when 
purified virus was analysed by SDS-PAGE, and additional dimeric forms of these by 
immunoblotting, appears inconsistent with the above reports.   
There is now strong evidence that the protein encoded by the V1 ORF of both PCV types is a 
Rep protein that participates in DNA replication by a rolling circle mechanism.  Recent studies 
have shown that replication of PCV1 requires two proteins, both encoded by ORF V1, also 
termed the rep gene (Mankertz and Hillenbrand, 2001).  The full length Rep protein is 35.6 
kDa and this was originally thought to be the sole replication initiator for PCV1 (Mankertz et 
al., 1998a; Meehan et al., 1997a).  However, the truncated version of Rep, designated Rep’, 
is 19.2 kDa (Mankertz and Hillenbrand, 2001) and plays an important role in replication.  In 
contrast to other viruses replicating via a rolling circle mechanism, Rep alone cannot promote 
replication; both Rep and Rep' are required to provide the functional replication initiator factor 
of PCV1 (Mankertz and Hillenbrand, 2001).   
Early and late virus-encoded antigens were detected using immunofluorescence when the 
PCV1 infection cycle in pig kidney cells was synchronised (Tischer, Peters, and Pociuli,   24
1995).  Using polyclonal antibodies or MAbs raised against purified virus, a late viral antigen 
presumed to be the capsid protein, was found in the cell nucleus only after onset of viral DNA 
replication.  Immunofluorescence techniques based on antisera from infected pigs detected 
an early antigen in nucleoli of infected cells (Tischer, Peters, and Pociuli, 1995) and it was 
suggested that this was a non-structural protein produced before the onset of DNA replication 
and recognised by the immune system of pigs.  Tischer, Peters and Pociuli (1995) suggested 
the early antigen possessed transforming activity; they suggested that in a normal growth 
cycle the early antigen is synthesised during G1 and may have roles in the regulation of gene 
expression and DNA replication. 
Cross-immunofluorescence of PCV1 and several PCV2 virus isolates from the USA and 
Europe using hyperimmune rabbit antisera and MAbs specific to PCV1 and PCV2 
demonstrated only low-level cross-reactivity between PCV1 and PCV2 viruses, while there 
was high level reactivity between homologous types (Allan et al., 1999a; Allan et al., 1998b).  
This result is consistent with the finding that the C1 ORFs possessed by PCV1 and PCV2 
exhibited a relatively low (62%) homology.  This cross-reactivity may be variable depending 
on isolates as evidence of antigenic change in PCV1 following passage in cell cultures was 
demonstrated in studies using a panel of PCV1 specific MAbs (Allan et al., 1994a); the cell 
line in which the virus was passaged (PK15 or Vero) and the level of passage were shown to 
influence the degree of antigenic change detected.   
BFDV purified from feather material was initially reported to contain three structural proteins 
of 26.3 kDa, 23.7 kDa, and 15.9 kDa (Ritchie et al., 1989) as shown in Table 2.2.  In a 
subsequent report, rigorously purified viruses prepared from feather material collected from 
four genera of psittacine birds were found to contain only two major proteins, one 26 kDa and 
the other 23 kDa (Ritchie et al., 1990).  On the basis of the similarity that exists between the 
genome of BFDV and the two PCV types, as well as the sequence homologies detected when 
cognate ORFs are compared, it is likely that the C1 ORF encodes the largest structural 
protein (26 kDa) and that the putative Rep protein encoded by the V1 ORF would be non-
structural and therefore not detected in purified virus.  The identity of the additional structural 
protein(s) detected remain undefined (Ritchie et al., 1990; Ritchie et al., 1989).  Given that the 
virus cannot be grown in cell culture, characterisation of the proteins specified by BFDV will 
be difficult to accomplish, although antibodies against particular virus-specific proteins or ORF 
expression products, used as immunocytochemical reagents, could be used to investigate 
this.   
No information is available concerning the proteins specified by PiCV; however, there would 
appear to be no antigenic cross-reactivity between PiCV and BFDV (Woods et al., 1994).  
Similarly, no antigenic relationships were detected between CAV, PCV1 and BFDV (Todd et 
al., 1991).   25
Mode of replication of the DNA genome of circoviruses 
Studies with bacteriophages and plant geminiviruses (Hanley-Bowdoin et al., 1999; Todd et 
al., 2001a) that possess small, circular ss DNA genomes, have been useful in elucidating the 
mechanism of DNA replication in circoviruses.  Circoviruses have very limited coding capacity 
and are highly dependent on cellular enzymes for DNA replication.  They probably have little 
or no means of manipulating the cell cycle in the manner described for larger DNA viruses 
such as adenoviruses (Todd et al., 2001a).  The dependence of CAV on cellular function is 
suggested by observations that virus antigen is present in only 30 to 40% of the cells in CAV-
infected cell cultures, a proportion that probably corresponds to cells that have undergone cell 
division.   
The mode of replication of PCV has been related to that of the autonomously replicating 
parvoviruses (Studdert, 1993; Tischer, Peters, and Pociuli, 1995).  Replication is known to 
occur in the nucleus of the host cell and is highly dependant on cellular functions during the 
S-phase of the cell cycle (Studdert, 1993; Tischer, Peters, and Pociuli, 1995).  It was 
suggested that viral nucleic acid enters the nucleus during cellular mitosis (Tischer, Peters, 
and Pociuli, 1995; Tischer et al., 1987).   
As with the plant and bacterial viruses with circular ss genomes, circular ds RF DNA is an 
essential intermediate in both the transcription and the replication of circovirus DNA genome.  
Open and closed circular RF species have been detected in PK15 cells infected with PCV1 
(Meehan et al., 1997a; Tischer and Buhk, 1988) and PCV2 (Meehan et al., 1998), and CAV-
infected MSB1 cells (Meehan et al., 1992; Noteborn et al., 1991) using Southern blot 
hybridisation.  PCV2 produced RF and genomic ss DNA in larger amounts than PCV1, 
suggesting PCV2 DNA was a more efficient replicon in PK15 cells than PCV1 (Meehan et al., 
1998).  Tischer and Buhk (1988) detected more than one type of DNA in PCV1-infected pig 
kidney cells, relaxed and open circular 11S RF, ss genomic 13S and 5S DNA.  The 5S DNA 
was single-stranded, of the same sense as the encapsidated virus strand, and detectable 
both within infected cells and in purified virus particles.  This 5S DNA varies in size and 
sequence but comprised the genomic DNA region from nt 1327-218 in which a central 
deletion of 100 to 200 nt was detected (Mankertz et al., 1997).  Virus particles containing this 
5S DNA were thought to be defective viruses unable to produce the full complement of virus 
proteins but which contained the sequence elements necessary to facilitate their DNA 
replication.   
The first step in the replication of the ss circovirus DNA genome is the synthesis of the 
complementary strand to generate the first RF.  Unless a virus structural protein is involved, 
this step must be accomplished by cellular enzymes since, in the absence of RF, no virus 
proteins are synthesised (Tischer et al., 1987).  A cellular DNA primase together with RNA 
primers are likely to be involved (Gassmann et al., 1988; Tischer et al., 1987).  In PCV1, the 
priming reaction is not entirely random and DNA elongation can occur using the α and δ DNA   26
polymerases (Gassmann et al., 1988; Tischer et al., 1987).  There is now strong 
circumstantial evidence that, at least in the cases of the two types of PCV and BFDV, further 
DNA replication proceeds using the RCR mechanism.  RCR is a process of continuous 
elongation of the open positive strand via endless copying around a closed circular negative-
strand template (Dressler, 1970).  During bacteriophage ϕX174 replication, the most-studied 
example of an agent using this replication strategy, a virus-coded protein (A protein) cleaves 
the virus DNA strand present in the RF at a unique site to provide a 3’-OH terminus, which 
acts as a primer for extension by a cellular DNA polymerase (Todd et al., 2001a).  The 
original virus strand is displaced as elongation of the 3’-OH terminus by the DNA polymerase 
proceeds.  After one round of replication, the A protein typically cleaves the displaced virus 
strand from the newly synthesised virus strand and then self-ligates the displaced strand to 
form a circular ss DNA.  In geminiviruses the virus-coded Rep protein performs a similar 
function to that of the A protein (Hanley-Bowdoin et al., 1999).  As a result of RCR, many 
copies of the circular virus strand can be produced and, depending on the stage in the 
infection cycle, these can be used as templates for complementary strand synthesis to 
generate more RF molecules, or they can be encapsidated into virus particles.   
Analyses of the predicted amino acid sequences indicated that the proteins encoded by the 
V1 ORFs of PCV1 and BFDV (Bassami et al., 1998; Meehan et al., 1997a; Niagro et al., 
1998) bear a striking similarity to geminivirus Rep proteins and to the putative Rep proteins 
found in plant nanoviruses, which also contain small, circular ss DNA genomes.  Of particular 
interest is the occurrence within these Rep proteins of three peptide motifs (Meehan et al., 
1997a; Niagro et al., 1998) that are associated with RCR (Ilyina and Koonin, 1992), as well as 
a GKS box or P-loop which may be involved in nucleotide binding (Desbiez et al., 1995).  
Alignment of the putative circovirus Rep sequences (Table 2.3) demonstrates a high degree 
of similarity with the nanovirus Rep proteins.  The phylogenetic relationships between 
circoviruses and other viruses that replicate via a rolling circle mechanism suggest that PCV, 
BFDV, BBTV and SCSV encode Rep proteins that originated from a common ancestor 
(Bassami et al., 1998).   
Mankertz  et al. (1998b) confirmed that the protein specified by the V1 ORF of PCV1 
possessed the ability to replicate PCV1 DNA.  They demonstrated that pig kidney cells, 
containing a transfected plasmid expressing the V1 ORF, were capable of replicating a 
second co-transfected plasmid which contained the PCV1 origin of DNA replication.  The 
PCV1 origin of replication was identified by investigating the ability of plasmid constructs 
containing selected PCV1 sequences to undergo replication in virus-infected cells.  It was 
characterised as an 111 bp fragment located from nt 1715 to 66 (Mankertz et al., 1997).  This 
sequence, which encompasses the short non-coding region between the beginning of the V1 
and C1 ORFs of both PCV1 and PCV2, contains distinctive features that also occur in BFDV 
and this lends further support to the view that the two PCV types and BFDV replicate their   27
Table 2.3.  Edited alignment of selected domains of the Rep proteins of PCV (Accession No. U49189), BFDV 
(Accession No. AF080560), BBTV (Accession No. 12586), SCSV (Accession No. U16731), MSV (Accession No. 
AF003952) (Boevink, Chu, and Keese, 1995), BCTV (Accession No. U56975) BGMV (Accession No. M88686) 
and TPCTV (Accession No. X84735).  Motifs indicated by red letters in columns I, II and III are three typical 
domains involved in RCR and red letters in the motifs in column IV indicate the nt-binding site (P-loop motif). 
 I  II  III IV 
PCV  -FTLNN- -GRT AHLQGF-  -YCSK-  -G . PPGCGKS- 
BFDV  -FTLNN- -G . T PHLQGY-  -YCSK-  -G . PPGCGKS- 
BBTV  -FTLNN- -G . QKHLQGY-  -YCSK-  -GPNGNEGKS- 
SCSV  -FTLNY- -G . QKHLQGF-  -YCCK-  -GSDGGEGKT- 
MSV  -FLTYP- -G . SL HLHAL-  -Y I LK-  -G . PTRTGKS- 
BCTV  -FLTYP- -G . SL HLHAL-  -Y I EK-  -G . DSRTGKT- 
BGMV  -FLTYP- -G . EP HLHVL-  -Y I EK-  -G . DSRTGKT- 
TPCTV  -FLTYP- -G . SLHLHAL- -Y I EK- -G . DSRTGKT- 
 
 
DNA by a RCR mechanism (Mankertz et al., 1997; Meehan et al., 1997a; Niagro et al., 1998).  
Of major significance is the occurrence in the virus strands of PCV1, PCV2 and BFDV of an 
inverted repeat with the potential to form a stem-loop structure, the apex of which contains a 
conserved nonanucleotide sequence (5’-TAGTATTAC-3’; nt position 1753-2 in PCV1; 
(Meehan  et al., 1997a; Meehan et al., 1998; Niagro et al., 1998).  This nonanucleotide 
element is of considerable interest since its sequence and location at the apex of the putative 
stem loop are very similar to those found in plant viruses and other replicons of bacterial 
origin, including ϕX174, with ss DNA genomes (Meehan et al., 1997a; Niagro et al., 1998).  
Mankertz et al. (1997) have shown that when mutations were introduced into the first two 
nucleotides of the motif, a total loss of replication function was observed.  It is of interest that 
the nonanucleotide motif possessed by PCV2 differs from those of PCV1 and BFDV in that 
the ‘T’ residue at the first nt position is changed to an A residue (Mankertz et al., 2000a).  
Investigations with geminiviruses have shown that the Rep protein cleaves the conserved 
nonanucleotide motif between the T and A at positions 7 and 8 of the motif (Hanley-Bowdoin 
et al., 1999) (Figure 2.2).  This nonanucleotide motif is considered to be the origin of viral 
plus-strand synthesis during RCR (Mankertz et al., 1998a; Meehan et al., 1997a).   
An additional feature of interest in connection with DNA replication is the occurrence in PCV1 
and PCV2 of three repetitions of a six nucleotide motif (CGGCAG) immediately adjacent to 
the potential stem loop (Mankertz et al., 2000a) and the occurrence of two repetitions of an 
eight nucleotide motif (GGGGCACC) adjacent to the potential stem loop of BFDV (Niagro et 
al., 1998).  On the basis of similarities observed with the geminivirus, tomato golden mosaic   28
virus (TGMV), Mankertz et al. (2000a) speculated that these short repeats may be the binding 
sites for the circovirus Rep protein.   
Although it is very probable that PCV and BFDV replicate their DNA by the RCR mechanism, 
the situation with CAV is less clear.  No CAV protein shares any obvious homology with Rep 
proteins specified by the other animal and plant circular ss DNA viruses, but the 50 kDa 
capsid protein of CAV contains the three peptide motifs found in proteins involved in RCR 
(Ilyina and Koonin, 1992).  CAV, however, unlike the other animal circoviruses, plant 
nanoviruses and geminiviruses, does not contain the GKS box or P-loop capable of binding 
dinucleotide triphosphates (dNTPs) (Desbiez et al., 1995).  Niagro et al. (1998) have 
suggested that CAV DNA replication probably depends on a host cell topoisomerase or 
helicase to provide local bending and/or unwinding functions.  CAV also differs from PCV and 
BFDV with regard to the nonanucleotide motif where the initiation step of RCR takes place.  In 
CAV, the nonanucleotide 
 
 
 
 
 
 
 
 
Figure 2.2.  (a) Sequence of the hairpin loop structure present in the PCV genome, containing the 
nonanucleotide motif.  (b) Alignment of the nonanucleotide motifs of BFDV, PCV, CFDV, SCSV, BBTV-
Taiwanese isolate, BBTV-Australian isolate, Geminivirus subgroups I, II and III and CAV.  From (Bassami et 
al., 1998). 
 
motif is semi-conserved and is located some 100 nt downstream of a distinctive G:C-rich 
inverted repeat sequence, which occurs close to the termination of the C1 ORF (Bassami et 
al., 1998; Claessens et al., 1991).  The CAV nonamer is not positioned at the apex of a 
potential stem loop and there is doubt, therefore, whether this sequence represents the 
cleavage site.  An attempt to identify the cleavage site where CAV RCR is initiated, using an 
approach employed successfully for geminiviruses (Stenger et al., 1991) and involving use of 
tandemly cloned chimeric RF fragments, was unsuccessful (Todd et al., 1996).   
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Several similarities can be seen between the genus Circovirus whose members are all 
present in vertebrates and the families Geminiviridae and Nanoviridae present in plants.  In 
the circoviruses: (1) the genome consists of only one molecule, whereas the other viruses 
contain one or more small, single-stranded, circular DNA molecules; (2) because of the small 
genome size, their viral life cycle relies extensively on host factors; (3) the origin of replication 
shows a characteristic stem loop structure with a conserved nonamer motif at the apex and a 
Rep binding site; (4) the Rep proteins belong to a family of enzymes initiating replication in 
the rolling circle mode (Ilyina and Koonin, 1992; Koonin and Ilyina, 1993) and contain three 
conserved amino acid motifs and a P-loop for dNTP binding.   
Although unsubstantiated, it has been proposed that circoviruses evolved by recombination 
between a nanovirus and an RNA virus such as a calicivirus (Gibbs and Weiller, 1999).   
According to phylogenetic analyses, PCV may represent a link between mammalian and plant 
viruses (Mankertz et al., 1997; Meehan et al., 1997a).   
Diseases associated with PCV 
Post-weaning multisystemic wasting syndrome 
Post-weaning multisystemic wasting syndrome was first recognised in 1991 (Ellis et al., 1998; 
Harding, 1997) and to date, cases in North America have been confirmed in the western 
provinces of Canada and Quebec, as well as in California, Indiana and Iowa (Harding, 1997).  
A similar disease has been described in Europe, including Ireland and Spain (Harding, 1997).  
The syndrome has been commonly associated with PCV2 (Allan and Ellis, 2000; Choi and 
Chae, 1999; Choi and Chae, 2000; Choi, Chae, and Clark, 2000; Kim and Chae, 2002; Kim 
and Chae, 2003).   
PMWS is associated with significant nursery and grow-finish mortality, characterised clinically 
by illthrift, dyspnoea, rough hair coat, pallor, jaundice, diarrhoea, and less frequently, by 
coughing and central nervous system disturbances (Harding and Clark, 1998).  Major clinical 
signs are weight loss, tachypnoea, dyspnoea, enlarged lymph nodes and jaundice.  Less 
common signs are diarrhoea, productive coughing and central nervous system disturbances 
(Harding and Clark, 1998).  Morbidity is usually low, but the case fatality rate may be high.   
Post-mortem examination of PMWS-affected pigs usually reveals skin pallor and muscle 
wasting, with lymph nodes three to four times normal size (Clark, 1997).  The lungs are 
rubbery and non-collapsed, the spleen is moderately enlarged, and the liver may be mottled 
or atrophic (Clark, 1997).  Gross and histopathological lesions may be found in virtually all 
tissues, but are most common in the lungs, liver, kidneys and lymph nodes (Harding and 
Clark, 1998).  The most common lesions are interstitial pneumonia and lymphadenopathy, 
and occasionally nephritis and hepatitis (Hamel, Lin, and Nayar, 1998).  Histologically, the 
disease is characterised by widespread granulomatous inflammation, multinucleated giant 
cells, and variable numbers of intracytoplasmic basophilic viral inclusion bodies within 
infiltrating histiocytes and macrophages. The intensely basophilic-staining inclusion bodies   30
are detected mostly in lymph nodes, tonsils and Peyer’s patches of the ileum (Choi and Chae, 
1999; Choi, Chae, and Clark, 2000; Hamel, Lin, and Nayar, 1998; Kim and Chae, 2002; Kim 
and Chae, 2003; Kiupel et al., 1998; Krakowka et al., 2000).  Features of the histopathological 
lesions suggest that monocyte/macrophage infiltration may be closely related to the 
pathogenesis and progression of PMWS.  However, there is little information regarding the 
factors that initiate and regulate the recruitment of monocytes to the granulomatous lesions 
seen in PMWS (Kim and Chae, 2003).   
Pigs with PMWS are generally affected two to three weeks post-weaning but signs may occur 
at other ages when pigs are subjected to stressors (Harding, 1997).  The morbidity rate 
associated with PMWS is usually low, but the case fatality rate is high.  In rare instances, the 
post weaning mortality rate due to PMWS has been very high (>50%) suggesting that the 
severity of PMWS in a population is affected by factors that may be more prevalent in some 
herds than in others.  It has been commonly observed that PMWS-affected pigs are spread 
diffusely in a population rather than being concentrated in specific pens or groups, and it is 
not uncommon for severely affected and unaffected pigs to co-exist in the same pen (Harding, 
1997).  This implies that there are as yet unknown reasons why individual pigs develop 
disease when larger numbers are probably exposed (Harding, 1997).   
Although PMWS was not reported as a disease syndrome until 1997 in Canada (Clark, 1997; 
Harding and Clark, 1998), retrospective data indicated that the disease may have been 
present as early as 1991 (Clark, 1997).  This was supported by a retrospective Japanese 
study of tissues from diseased pigs, collected from 1985 to 1999, in which lesions suggestive 
of PMWS were detected from 1990 onwards (Sato et al., 2000).  The lesions the Japanese 
group detected were typical of PMWS.  Histopathological lesions were found mainly in the 
lymphoid organs, and included lymphocellular depletion and apoptosis, with replacement by 
multinucleate giant cells (Sato et al., 2000).  Granulomatous inflammation was present in 
some cases.  Spherical inclusion bodies were present in macrophages and also occasionally 
in giant cells (Sato et al., 2000).  Similar changes were noted in the spleen, tonsils and 
Peyer’s patches, but the changes in these organs were less severe (Sato et al., 2000).   
Cytoplasmic inclusions were also found in the lungs, liver and kidneys.  Macrophages and 
lymphocytes usually accumulated in the kidneys and liver, and hepatocytic necrosis was also 
present in a large percentage of cases (Sato et al., 2000).  Interstitial pneumonia was 
commonly found in the lungs.  PCV2 antigen was found mainly in cytoplasmic inclusions of 
macrophages, but also in lymphatic organs, small intestine, lungs, kidney and liver.   
Generally, disease was more severe in those animals where various tissues were affected, 
rather than just the tonsils and lymph nodes (Sato et al., 2000).   
In the initial searches for a cause of PMWS, the discovery of a PK15 PCV-like antigen and 
nucleic acid in tissues of pigs suffering from PMWS led to speculation of a new, pathogenic 
strain of PCV.  Meehan et al. (1998) found that PCV-like viruses isolated from PMWS-
affected pigs in Canada and Europe were over 96% similar when sequence homologies were   31
compared.  However, these viruses shared less than 80% identity at the nucleotide level with 
the PCV infecting PK15 cells (Hamel, Lin, and Nayar, 1998).  It was therefore concluded that 
there were two types of PCV and  Meehan et al. (1998)  proposed that the original PK15 cell 
culture isolate should be referred to as PCV1 and the genetically different strains isolated 
from pigs with PMWS should be referred to as PCV2.  It was subsequently shown that the V1 
ORF proteins of PCV1 and PCV2 were antigenically related, and showed high levels of 
serological cross-reactivity (Mahe et al., 2000).  This correlated with the high sequence 
conservation of V1 ORF between PCV1 and -2 and suggested conservation in the function of 
the Rep protein (Mahe et al., 2000).  Both PCV types have very similar stem-loop structures, 
essential for viral replication, and the amino acid sequence of the V1 ORF proteins of PCV1 
and PCV2 are 85% similar (Hamel, Lin, and Nayar, 1998).  The C1 ORF proteins from PCV1 
and PCV2 were, however, antigenically distinct, and exhibited very low levels of cross-
reactivity antigenically, which is consistent with their lower sequence identity (~56%) (Mahe et 
al., 2000).   
Numerous studies have now demonstrated that PCV2 is widespread in pig populations, and it 
has been associated with wasting disease in many countries including Spain, Denmark, 
Northern Ireland (Allan et al., 1999b), the Netherlands (Wellenberg et al., 2000), France 
(Rose et al., 2001), Japan (Onuki et al., 1999), Canada (Hamel, Lin, and Nayar, 1998) and 
the United Kingdom (Done et al., 2001).  Ouardani et al. (1999) used a multiplex PCR to 
detect PCV2 in 94.2% of suspected PMWS-affected pigs tested, and PCV2 has also been 
found in tissues of PMWS pigs using immunohistochemistry (Sorden et al., 1999).   
In contrast, while PCV1 has been detected in pigs with PMWS, it does not seem to be 
associated with PMWS directly.  While LeCann et al. (1997) found only a PCV1 infection in 
piglets in Brittany affected by a wasting disease with lesions similar to PMWS, Ouardani et al. 
(1999) reported that PMWS-affected pigs infected with PCV1 are usually co-infected with 
PCV2.  Co-infection may be important in the severity of the lesions detected; respiratory 
problems were more severe in herds co-infected with PCV2 and porcine reproductive and 
respiratory syndrome virus (PRRSV) (LeCann et al., 1997).   
Potential strain variation of PCV associated with PMWS 
Most publications and reports associating PCV2 with PMWS refer to PCV2 without reference 
to possible strain variation.  Strain variation in the pathogenicity of PCV and especially PCV2 
is a possible explanation, but not a certain explanation, for the variation in the occurrence and 
prevalence of PMWS in different herds, for regional variations in prevalence, and especially 
for country variations, eg. why PMWS may not occur in Australia even though PCV2 is 
present.   
Genetic change over time occurs in all viruses, due to mutation, recombination and 
reassortment, albeit at different rates.  The most common mutations involve single nucleotide 
substitutions known as point mutations, and sometimes deletions or insertions (White and 
Fenner, 1994).  The rate of mutation and therefore evolution is faster in the RNA viruses than   32
the DNA viruses, although some RNA viruses evolve at higher rates than others (Ngui, Hallet, 
and Teo, 1999).  Mutations in the RNA viruses are largely caused by errors in replication, due 
to the absence of a 3` to 5` exonuclease proofreading activity in the RNA polymerase (Ngui, 
Hallet, and Teo, 1999).  This lack of proofreading ability can lead to point substitutions, 
generating a large number of natural mutants from the original RNA virus (Ngui, Hallet, and 
Teo, 1999).  Retroviral reverse transcription enzymes, for example, are particularly error-
prone.  Human immunodeficiency virus type 1 (HIV-1) reverse transcriptase can introduce 
base-substitution errors translating to five to ten errors per HIV genome per round of 
replication (Preston, Poiesz, and Loeb, 1988).  Low fidelity of HIV-1 reverse transcriptase is 
suggested to be responsible, at least in part, for the hypermutability of the virus (Preston, 
Poiesz, and Loeb, 1988).  Selection forces, such as the immune response and the limited 
availability of appropriate target cells during transmission and persistence, can act on new 
viral variants and are likely to control the diversity and rate of evolution, and therefore 
sequence variation, of highly mutable viruses such as retroviruses (Overbaugh and Bangham, 
2001).  In contrast to the RNA viruses, DNA viruses such as the Circoviridae, are more stable 
and evolve more slowly, due to the proofreading ability of DNA polymerase (Ngui, Hallet, and 
Teo, 1999).  Replicative DNA polymerase proteins possess multiple proofreading 
mechanisms to prevent errors in replication (Perlow and Broyde, 2001), resulting in the lower 
mutability and therefore sequence variation of DNA viruses.   
When the sequences of PCV1 and PCV2 were compared, Hamel, Lin and Nayar (1998) 
found 65% similarity and Morozov et al. (1998) found 80% similarity.  It was suggested that 
the differences in amino acid sequences between these two strains may account for variation 
in pathogenicity (Hamel, Lin, and Nayar, 1998).  A recent study of CAV identified a single 
amino acid change as a determinant of pathogenicity, so therefore point mutations are 
capable of altering virus pathogenicity (Yamaguchi et al., 2001).  It has been suggested by  
Ellis et al. (1998  that point mutations may have occurred in PCV1, generating the pathogenic 
variant PCV2.  The available evidence indicates that a small number of point mutations and 
resultant substitutions of one or two amino acids in another small DNA virus, feline 
parvovirus, allowed a shift in host range from cats to dogs (Chang, Sgro, and Parrish, 1992; 
Ellis et al., 1998).  These mutations resulted in a virus that was highly pathogenic in dogs 
(Ellis et al., 1998).   
It seems as if strain variation is possible in PCV and that it might affect pathogenicity, and 
significant changes could be induced by single nucleotide mutations at significant regions of 
the genome, especially those motifs associated with replication.   
Aspects of the epidemiology of PCV associated with PMWS 
Serological tests are a basic tool in epidemiological studies and until recently serological tests 
that would differentiate antibody to PCV1 and PCV2 were unavailable.  The serological test 
used most commonly is an IIF test that does not discriminate between antibody to the two 
viruses (Allan et al., 1998b; Dulac and Afshar, 1989; Ellis et al., 1998; Tischer et al., 1995b;   33
Tischer et al., 1986).  More recently, type-specific serological tests have been developed that 
will differentiate between antibody to PCV1 and PCV2 (Allan et al., 1994a; Allan et al., 1999b; 
Nawagitgul  et al., 2002; Sala et al., 2000; Truong et al., 2001).  Consequently, in the 
remainder of this thesis, where tests used would not have been expected to differentiate 
antibody against the two types of PCV, the antibody will be referred to as “PCV” antibody to 
differentiate it from antibody specific to PCV1 or PCV2.   
As reported earlier in this Chapter, serological studies have indicated that PCV infection of 
pigs is ubiquitous throughout the world.  Serum antibodies to PCV have been demonstrated in 
pigs in Canada (Dulac and Afshar, 1989), Germany (Tischer et al., 1995b; Tischer et al., 
1982), the United Kingdom (Allan et al., 1994c; Edwards and Sands, 1994), and New Zealand 
(Horner, 1991).  Cottrell et al. (1999) reported that PCV antibody was widespread in eastern 
Canada, occurred in high health status specific-pathogen-free (SPF) herds, large fattening 
units, and small “back yard” herds.  Similar results were obtained in western Canada (Harding 
and Clark, 1998).   
There are reports of age-associated variations in prevalence.  In Germany, Tischer et al. 
(1986) found that up to 95% of pigs slaughtered contained antibody titres to PCV as high as 
those found two to six weeks after experimental infection of pigs, suggesting that continual 
infection and exposure of pigs with PCV probably occurred in grower units where animals 
were in close contact.  In contrast, another detailed study in Germany (Tischer et al., 1995b), 
reported a decrease in the percentage of PCV-seronegative pigs with increasing age of the 
pigs, from 65% in recently weaned pigs to 5.6% for older breeder pigs.  In a longitudinal study 
carried out in two litters of pigs in Northern Ireland, maternally-derived serum antibodies to 
PCV disappeared eight to nine weeks after birth and then antibodies reappeared 13-15 weeks 
after birth; the reappearance of antibody corresponded with possible re-infection associated 
with movement of pigs from the breeding unit to the grower unit within the farm (Allan et al., 
1994c).   
There is limited information available on the mode of excretion and transmission of PCV.  
Early studies were naturally focused on PCV1, and there have been no studies on the 
excretion of PCV1 or on the mode of transmission of infectious virus between pigs in 
naturally-infected animals.  In experimentally-infected seronegative day-old pigs, PCV1 was 
detected in faeces and nasal mucus 13 and 14 days p.i. (Tischer et al., 1986).  The isolation 
of a PCV-like virus from cases of CT and the reproduction of this condition by vertical 
transmission of the virus after experimental infection of pregnant sows (Choi et al., 2002) 
suggests the likelihood of vertical transmission of PCV1.  It was also reported by Allan et al. 
(1995) that PCV1 could be isolated from stillborn piglets, further supporting the likelihood of 
vertical transmission of this virus, although in the same study, a survey of foetal tissues from 
pigs with reproductive problems in Northern Ireland failed to detect any evidence of PCV1 
infection.     34
There is little information available on the route of transmission of PCV2.  After experimental 
infection of one-day-old gnotobiotic piglets with a cell culture isolate of PCV2, viral nucleic 
acid was detected in faeces, saliva, and eye swabs at 31 days post-inoculation; this was the 
only time point sampled in this experiment (Allan and Ellis, 2000; Krakowka et al., 2001).  As 
with PCV1, evidence of vertical transmission of PCV2 has also recently emerged; in western 
Canada there has been an association of PCV2 with abortions, PCV2 antigen was identified 
in lesions of aborted foetuses, and PCV2 was isolated from foetal tissues (West et al., 1999).   
Experimental reproduction of PMWS by inoculation of PCV2 
The study of the pathogenesis of PMWS has been frustrated by the inconsistency of clinical 
signs between and within infected herds, and the difficulty of inducing PMWS experimentally.  
Attempts to reproduce PMWS by experimental inoculation of PCV2 into piglets have been 
largely unsuccessful, with no clinical signs of disease recorded in most cases (Pogranichnyy 
et al., 2000).  Mild to moderate lesions typical of PMWS, such as lymphoid depletion (Allan et 
al., 1999a), mild pneumonia, lymphoid inflammation (Ellis et al., 1999; Magar et al., 2000), 
multinucleated giant cells (Magar et al., 2000) and mild nephritis and hepatitis (Ellis et al., 
1999) have been found in pigs inoculated with PCV2, but typical PMWS has not been 
reproduced by inoculation with PCV2 alone.  Pigs inoculated with tissue homogenates from 
PMWS-affected pigs have also failed to develop major clinical signs of the disease, and only 
slight lymphocyte depletion (Balasch et al., 1999), nephritis, hepatitis, pneumonia and 
myocarditis (Ellis et al., 1999) were detected.  PCV2 has been widely detected in clinically 
normal pigs (Done et al., 2001), and antibodies have been detected on farms with no history 
of PMWS (Larochelle et al., 1999b; Rodriguez-Arrioja et al., 2000), so it seems that another 
factor must be involved in disease development.  Factors suggested have included 
concurrent infections with other organisms and immune activation (Segales and Domingo, 
2002).   
Diagnosis of PMWS 
Definitive diagnosis of PCV-associated diseases can be obtained only by demonstration of 
PCV nucleic acid and/or antigen associated with lesions.  Currently, no generally accepted 
“case definition” exists for PMWS but the presence of characteristic PCV2-containing lesions 
in one or more organ systems together with a history and typical clinical signs, are compatible 
with a diagnosis of PMWS (Harding, 1997; Harding and Clark, 1998).   
The ongoing emergence of a number of clinical conditions and syndromes in pigs that have 
now been associated with PCV2 infection, in conjunction with the possibility that previously 
diagnosed cases of PRRS may, in fact, involve co-infection with PCV2 (Ellis et al., 1999) 
suggests that, when possible, PCV2 infection should be considered in a variety of porcine 
diseases, regardless of the presumptive diagnosis arising from clinical examinations.   
The detection of antibody is of limited value for diagnosis and various studies have suggested 
that detection of serum antibody to PCV1 or PCV2 in pigs does not appear, in itself, to be   35
indicative of an existing or potential disease problem.  Antibody prevalence rates can also be 
high in herds without evidence of PMWS (André Jestin, personal communication).  The 
demonstration of serum antibody to PCV1 or PCV2 in pigs can be achieved by an IIF test 
(Allan et al., 1998b; Ellis et al., 1998) but care must be taken in interpretation of the results of 
these tests because antigenic cross-reactivity between PCV1 and PCV2 isolates has been 
demonstrated (Allan et al., 1998b).  Allan et al. (1998b) recommended testing sera at 1/10, 
1/100 and 1/1000 dilutions to facilitate interpretation of results.  A PCV2-specific serological 
test is required and a PCV2 specific antibody-detection ELISA was investigated by utilising 
recombinant proteins, purified virus or synthetic peptides by a number of researchers with 
varying degrees of success (Blanchard et al., 2003b; Nawagitgul et al., 2002; Sala et al., 
2000; Truong et al., 2001; Walker et al., 2000).   
Immunostaining for the detection of PCV protein in tissues, especially in association with 
lesions, is also possible.  PCV1- and PCV2-specific MAbs have been produced (Allan et al., 
1994a; Allan et al., 1999b), and used for immunostaining of acetone-fixed tissue impression 
smears, cryostat sections, formalin-fixed paraffin-embedded tissues, or inoculated cell 
cultures (Allan et al., 1994a).  Immunostaining and ISH assays have been described for 
detection of PCV in tissues from field cases of wasting disease (Choi and Chae, 1999; Ellis et 
al., 1998; Kiupel et al., 1998; Morozov et al., 1998; Rosell et al., 1999) and reproductive 
disorders (West et al., 1999).   
The detection of PCV genetic material in tissue is critical for the detection of PCV1 and PCV2 
as, although they can be cultured in vitro they are non-cytopathic in culture (Allan and Ellis, 
2000).  The two most common techniques used are PCR and ISH.  Differential PCR tests 
have been described for the detection of PCV1 and PCV2 and the diagnosis of PCV-related 
diseases (Allan et al., 1999b; Hamel, Lin, and Nayar, 1998; Larochelle et al., 1999b; Nayar, 
Hamel, and Lin, 1997).  However, the use of this test for diagnosis of PCV-related diseases 
can be problematic as while the unique sensitivity of the PCR is ideal for the detection of 
minimal amounts of viral nucleic acid in tissue samples, this unique sensitivity can, in itself, be 
an inherent problem as PCV1 appears to be endemic in pig populations throughout the world, 
and PCV2 infection of pigs can occur without progression to disease.  The possibility also 
exists that PCV may integrate into the host genome (Tischer, Peters, and Pociuli, 1995) 
although this has not been verified.  Although great care can be taken in laboratories 
dedicated to PCR diagnostics to avoid cross contamination, the possibility of contamination of 
tissue samples with PCV at necropsy on farms or in post-mortem facilities is more difficult to 
control.  Under these circumstances, the demonstration of a PCV PCR product from tissues 
from diseased pigs does not necessarily equate with a PCV-related disease.  The emergence 
and application of quantitative PCR technology to diagnostics may, in the future, go some 
way to alleviating the problems outlined above with the application of current diagnostic PCR 
to endemic agents.     36
A comparison of ISH and immunocytochemistry techniques for the detection of PCV2 in 
formalin-fixed paraffin-embedded tissues from experimentally infected pigs and PMWS-
affected pigs has shown immunocytochemistry to be more sensitive than ISH (McNeilly et al., 
1999).  The hybridisation probes used by McNeilly et al. (1999) were based on the genome of 
PCV1 and in view of the significant genomic differences now known to exist between PCV1 
and PCV2 isolates, probes for detection of PCV2 should be designed based on the specific 
sequence of this virus type.  Three to four times greater sensitivity of ISH for the detection of 
PCV2 nucleic acid has been demonstrated with an antisense strand probe when compared 
with a sense strand probe (Morozov et al., 1998).   
Concurrent infections and PMWS 
It has been suggested that co-pathogens (or co-factors) may be required for the development 
of PMWS, accounting for the difficulty of reproducing the disease using PCV2 alone.  There 
are several indications that this is true, one of which is the absence of PMWS in Australia 
although there is evidence of widespread PCV2 infection of pigs (Ross Buddle, personal 
communication).  Co-infection of pigs with PCV2 and porcine parvovirus (PPV) was shown to 
produce more severe clinical signs of PMWS, such as depression, anorexia, icterus and liver 
disease, than either agent alone (Krakowka et al., 2000).  PPV alone is not considered a 
major pathogen in the age of pigs affected by PMWS, so it is suggested that either temporary 
PPV infection of macrophages could promote higher levels of PCV2 replication, or perhaps 
that PPV is immunosuppressive, allowing the spread of PCV2 throughout the body (Krakowka 
et al., 2000).  Allan et al. (1999a) inoculated pigs with PCV2 and PPV, producing severe, 
sometimes fatal disease, with lesions in the liver, lymph nodes and kidneys.  However, only a 
small percentage of PMWS cases are naturally co-infected with PPV (Ellis et al., 2000), 
therefore co-infection with PCV2 and PPV is not the only way to produce PMWS.   
Not surprisingly, mixed infections in pigs are common.  Sato et al. (2000) found various mixed 
infections in tissue samples from diseased pigs suspected of having PMWS; of those animals 
with PCV2, over 90% were also infected with another pathogen.  These included bacteria, 
such as Pasteurella multocida, but the most common co-infection was with PRRSV, which 
was present in over 50% of pigs with PCV2.   
PRRS has also been suspected to play a role in conjunction with PCV2, at least in some 
cases, and to be difficult to distinguish from PMWS.  PRRS was recognised in the USA in 
1987 as causing late-term reproductive failure and severe pneumonia in neonatal pigs 
(Rossow, 1998).  PRRSV is an enveloped, single-stranded RNA virus, not present in 
Australia.  The virus is classified in the Arteriviridae family, in the genus Arterivirus (Rossow, 
1998).  After infection, the virus replicates in the regional macrophages, followed by a 
prolonged period of viraemia and systemic distribution of virus to other macrophage 
populations (Rossow, 1998).  Macrophages are the only cell type known to support PRRSV 
replication (Rossow, 1998).  Pneumonia caused by PRRSV is generally more severe in young 
pigs, and may be complicated by single or multiple concurrent bacterial infections (Rossow,   37
1998).  With clinical signs such as ill-thrift, dyspnoea, tachypnoea, anorexia, lethargy, 
pneumonia and rough hair coat, and gross lesions such as lung consolidation and enlarged 
lymph nodes (Rossow, 1998), PRRS can be difficult to differentiate clinically from PMWS.  
Hamel et al. (2000) found PCV2 in 55% of pigs with respiratory signs and lesions similar to 
PRRS.   
Immune activation as a factor in the pathogenesis of PMWS 
Krakowka  et al. (2001) suggested that activation of the immune system during the early 
phase of PCV infection allows the rapid replication and distribution of PCV2, producing 
wasting disease.  These authors injected piglets with keyhole limpet haemocyanin (KLH) in 
incomplete Freund’s adjuvant (ICFA).  The non-infectious irrelevant immunogen (KLH) 
combined with a strong adjuvant, a substance that non-specifically enhances the immune 
response to an antigen, stimulated the immune system, activating macrophages and other 
immune cells (Krakowka et al., 2001).  The injected adjuvant induced new DNA synthesis, 
mitosis, and proliferation of histiocytes and macrophages, which seemed to provide the 
optimal conditions for PCV2 replication and dissemination in vivo (Krakowka et al., 2001).  
Since PCV2 can replicate in macrophages, the immunoproliferation induced by ICFA and 
KLH was thought to lead to heightened PCV2 replication and therefore greater PCV2 virion 
production (Krakowka et al., 2001).  Krakowka et al. (2001) produced moderate to severe 
PMWS in piglets by injecting them with KLH and ICFA, and then infecting them with PCV2.  
Due to the resulting enhanced or prolonged virion production, PCV2 spread to other tissues, 
producing PMWS (Krakowka et al., 2001).  An increase in PCV2 replication, due to 
macrophage activation, was therefore proposed to be essential for the development of PCV2 
mediated PMWS (Krakowka et al., 2001).  The most severe lesion produced in piglets 
inoculated with the adjuvant and PCV2 was liver damage.  All piglets in this group suffered 
liver cell damage and loss, with missing hepatocytes replaced by macrophages.  These 
macrophages contained PCV2 viral inclusion bodies, which were also found in the lymph 
nodes (Krakowka et al., 2001).  Piglets inoculated with PCV2 alone developed no clinical 
signs of disease (Krakowka et al., 2001).   
It is unclear which secondary agent or agents could activate the pig’s immune systems in the 
field; PRRSV and PPV have been suggested as possible candidates, but PMWS can affect 
herds free of both these pathogens (Segales et al., 2001).  In herds naturally infected with 
PMWS, the primary organ system that is affected and the mortality rate varies within and 
between infected herds (Krakowka et al., 2001).  It has been suggested that if other infectious 
agents such as PRRSV and PPV are involved, they may combine with PCV2 to determine the 
major organ system affected (Krakowka et al., 2001).  For example, pigs co-infected with 
PCV2 and PRRSV may have more severe lung lesions (Krakowka et al., 2001).   
Recently, it was proposed that enhanced pathogenicity of PCV2 may result from an 
overwhelming challenge to a pig’s immune system after early weaning.  The growing use of a 
variety of vaccines administered to young pigs is hypothesised to present such a powerful   38
antigenic challenge that the young pig’s immune system is overwhelmed (Segales and 
Domingo, 2002).  To test this theory, these authors withdrew a Mycoplasma hyopneumoniae 
vaccination program from about half the piglets born on a farm over a four month period.  In 
the non-vaccinated animals, losses due to PMWS were significantly reduced in four out of the 
five groups studied (Segales and Domingo, 2002).   
Porcine dermatitis and nephropathy syndrome 
Although first described in 1976, another swine disease to recently increase in prevalence is 
porcine dermatitis and nephropathy syndrome (PDNS).  PDNS-affected pigs, which are 
usually 12-14 weeks old, develop dark skin lesions, especially on the hindquarters, and are 
pale, dull, depressed and reluctant to move (Done et al., 2001).  Lymph node inflammation 
and kidney dysfunction are common (Done et al., 2001).  In acutely affected pigs, mortality 
may approach 80% (Done et al., 2001).   
PCV2 nucleic acid has recently been discovered in tissues of pigs suffering from PDNS 
(Rosell et al., 2000).  Since PCV2 replicates in macrophage cells (Krakowka et al., 2001), and 
both PMWS and PDNS pigs display similar lesions such as inflamed lymph nodes, it has 
been suggested that the two diseases are different manifestations of the same pathogenic 
factors (Done et al., 2000).  PMWS and PDNS may occur separately, together or following 
each other.   
Congenital tremor 
Congenital tremor (CT) is a condition associated with deficient and abnormal myelination 
(Stevenson et al., 2001).  Piglets affected by congenital tremor suffer from clonic contractions 
of their skeletal muscles, sometimes resulting in a fatal inability to suck (Stevenson et al., 
2001).   
There are various types of CT with various causes.  One type (type A2) has been associated 
with PCV1 and PCV2 (Choi et al., 2000; Choi et al., 2002; Kennedy et al., 2003; Stevenson et 
al., 2001) but the reports have been contradictory.  Stevenson et al. (2001) reported that 
PCV2 was found in young pigs with CT, and postulated that CT type A2 was possibly due to 
PCV2 infection of spinal cord motor neurons, affecting their function and making them more 
excitable (Stevenson et al., 2001).  Kennedy et al. (2003) were unable to find any association 
between PCV and CT.  They investigated the presence of PCV1 and PCV2 in the central 
nervous system and non-neural tissues of 40 CT piglets from Spain, the United Kingdom, 
Ireland, and Sweden using ISH and immunohistochemical labelling on paraffin sections.  A 
PCR for PCV2 was also carried out on sera from the Spanish CT cases.  No evidence of 
circovirus nucleic acid or antigen was found in any CT piglet.   
It is unclear whether there might be unique strains of PCV associated with CT, or if the PCV 
associated with CT might be of multiple types.  Sequence analysis of PCV2 detected in CT-
affected pigs showed over 96% sequence identity with previously sequenced PCV2 isolates    39
(Choi et al., 2002) but one isolate originating from the 1960’s from a neonatal pig with CT type 
A2 showed 98% identity to PCV1 sequences and only 72% identity to PCV2 sequences (Choi 
et al., 2002).  Further analysis of PCV strains associated with CT would seem to be essential 
to clarify the possible diversity of genotypes involved, and consequently develop a hypothesis 
regarding the possible role of PCV in the pathogenesis of the disease.   
Current taxonomic situation of circoviruses  
The major change involving circoviruses in the current seventh ICTV Report (Todd et al., 
2000) was the removal of the so-called ‘plant circoviruses’ from the family Circoviridae and 
their assignment to the newly established plant Nanovirus genus.  The pigeon circovirus was 
introduced as a tentative member of the family Circoviridae.   
More recent research findings since the seventh ICTV Report have led to moves for further 
taxonomic changes.  The strategies of genome expression and replication employed by CAV 
differ significantly from those employed by PCV and BFDV.  These differences and those 
related to virion size and morphology prompted a new taxonomic proposal that was 
considered and accepted by the ICTV at the International Congress of Virology, Sydney, 
1999.  This proposal established a second genus within the family Circoviridae (Pringle, 
1999a).  As a consequence, the originally-established Circovirus genus now contains PCV 
and BFDV, with PCV being regarded as the type species, and the new genus, Gyrovirus, 
contains CAV as the only and proposed type species.  Although past taxonomic practice 
would have dictated that CAV, as the original type species, should have remained within the 
circovirus genus and that PCV and BFDV should have been assigned to a new genus, the 
proposal was accepted on the basis of its forward-looking and strategic nature (Todd et al., 
2001a).  Thus if the numbers of viruses assigned to the proposed Gyrovirus and Circovirus 
genera were to increase substantially and demarcation criteria, by which the genera are 
separated, are considered sufficient, it is possible that viruses comprising the two genera 
would eventually be separated at the family level.  The proposal avoided a future scenario in 
which viruses such as PCV and PiCV, which bear the circovirus name, are classified in a 
virus family bearing a different name, such as gyrovirus (Todd et al., 2001a).   
The Circovirus Study Group established to prepare the eighth ICTV Report will have to 
address the classification of a number of viruses that have recently been described as 
circoviruses or circovirus-like viruses.  In this connection, molecular evidence must be 
obtained to determine whether the tentatively assigned PiCV (Woods et al., 1994) and the so-
called ‘circovirus-like’ viruses from geese (Soike, Kohler, and Albrecht, 1999) and a southern 
black-backed gull (Todd et al., 2001a) all of which produce similar histopathology and appear 
to be 12-20 nm in diameter, resemble PCV and BFDV.  In addition, the taxonomic position of 
the TT virus (TTV) will also have to be considered.  This virus was first recognised using 
representational differential analysis from a Japanese patient (initials T.T.) with post 
transfusion hepatitis (Nishizawa et al., 1997).  PCR techniques have shown that the TTV 
genome is a circular ss DNA (3852 nt) and filtration studies have indicated that virus particles   40
are between 30-50 nm, findings that prompted speculation that TTV may be the first human 
circovirus (Miyata et al., 1999) or indeed the first new member of a new virus family for which 
the name Circinoviridae was proposed (Mushahwar et al., 1999).  DNA sequence analysis 
has revealed that there is no substantial homology between TTV and the three existing 
circoviruses.  However, the genome organisation of TTV is broadly similar to that of CAV 
(Miyata et al., 1999; Mushahwar et al., 1999).  Interestingly, sequence studies performed with 
PCR-amplified DNA have indicated that TTV can be subdivided into a number of genotypes 
(Nishizawa et al., 1999) and PCR-based studies have also suggested the presence of TTV-
like viruses in a variety of animal species including cattle, sheep, pigs and chickens (Leary et 
al., 1999).  While TTV would appear to meet existing criteria concerning genome type for 
classification as circoviruses, their long-term taxonomic position is uncertain.   
Similarities between some animal circoviruses and the plant nanoviruses such as SCSV, 
BBTV and CFDV have been identified in a number of studies (Mankertz et al., 1997; Meehan 
et al., 1997a; Niagro et al., 1998) and referred to previously.  On the basis of similarities 
between these plant and animal viruses, and bacterial replicons such as ϕX174 (Heidekamp, 
Baas, and Jansz, 1982) and pC194 (Michel and Ehrlich, 1986), Meehan et al. (1997a) 
speculated that PCV may possibly be the most ancient mammalian replicon.  Recent 
research involving protein sequence comparisons suggests that the animal circoviruses 
typified by PCV and BFDV may have originated when plant nanovirus DNA was transferred to 
a vertebrate (Gibbs and Weiller, 1999).  Niagro et al. (1998) alluded to this possibility when 
they pointed out that the geographic distributions of BFDV and plant nanoviruses such as 
BBTV, CFDV, and SCSV viruses were similar.  These animal circoviruses are of additional 
interest from a molecular evolutionary standpoint in that Gibbs and Weiller (1999) provided 
evidence that, once within the vertebrate host, a recombination event occurred in which DNA 
sequence specifying part of the nanovirus Rep protein combined with DNA sequence which 
specified part of the 2C protein derived from a calici-like virus.  In this way the dNTP binding 
motif present in the C-terminal region of the BFDV and PCV Rep proteins was derived 
differently from that possessed by the plant nanoviruses (Gibbs and Weiller, 1999).   
The origin of CAV would appear to be different.  The transcription strategy of CAV, which 
involves the use of a polycistronic transcript, differs from those of all other eukaryotic viruses.  
It does, however, resemble that of DNA bacteriophages with circular ss DNA genomes, 
typified by ϕX174, which uses a polycistronic messenger RNA encoding nine overlapping 
ORFs (Todd et al., 2001a).  In addition, the 50 kDa CAV capsid protein, with which replicase 
activity is associated, lacks the dNTP binding motif (P-loop), that is postulated to contribute to 
the topoisomerase or helicase activity, and in this respect it resembles the gene A replicase 
protein of bacteriophage ϕX174.  Thus, CAV may be more closely related to prokaryotic 
replicons than the other animal circoviruses.     41
PCV in Australia 
At the time of commencement of the studies reported in this thesis, there was no information 
on the occurrence and prevalence of PCV in Australia.  Then and now, no cases or outbreaks 
of PMWS have been reported in Australia, although there was one recent report of PDNS 
(Cameron, 1995) and CT has been present for decades (Ross Buddle, personal 
communication).  The technology for the detection of PCV was not available and this 
necessitated, for the first time in Australia, the development of methods for the detection of 
PCV in tissues, and for the detection of antibody and especially type-specific PCV antibody.  
This technology and its application to epidemiological and pathogenicity  studies of PCV 
infection in the Australian pig herd are reported in the remainder of this thesis.     42
 
Chapter 3.  Detection and initial characterisation of 
porcine circoviruses present in the Australian pig 
herd 
 
Summary 
This Chapter reports for the first time the detection of porcine circovirus virus (PCV) in the 
Australian pig herd.  PCV DNA was detected in the tissues of pigs from several Australian 
states using a multiplex polymerase chain reaction (PCR) assay, the primers for which were 
based on the sequence of PCV1 and PCV2 strains detected in North America and Europe.  
PCV type 1 or 2 was detected in 80 of 367 (21.7%) pigs tested.  In the 80 positives, both 
PCV1 and PCV2 were detected in 14 samples.  Virus was detected in pigs from all states 
from which samples were obtained: Western Australia, South Australia, New South Wales 
and Queensland.   
The complete genomes of 13 strains of Australian PCV were sequenced.  Analysis of the data 
indicated there was extremely high homology between the Australian strains of PCV1 and 
PCV2 and previously published sequences of PCV1 and PCV2 strains from North America 
and Europe.  There were no consistent differences between the genome of the Australian 
strains and strains in North America and Europe   
The widespread occurrence of PCV in the tissues of pigs was confirmed by a small scale 
serological study of the Western Australian pig herd using an immunofluorescence assay, 
which did not discriminate between antibody to PCV1 and PCV2.  This assay detected PCV 
antibody in 11 of 14 pig herds in Western Australia, with a prevalence in positive herds 
varying from 25 to 47%.     43
Introduction 
Postweaning multisystemic wasting syndrome was initially identified in 1991 in Saskatchewan 
(Canada) but not reported until several years later (Clark, 1997; Harding and Clark, 1998).  It 
was claimed to be reported worldwide in all regions except Oceania (Allan and Ellis, 2000), 
although serological evidence of PCV infection in New Zealand had been reported (Horner, 
1991).  There had been no reports of the occurrence of PMWS in Australia, and no reports of 
the detection of PCV in the Australian pig herd.  Observers and researchers had noted the 
strange coincidence of the occurrence of PMWS in different countries of the world, almost at 
the same time.   
Although PCV2 seems to be definitely associated with PMWS (Chapter 2) the emergence of 
the disease in the 1990’s when PCV2 had been present in swine herds since at least 1969 in 
Belgium (Segales and Domingo, 2002), 1973 in Northern Ireland (Walker et al., 2000) and 
1985 in Canada (Magar, Muller, and Larochelle, 2000) and Spain (Rodriguez-Arrioja et al., 
2003) suggests the relationship between PMWS and PCV2, if indeed there is a direct cause-
and-effect relationship, is complex.  Changes in pig breeding and husbandry have been 
evoked as possible reasons of the emergence of this disease (Segales and Domingo, 2002) 
but outbreaks of PMWS have also occurred in totally confined farms where no living pigs had 
been introduced for 2 or more years and where high biosecurity measures were applied.   
Although PMWS has never been reported in Australia, the pig industry has been concerned 
about the lack of information regarding the occurrence, prevalence and types of PCV present, 
and the lack of available technology in Australia for the detection of PCV.  In this Chapter, the 
development of PCR-based techniques for the detection of PCV, the detection of PCV 
antibody using an immunofluorescence assay, and the use of these techniques to provide 
preliminary information of the occurrence of PCV in the Australian pig herd are described.  To 
enable comparison of Australian strains of PCV with those detected elsewhere, sequence 
analysis of the PCV detected was undertaken and is also reported.   
Materials and methods 
Control DNA templates 
Standard positive controls for PCR assays for the detection of PCV1 and PCV2 were 
prepared.  For PCV1, DNA was extracted from PK15 cells (ATCC-CCL31) which are 
persistently infected with PCV1, using a QIAamp Blood Kit (Qiagen) following the ‘Blood and 
Body Fluid’ protocol as recommended by the manufacturer.  For PCV2, spleen tissue from a 
single animal (designated 00/194) that was shown to be positive for PCV2 and negative for 
PCV1, using the primers described below, was used as a source of PCV2 DNA for all PCR 
assays; the DNA was extracted with a QIAamp DNeasy Tissue Kit (Qiagen).  Subsequent 
sequence analysis of this PCV2 DNA showed it to have 98% identity to the nucleic acid 
sequence of overseas strains of PCV2.  Negative control template in PCR assays included   44
distilled water and DNA extracted from a PCV-free PK15 cell line (PK15A) kindly supplied by 
Mr Chris Morrissy (Australian Animal Health Laboratory, Geelong, Australia).   
A total of 375 field cases from Australia were tested by multiplex PCR assay to ascertain the 
presence and type of PCV in each case.  In some instances the samples had already been 
tested by an initial PCR unable to differentiate between PCV1 and PCV2.  The samples 
examined were collected by veterinary practitioners and submitted to Murdoch University for 
examination between January 1998 and January 2002.   
PCR primers 
Oligonucleotide primers were designed based upon the published sequences of the non-
pathogenic PCV1 (Mankertz et al., 1997; Meehan et al., 1998) using Primer Designer 
software (Education and Scientific Software, USA), but were subsequently found to also bind 
to the corresponding region of the V1 ORF in PCV2.  Three primers were then designed 
within the V1 ORF (Table 2.2, Chapter 2) of PCV1 and are shown in Table 3.1.  The primers 
were used in two different combinations: primers PCV3a and PCV3b were used to amplify a 
product approximately 480 bp in length, and primers PCV3a and PCV3c were used to amplify 
a product of 150 bp.  All primers were tested using the Amplify program (Engels, W. R.   
Amplify, Version 1.2, University of Wisconsin, USA, 1993) for possible primer-dimer formation 
and specificity for the target DNA sequence.  Predicted binding positions to the appropriate 
target genome, PCV1 or PCV2, are indicated in Table 3.1.   
For multiplex PCR detection of PCV1 and PCV2, two sets of primers were used as described 
by Larochelle et al. (1999a).  The first set of primers, CF8 and CR8 (Table 3.1), was designed 
to amplify a fragment of 263 bp from ORF C1 of PCV2.  The second set of primers, PF2 and 
PR2 (Table 3.1), was intended to amplify a 349 bp fragment from ORF V1 of PCV1.   
 
Table 3.1.  Sequence of oligonucleotide primers used in PCR assays. 
Primer name  Primer sequence (5’ → 3’)  bp position  Target genome 
PCV3a CGACCTGTCTACTGCTGTG  388-407  PCV1,  PCV2 
PCV3b TAATCCTCCGATAGAGAGC  853-872  PCV1,  PCV2 
PCV3c CTGTCTTCCAATCACGCTC  520-539  PCV1,  PCV2 
CF8 TAGGTTAGGGCTGTGGCCTT  1323-1342  PCV2 
CR8 CCGCACCTTCGGATATACTG  1567-1586  PCV2 
PF2 TTGCTGAGCCTAGCGACACC  597-616  PCV1 
PR2 TCCACTGCTTCAAATCGGCC  926-945  PCV1 
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Conventional PCR and thermal cycling conditions 
Conventional PCR assays, using either a combination of primers PCV3a and PCV3b or 
PCV3a and PCV3c, were performed in a total volume of 25 µL, comprising 0.8 units of 
AmpliTaq
® DNA polymerase (Perkin Elmer), PCR buffer (Perkin Elmer), 0.2 mM each dNTP, 
3.0 mM MgCl2, 35-50 ηg DNA template and 3 µM of each primer.  The reaction mix was 
made up to 25 µL with pure distilled water (Fisher Biotech).  The reactions were carried out 
on a GeneAmp
® PCR System 2400 thermal cycler (Applied Biosystems) with an initial 
denaturation step of 95°C for 7 min followed by 32 cycles of denaturing at 95°C for 45 s, 
annealing at 60°C for 1 min and extension at 72°C for 2 min.  The PCR was ended with a final 
extension step of 7 min at 72°C.  The amplified products were analysed by 1.5 % (w/v) 
agarose gel electrophoresis for 45 min at 90 V and subsequently stained with ethidium 
bromide.   
Multiplex PCR and thermal cycling conditions 
Reaction mixtures consisted of PCR Buffer (Perkin Elmer), 1.25 mM MgCl2, 0.2 mM each 
dNTP, 1.0 µM each primer (CF8, CR8, PF2 and PR2), 1.0 U AmpliTaq
® DNA Polymerase 
(Perkin Elmer) and 1 µL template DNA per 25 µL reaction.  Amplification of DNA was 
achieved with an initial denaturation step of 95°C for 5 min, followed by 35 cycles of 
denaturing at 95°C for 1 min, annealing at 65°C for 1 min and extension at 72°C for 1 min.  
The PCR was ended with a final extension step of 10 min at 72°C.  Amplified PCR products 
were analysed by 2% (w/v) agarose gel electrophoresis.   
Sample preparation 
Tissue samples were obtained from pigs from herds with any possible suggestion of 
excessive mortality rates in weaners or from weaners found dead in herds without such a 
history.  Typically, tissue samples submitted for testing were spleen and mesenteric lymph 
nodes.  In some cases lung, liver, kidney, bronchial lymph nodes and iliac lymph nodes were 
also submitted.  Tissues were sometimes supplied fresh and kept chilled on ice in refrigerated 
containers, were sometimes frozen, and sometimes submitted as formalin-fixed paraffin-
embedded blocks.  The total genomic DNA from approximately 5 mg of each tissue was 
extracted using a QIAamp DNeasy Tissue Kit (Qiagen).  Formalin-fixed paraffin-embedded 
blocks were first subjected to three washes of xylene in order to de-paraffinise the tissue 
blocks before DNA was extracted.   
For serological analysis, blood was collected in Vacutainer
® tubes (Becton Dickinson) and left 
overnight at room temperature to clot.  Sera was then collected and stored at -20°C until 
required.  In the initial serological survey blood was only collected from pigs 23-27 weeks of 
age, slaughtered at a local abattoir, from farrow-to-finish herds: the number of samples 
collected from each batch of pigs from individual farms was dependent upon the number of 
pigs from each farm being killed on the day of collection.  Farm number five, identified as 
positive in the initial serological survey, was chosen for further investigation.  Twenty samples   46
were collected from pigs of each of the following ages on the farm: 2, 4, 6, 8, 10 and 12 
weeks.  Sera was processed as described above and stored at -20
oC until required.   
Cell culture 
The PK15 cell line (ATCC-CCL31), persistently infected with PCV1, was passaged weekly for 
routine maintenance of the cell line.  Cultures were grown in 25 cm
2  tissue culture flasks at 
37
oC in 5-7% CO2-in-air atmosphere, with growth medium consisting of Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% (v/v) new-born calf serum (NBCS), 60 
µg/mL penicillin, 135 µg/mL streptomycin and 2.5 µg/mL amphotericin B.  To passage the 
cells, growth medium was aspirated and the cell monolayer washed briefly in PBS.  After 
removal of PBS, 0.5 mL ATV (NaCl 80 g/L, KCl 4 g/L, glucose 10 g/L, NaHCO3 6 g/L, trypsin 
[1:250 of a 5 g/L solution], EDTA 2 g/L, 1% phenol red 4 mL/L, and distilled water [dH2O] to 1 
L) was added and the cells left at 37
oC until the monolayer was detached from the flask.  The 
detached cells were suspended in an appropriate volume of DMEM and dispensed into sterile 
25 cm
2 or 75 cm
2 tissue culture flasks.   
The indirect immunofluorescence (IIF) assay was performed on acetone-fixed PK15 cells 
treated with glucosamine (Tischer et al., 1995a; Tischer et al., 1987).  Briefly, 25 cm
2 flasks of 
PK15 cells were trypsinised with ATV as detailed above and resuspended in 2 mL of DMEM; 
the cells were then centrifuged for 5 min at 1000 x g and the resultant supernatant aspirated.  
The cell pellet was resuspended in 1.5 mL of 300 mM, d-(+)-glucosamine-HCl (ICN,) in 
Hank's salt solution (ICN) for 45 min at 37
oC.  The cells were then centrifuged at 1000 x g for 
5 min, the supernatant aspirated and the pellet resuspended in 4.5 mL of DMEM.  Cells were 
seeded onto 12-well multi-test slides (ICN) at a seeding density of 1.45 x 10
6 cells/mL, and 
kept at 37
oC in an atmosphere of 5-7% CO2-in-air.  One day after seeding, DMEM 
maintenance medium containing 2% (v/v) NBCS, 2.5 µg/mL fungizone, 60 µg/mL penicillin 
and 135 µg/mL streptomycin was added and the cells were incubated for a further 24 h at 
37
oC.  Slides were washed in PBS and then fixed in ice-cold acetone for 30 min at -20
oC and 
could be stored at -20
oC for up to 2 months.   
Indirect immunofluorescence assay 
The procedure for the IIF assay was based upon that described by Tischer et al. (1987) and 
Tischer et al. (1995a).  Test sera were diluted 1:10 and 1:100 in PBS and each dilution added 
to fixed cells for 40 min at room temperature.  Slides were then washed twice for 15 min each 
time with PBS.  An optimal dilution (1:500 in PBS) of fluorescein-conjugated rabbit anti-swine 
IgG (ICN) was added in sufficient volume to cover the cells.  After a 45 min incubation in an 
atmosphere of 5-7% CO2 at 37
oC, the cells were again washed twice in PBS.  The stained 
cells were covered with a coverslip using buffered glycerol (glycerol: 1 x PBS at a ratio of 9:1) 
as a mountant, and then examined for specific fluorescence using a fluorescent microscope 
(Olympus BH-2).     47
Porcine serum from an animal on a farm identified by preliminary IIF tests as being PCV 
antibody-free was used as a negative control, and porcine serum from an animal on a farm 
identified by initial IIF tests as containing PCV antibodies was used as the positive control in 
these tests.   
Cloning of circovirus DNA 
The entire genome of field PCV1 isolates was amplified by PCR using two primer sets: primer 
set PF2 and PR2 (Table 3.1) and primer set PF2A and PR2A (Table 3.2).  Primers PF2 and 
PR2 were previously used in the multiplex PCR assay to amplify a 351 bp fragment of PCV1, 
while the complimentary primers, PF2A and PR2A, amplified the remainder of the genome, 
approximately 1400 bp.  Template DNA from the PCV1 positive field isolates was amplified by 
PCR using the described primer pairs.  Each reaction contained 0.5 U AmpliTaq
® DNA 
polymerase (Perkin Elmer), 2.0 mM MgCl2, 0.2 mM of each dNTP (Perkin Elmer), 1 µM each 
primer, 2 µL template DNA and ultra-pure water (Fisher Biotech) added to a final volume of 
25 µL with PCR buffer.  Cycling conditions for the PCR involved an initial denaturation step at 
95°C for 7 min followed by 35 cycles of denaturation at 95°C for 1 min, annealing at 65°C for 
1 min and extension at 72°C for 1 min.  The final extension step was carried out at 72°C for 
10 min.   
The entire genome of PCV2 isolates was amplified using 2 sets of primers: primer set 
PCV2Seq1F and PCV2Seq1R (Table 3.2); and primer set PCV2Seq1Fcomp and 
PCV2Seq1Rcomp (Table 3.2).  PCV2Seq1F and PCV2Seq1R amplified a fragment of 
approximately 1120 bp, whereas PCV2Seq1FComp and PCV2Seq1RComp amplified the 
remaining 690 bp of the genome.  For the two primer sets, reactions were performed using 
the Eppendorf TaqMaster
® system.  Each reaction contained 0.75 U Taq DNA polymerase 
(Eppendorf), PCR buffer (Eppendorf), TaqMaster additive (Eppendorf), 0.2 mM of each dNTP, 
0.5  µM each primer, 2 µL template DNA and ultra-pure water (Fisher Biotech) to a final 
volume of 25 µL.  The thermal cycling protocol used for the primer pair PCV2Seq1F and 
PCV2Seq1R involved an initial denaturation step for 5 min at 95°C, followed by 35 cycles of 
denaturation for 45 s at 95°C, 1 min of annealing at 53°C, 2 min of extension at 72°C, and a 
final extension step of 72°C for 7 min.  The thermal cycling protocol utilised with primers 
PCV2Seq1FComp and PCV2Seq1RComp was the same except that the annealing 
temperature was 56°C.     48
Table 3.2.  DNA sequence of oligonucleotide primers used to amplify PCV isolates for cloning into pCR
®2.1-
TOPO
®. 
Primer  Sequence (5’ → 3’)  Genome position (bp) 
PF2A  GGTGTCGCTAGGCTCAGCAA  597 - 616 
PR2A  GGCCGATTTGAAGCAGTGGA  926 - 945 
PCV2Seq1F  AGAAGTGCGCTGTAAGTAT  1749 - 1767 
PCV2Seq1R  TCCGTGTAACYATGTATGT  1080 - 1098 
PCV2Seq1FComp  ATACTTACAGCGCACTTGT  1749 - 1767 
PCV2Seq1RComp  ACATACATGGTTACACGGA  1080 - 1098 
 
Freshly amplified PCR products were cloned into the bacterial plasmid pCR
®2.1-TOPO
® 
facilitated by a topoisomerase reaction supplied in a TOPO TA Cloning
® kit, version M 
(Invitrogen), according to the manufacturers’ methods.  Plasmids were then transformed into 
chemically competent Top10F’ E. coli cells (F´ endA1 recA1 hsdR17 [rk
-, mk
+] supE44 thi-1 
gyrA96  relA1  φ80lacZ∆M15  ∆[lacZYA-argF]U169λ
-) by heat-shock.  Clones containing 
circovirus inserts were checked by restriction endonuclease digestion prior to plasmid 
purification using a Quantum Prep
® Plasmid Miniprep kit (BioRad) in accordance with the 
manufacturer’s instructions.   
Nucleic acid sequence determination 
Selected conventional or multiplex PCR fragments of the appropriate size for PCV1 or PCV2 
were subjected to sequence analysis using dideoxy chemistry.  Reactions were carried out 
using a Dye Terminator Ready Reaction Cycle Sequencing kit utilising AmpliTaq DNA 
polymerase FS (Perkin Elmer) on an Applied Biosystems ABI 373A automated DNA 
sequencer in accordance with the manufacturers’ instructions.  Initial sequencing reactions 
were carried out using the M13 forward and reverse primers of pCR
®2.1-TOPO
® (Invitrogen).  
The remaining sequence data were generated with a primer walking strategy.  Nucleic acid 
sequence data were assembled and edited using a combination of the Applied Biosystems 
373A Sequencer Data Analysis Program and SeqEd (version 1.0.3) software.   
The nucleotide sequences were analysed using a combination of the GCG sequence analysis 
software and the BLAST algorithm through the Australian National Genome Information 
Service (ANGIS) and the non-redundant nucleic acid sequence database at the National 
Centre for Biotechnology Information (NCBI).  All samples were amplified and cloned three 
times, and the nucleotide sequence of each PCV clone was determined in triplicate to obtain 
a consensus sequence.  Alignments were obtained by using the Prettyfit and Clustal 
programs, and dendrograms constructed by using the DNAdist, Protdist and Fitch programs, 
available on the ANGIS website.   49
Results 
Detection of PCV DNA in pig tissues by PCR 
PCR assays were performed on the extracted tissue DNA with the primer pairs 
PCV3a/PCV3b and PCV3a/PCV3c (Table 3.1), and amplified products of the predicted size 
were obtained in all cases (Figure 3.1).  Specificity for PCV DNA was extremely high and 
there was little evidence of primer dimer or spurious PCR products.  
PCV1 or PCV2 was detected in 80 of 367 (21.7%) pigs tested using the PCR techniques 
described above (Table 3.3).  In the 80 positives, both PCV1 and PCV2 were detected in 14 
samples.  These 14 samples represented 17.5% of the positive samples and 3.8% of the total 
samples tested.   
 
                                                    
        (a)                      (b) 
Figure 3.1.  Agarose gel showing PCR products from primers PCV3a/PCV3b (a) and PCV3a/PCV3c (b).  Lane 
1, 100 bp ladder (Invitrogen) molecular weight marker; lane 2, distilled water; lane 3, PCV positive control 
template; lane 4, negative control template DNA.  Molecular sizes are given in bp.   
 
These PCR assays, however, were unable to differentiate between PCV1 and PCV2 and as a 
result a multiplex PCR assay was used where a 349 bp product was indicative of amplified 
PCV1 DNA and a 263 bp product indicated amplified PCV2 DNA (Figure 3.2). The samples 
examined included formalin-fixed paraffin-embedded tissues from three pigs presenting 
symptoms typical of PMWS from Queensland.  Unspecified lymph node tissues were supplied 
from all three pigs, and a liver sample from one of the pigs.  Examination of haematoxylin and 
eosin stained sections of these tissues revealed cytoplasmic inclusions consistent with a 
circovirus infection in the lymph nodes of one pig (Dr Shane Raidal, personal communication).  
Multiplex PCR assay on the lymph nodes and the one liver sample did not result in detectable 
PCR products.   
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Figure 3.2.  Agarose gel showing products from multiplex PCR assay.  Lane 1, 100 bp ladder (Promega); lane 
2, negative control; lane 3, PCV2 positive control; lane 4, PCV1 positive control; lane 5, distilled water.   
 
 
Table 3.3.  Summary of the PCR results on tissues of all pigs submitted for determining the presence of PCV 
DNA. 
State Number  of 
farms 
sampled 
Number of 
farms with 
PCV 
Total 
number of 
pigs tested 
PCV1 
positive (%) 
PCV2 
positive (%) 
PCV1 & PCV2 
positive (%) 
WA  14  12  213  39 (18.3)  23 (10.8)  13 (6.1) 
SA  2  1  17  1 (5.9)  0 (0)  0 (0) 
NSW  7  5  108  6 (5.6)  2 (1.9)  1 (0.9) 
QLD  4  1  29  0 (0)  9 (31)  0 (0) 
Total  27  19  367  46 (12.5)  34 (9.3)  14 (3.8) 
 
Additional samples were obtained from an outbreak of CT type A2 in a WA pig herd.  Cases 
02/822 and 02/823 (Table 3.4) were two piglets from the CT-affected farm, and a number of 
tissue samples were sent from each of these piglets for testing the presence of circovirus 
DNA.  As this outbreak persisted, brain and spinal chord samples were submitted (02/992-
02/1006) for testing.  Both types of PCV were detected by multiplex PCR (Table 3.4). 
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Table 3.4.  Summary of the PCR results from pigs with CT type A2.   
Case No.  Brain  Spine  Spleen  Lung  Liver  Lymph node
1 
02/822  PCV1, PCV2  PCV2  PCV1, PCV2  PCV1, PCV2  PCV1, PCV2  PCV2 
02/823  PCV1, PCV2  PCV1, PCV2  PCV1, PCV2  PCV1, PCV2  PCV1  PCV1, PCV2 
02/992  -  PCV1  NT NT NT NT 
02/993  -  -  NT NT NT NT 
02/994  PCV1  PCV1  NT NT NT NT 
02/995  -  PCV1  NT NT NT NT 
02/996  PCV1  PCV1  NT NT NT NT 
02/997  PCV1  -  NT NT NT NT 
02/998  PCV1  -  NT NT NT NT 
02/999  -  PCV1  NT NT NT NT 
02/1000  PCV1  PCV1  NT NT NT NT 
02/1001  PCV1  -  NT NT NT NT 
02/1002  -  -  NT NT NT NT 
02/1003  -  -  NT NT NT NT 
02/1004  -  -  NT NT NT NT 
02/1005  -  -  NT NT NT NT 
02/1006  -  -  NT NT NT NT 
1The type of lymph node supplied was not specified. 
NT denotes that tissue samples were not supplied for testing. 
 
Immunofluorescence assay for PCV antibody 
The IIF assay was initially used to examine collected sera for the presence of antibodies to 
PCV.  The IIF assay conducted on samples collected from a local abattoir indicated the 
presence of antibodies in 11 of the 14 farms that were sampled (Table 3.5).  The percentage 
of positive samples from each farm ranged from 25.6-57.1% (Table 3.5), and the ages of the 
pigs from which the serum was collected ranged between 23 and 27 weeks of age.   
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Table 3.5.  IIF assay results indicating antibody-positive pigs detected in 14 farrow-to-finish pig herds in WA.   
Farm  Number of sows on farm  Number of sera tested  Percent antibody-positive sera 
1 20  6  0 
2 30  14  43 
3 45  15  47 
4 50  39  26 
5 60  12  25 
6 100  15  33 
7 100  14  57 
8 100  18  0 
9 110  21  38 
10 140  40  40 
11 470  14  0 
12 550  43  28 
13 1275  23  26 
14 2500  23  35 
Total   297  30 
 
On Farm 14, an age-associated prevalence study was conducted and antibody was detected 
in 50% of 2-week-old pigs, was not detected in pigs 4, 6 and 8 weeks of age but was detected 
in pigs at 10 and 12 weeks of age (Table 3.6).   
Sequence of Australian PCV strains 
The nucleotide sequence of three PCV1 and ten PCV2 isolates was determined.  The 
sequenced isolates were from New South Wales, Western Australia and Queensland.  Two of 
the PCV1 sequences were 1760 nt and a third was 1759 nt in length (Table 3.7).  Of the two 
sequences that were 1760 nt (00/154 and 02/015) it was observed that there was a single 
insertion of a ‘T’ residue at nt position 942.  The sequenced PCV2 strains were all 1768 nt in 
length.  The complete sequences of the three strains of PCV1 and 10 strains of PCV2 are 
shown in Figures 3.3 and Fig. 3.4, respectively.   
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Table 3.6.  Age-associated variations in the prevalence of PCV-antibody in pigs from Farm 14 (Table 3.5).   
Age of pigs(weeks)  Location on farm  Number sampled  Percent antibody-positive sera 
2 Farrow  shed  20  50 
4 Weaner  shed  20  0 
6 Weaner  shed  20  0 
8 Grower  shed  20  0 
10 Grower  shed  20  15 
12 Grower  shed  20  5 
 
When the PCV1 strains were compared to the PCV1 type sequence (GenBank Accession No. 
PCU49186) described by Meehan et al. (1997a) and a French strain of PCV1 (AF012107) 
from a pig with piglet wasting disease, all exhibited greater than 98% nucleotide identity and 
96% amino acid similarity (Table 3.8).  Similarly, the PCV2 sequences determined from the 
ten Australian isolates showed a high percentage identity and similarity to the originally 
published PCV2 sequence described by Hamel, Lin, and Nayar (1998) (Table 3.8).  A 
phylogenetic analysis of all Australian PCV1 strains, conducted through ANGIS, compared to 
all published PCV1 sequences is shown in Figure 3.5.  A similar phylogenetic analysis of the 
ten Australian strains and six different PCV2 isolates associated with PMWS from different 
countries is shown in Figure 3.6.   
Discussion 
Numerous differential PCR tests have been described for the detection of PCV1 and PCV2 
(Allan et al., 1999b; Hamel, Lin, and Nayar, 1998; Larochelle et al., 1999a; Larochelle et al., 
1999b; Nayar, Hamel, and Lin, 1997; Ouardani et al., 1999).  While the unique sensitivity of 
the PCR enables the detection of minimal amounts of viral nucleic acid in tissue samples, the 
unique sensitivity can be a problem.  One problem is that while higher viral loads might be 
expected in animals with disease, PCV seems to be endemic in pig populations throughout 
the world and PCV infection can occur without progression to disease (Todd et al., 2001a); in 
the absence of disease it is likely that the virus loads may be lower but the conventional PCR 
assays used did not differentiate high versus low loads, which might give some indication of 
the level of replication and likelihood of an association with disease.  A second potential 
problem is that PCV might integrate into the host genome (Tischer, Peters, and Pociuli, 
1995); if this was true, and integration has not been confirmed, PCR would detect both 
integrated and non-integrated virus.  Thirdly, although great care can be taken in laboratories 
dedicated to PCR diagnostics to avoid cross contamination, the possibility of contamination of 
tissue samples with PCV at necropsy on farms or in post-mortem facilities is difficult to    54
 
                       1         11        21        31        41         
consensus              ATGCCCAGCAAGAAAAGCGGCCCGCAACCCCATAAGAGGTGGGTGTTCAC 
AF012107               .....A............................................ 
PCU49186               .....A............................................ 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
                       51        61        71        81        91         
consensus              CCTTAATAATCCTTCCGAGGAGGAGAAAAACAAAATACGGGAGCTTCCAA 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
                       101       111       121       131       141        
consensus              TCTCCCTTTTTGATTATTTTGTTTGCGGAGAGGAAGGTTTGGAAGAGGGT 
AF012107               .........................T..C..................... 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .........................T..C..................... 
  
                       151       161       171       181       191        
consensus              AGAACTCCTCACCTCCAGGGGTTTGCGAATTTTGCTAAGAAGCAGACTTT 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
Figure 3.3.  Multiple nucleotide sequence alignment of 3 Australian strains of PCV1 in comparison to the 
original PCV1 type strain (PCU49186) (Meehan et al., 1997a) and a French field isolate of PCV1 (AF012107) 
[LeCann, P. Albina, E. Blanchard, P. Hutet, E. Arnauld, C. Jestin, A.  "Complete genomic sequence of porcine 
circovirus associated with 'dfp' (deperissement fatal du porcelet)" [Unpublished].  The alignment was 
generated and displayed by the PileUp program within ANGIS.  A consensus sequence was computed and 
has been shown in capital letters, dots indicate the identical nt in comparison to the consensus sequence.  
The numbers showing the position of nucleotides are not the actual position, as the alignment created gaps 
among nucleotides.   
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                       201       211       221       231       241        
consensus              TAACAAGGTGAAGTGGTATTTTGGTGCCCGCTGCCACATCGAGAAAGCGA 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 ...................C.............................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
                       251       261       271       281       291        
consensus              AAGGAACCGACCACCAGAATAAAGAATACTGCAGTAAAGAAGGCCACATA 
AF012107               .............G.................................... 
PCU49186               .............G.................................... 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
                       301       311       321       331       341        
consensus              CTTATCGAGTGTGGAGCTCCGCGGAACCAGGGGAAGCGCAGCGACCTGTC 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 .........................................T........ 
CTBEV                  .........................................T........ 
00/154                 .................................................. 
  
                       351       361       371       381       391        
consensus              TACTGCTGTGAGTACCCTTTTGGAGACGGGGTCTTTGGTGACTGTAGCCG 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
                       401       411       421       431       441        
consensus              AGCAGTTCCCTGTAACGTATGTGAGAAATTTCCGCGGGCTGGCTGAACTT 
AF012107               .......T.......................................... 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .......T.......................................... 
  
Figure 3.3.  (continued). 
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                       451       461       471       481       491        
consensus              TTGAAAGTGAGCGGGAAGATGCAGCAGCGTGATTGGAAGACAGCTGTACA 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
                       501       511       521       531       541        
consensus              CGTCATAGTGGGCCCGCCCGGTTGTGGGAAGAGCCAGTGGGCCCGTAATT 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
                       551       561       571       581       591        
consensus              TTGCTGAGCCTAGCGACACCTACTGGAAGCCTAGTAGAAATAAGTGGTGG 
AF012107               .............G.................................... 
PCU49186               .............G.................................... 
02/015                 ......................T........................... 
CTBEV                  ......................T........................... 
00/154                 .................................................. 
  
                       601       611       621       631       641        
consensus              GATGGATATCATGGAGAAGAAGTTGTTGTTTTGGATGATTTTTATGGCTG 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
                       651       661       671       681       691        
consensus              GTTACCTTGGGATGATCTACTGAGACTGTGTGACCGGTATCCGTTGACTG 
AF012107               ..........................................A....... 
PCU49186               ..........................................A....... 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
Figure 3.3.  (continued). 
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                       701       711       721       731       741        
consensus              TAGAGACTAAAGGGGGTACTGTTCCTTTTTTGGCCCGCAGTATTTTGATT 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
                       751       761       771       781       791        
consensus              ACCAGCAATCAGGCCCCCCAGGAATGGTACTCCTCAACTGCTGTCCCAGC 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
                       801       811       821       831       841        
consensus              TGTAGAAGCTCTCTATCGGAGGATTACTACTTTGCAATTTTGGAAGACTG 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
                       851       861       871       881       891        
consensus              CTGGAGAACAATCCACGGAGGTACCCGAAGGCCGATTTGAAGCAGTGGAC 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
                       901       911       921       931       941        
consensus              CCACCCTGTGCCCTTTTCCCATATAAAATAAATTACTGAGTC.TTTTTTG 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 .....T....................................T....... 
CTBEV                  .....T............................................ 
00/154                 ..........................................T....... 
  
Figure 3.3.  (continued). 
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                       951       961       971       981       991        
consensus              TTATCACATCGTAATGGTTTTTATTTTTATTCATTTAGAGGGTCTTTCAG 
AF012107               .................................................. 
PCU49186               ...............................T...............T.. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
                       1001      1011      1021      1031      1041       
consensus              GATAAATTCTCTGAATTGTACATAAATAGTCAGCCTTACCACATAATTTT 
AF012107               ................................A................. 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 ................................A................. 
  
                       1051      1061      1071      1081      1091       
consensus              GGGCTGTGGCTGCATTTTGGAGCGCATAGCCGAGGCCTGTGTGCTCGACA 
AF012107               .........T.....................C.................. 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 ...............................T...........G...... 
  
                       1101      1111      1121      1131      1141       
consensus              TTGGTGTGGGTATTTAAATGGAGCCACAGCTGGTTTCTTTTATTATTTGG 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 ................................A..C.............. 
CTBEV                  ................................A................. 
00/154                 .................................................. 
  
                       1151      1161      1171      1181      1191       
consensus              CTGGAACCAATCAATTGTTTGGTCCAGCTCAGGTTTGGGGGTGAAGTACC 
AF012107               ........................T.....T................... 
PCU49186               G................................................. 
02/015                 .................................................. 
CTBEV                  ................................................T. 
00/154                 ................................................T. 
  
Figure 3.3.  (continued). 
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                       1201      1211      1221      1231      1241       
consensus              TGGAGTGGTAGGTAAAGGGCTGCCTTATGGTGTGGCGGGAGGAGTAGTTA 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .......................T.......................... 
  
                       1251      1261      1271      1281      1291       
consensus              ATATAGGGGTCATAGGCCAAGTTGGTGGAGGGGGTTACAAAGTTGGCATC 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
                       1301      1311      1321      1331      1341       
consensus              CAAGATAACAACAGTGGACCCAACACCTCTTTGATTAGAGGTGATGGGGT 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 ....................................T............. 
  
                       1351      1361      1371      1381      1391       
consensus              CTCTGGGGTAAAATTCATATTTAGCCTTTCTAATACGGTAGTATTGGAAA 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
                       1401      1411      1421      1431      1441       
consensus              GGTAGGGGTAGGGGGTTGGTGCCGCCTGAGGGGGGGAGGAACTGGCCGAT 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
Figure 3.3.  (continued). 
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                       1451      1461      1471      1481      1491       
consensus              GTTGAATCTCAGCTGGTTAACATTCCAAGATGGCTGCGAGTGTCCTCCTT 
AF012107               ..............C..................................C 
PCU49186               .......T.G..G.A..........................A........ 
02/015                 ....................................T............. 
CTBEV                  ....................................T............. 
00/154                 .................................................. 
  
                       1501      1511      1521      1531      1541       
consensus              CTATGGTGAGTACAAATTCTCTAGAAAGGCGGGAATTGAAGATACCCGTC 
AF012107               T................................................. 
PCU49186               T...................G............................. 
02/015                 ......................G........................... 
CTBEV                  ......................G........................... 
00/154                 ..................................G............... 
  
                       1551      1561      1571      1581      1591       
consensus              TTTCGGCGCCATCTGTAACGGTTTCTGAAGGCGGGGTGTGCCAAATATGG 
AF012107               .......................................A.......... 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
                       1601      1611      1621      1631      1641       
consensus              TCTTCTCCGGAGGATGTTTCCAAGATGGCTGCGGGGGCGGGTCCTTCTTC 
AF012107               ............................................G..... 
PCU49186               .................................................. 
02/015                 ............A..................................... 
CTBEV                  ............A..................................... 
00/154                 ........................................T......... 
  
                       1651      1661      1671      1681      1691       
consensus              TGCGGTAACGCCTCCTTGGCCACGTCATCCTATAAAAGTGAAAGAAGTGC 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 ...............G.................................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
Figure 3.3.  (continued). 
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                       1701      1711      1721      1731      1741       
consensus              GCTGCTGTAGTATTACCAGCGCACTTCGGCAGCGGCAGCACCTCGGCAGC 
AF012107               .................................................. 
PCU49186               .................................................. 
02/015                 .................................................. 
CTBEV                  .................................................. 
00/154                 .................................................. 
  
                       1751       
consensus              GTCAGTGAAA 
AF012107               .......... 
PCU49186               .......... 
02/015                 .......... 
CTBEV                  .......... 
00/154                 .......... 
 
Figure 3.3.  (continued). 
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              1         11        21        31        41        51         
consensus     ATGCCCAGCAAAAAGAATGGAAGAAGCGGACCCCAACCACACAAAAGGTGGGTGTTCACG 
00/186        ............................................................ 
00/182        ............................................................ 
00/194        ............................................................ 
99/032        ...........................................................T 
LW1998        ...........................................................T 
1999a         ...........................................................C 
1999b         ...........................................................C 
FAC           ............................................................ 
00/180        ..........G.........C....................................... 
02/014        ...........G.............................T.................T 
AF027217      ...........G.............................T.................. 
               61        71        81        91        101       111        
consensus     CTGAATAATCCTTCCGAAGACGAGCGCAAGAAAATACGGGAGCTTCCAATCTCCCTTTTT 
00/186        ............................................................ 
00/182        ............................................................ 
00/194        ...........................................................C 
99/032        ............................................................ 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           T........................................................... 
00/180        ............................................................ 
02/014        ............................................C...........A... 
AF027217      ............................................C...........A... 
  
              121       131       141       151       161       171        
consensus     GATTATTTTATTGTTGGCGAGGAGGGGAATGAGGAAGGACGAACACCCCACCTCCAGGGG 
00/186        ............................................................ 
00/182        ............................................................ 
00/194        ............................................................ 
99/032        ............................................................ 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           ..........................T................................. 
00/180        ..............G...........T................................. 
02/014        .............A............T....................T............ 
AF027217      ..........................T....................T............ 
  
Figure 3.4.  Multiple nucleotide sequence alignment of 10 Australian strains of PCV2 in comparison to the 
PCV2 strain described by (Hamel, Lin, and Nayar, 1998) (AF027217).  The alignment was generated and 
displayed by the PileUp program within ANGIS.  A consensus sequence was computed and has been shown 
in capital letters, dots indicate the identical nt in comparison to the consensus sequence.   
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              181       191       201       211       221       231        
consensus     TTCGCTAATTTTGTGAAGAAGCAAACATTTAATAAAGTGAAATGGTATTTCGGTGCCCGC 
00/186        ..................................................G......... 
00/182        ..................................................G......... 
00/194        ............................................................ 
99/032        ............................................................ 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           ..................................................G......... 
00/180        ............................................................ 
02/014        ..........................T..............G........G......... 
AF027217      ..........................T..............G........G......... 
 
              241       251       261       271       281       291        
consensus     TGCCACATCGAGAAAGCGAAAGGAACTGATCAGCAGAATAAAGAATATTGCAGTAAAGAA 
00/186        ............................................................ 
00/182        ............................................................ 
00/194        ............................................................ 
99/032        ............................................................ 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           ............................................................ 
00/180        ............................................................ 
02/014        .........T.C.....C.......................................... 
AF027217      ...T.............C.......................................... 
  
              301       311       321       331       341       351        
consensus     GGCAACTTACTGATGGAATGTGGAGCTCCTAGATCTCAAGGACAACGGAGTGACCTGTCT 
00/186        ............................................................ 
00/182        ............................................................ 
00/194        ............................................................ 
99/032        ............................................................ 
LW1998        ..................................................C......... 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           ............................................................ 
00/180        ............................................................ 
02/014        ..T........T..T...............C............................. 
AF027217      ...........T..T...............C............................. 
  
Figure 3.4 (continued) 
              361       371       381       391       401       411        
consensus     ACTGCTGTGAGTACCTTGCTGGAGAGCGGGAGTCTGGTGACCGTTGCAGAGCAGCACCCT 
00/186        ............................................................   64
00/182        ............................................................ 
00/194        ..................T......................................... 
99/032        ............................................................ 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           ............................................................ 
00/180        ............................................................ 
02/014        ..................T......................................... 
AF027217      ..................T......................................... 
 
              421       431       441       451       461       471        
consensus     GTAACGTTTGTCAGAAATTTCCGCGGGCTGGCTGAACTTTTGAAAGTGAGCGGGAAAATG 
00/186        ............................................................ 
00/182        ............................................................ 
00/194        ............................................................ 
99/032        ............................................................ 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           ............................................................ 
00/180        ............................................................ 
02/014        ............................................................ 
AF027217      ............................................................ 
  
              481       491       501       511       521       531        
consensus     CAGAAGCGTGATTGGAAGACGAATGTACACGTCATTGTGGGGCCACCTGGGTGTGGCAAA 
00/186        ............................................................ 
00/182        .............................T.............................. 
00/194        ............................................................ 
99/032        ............................................................ 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           ............................................................ 
00/180        ....................T....................................... 
02/014        ....................C...................................T... 
AF027217      ....................C...................................T... 
 
Figure 3.4. (continued). 
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              541       551       561       571       581       591        
consensus     AGCAAATGGGCTGCTAATTTTGCAGACCCGGAAACCACATACTGGAAACCACCTAGAAAC 
00/186        ............................................................ 
00/182        ............................................................ 
00/194        ............................................................ 
99/032        ............................................................ 
LW1998        ..........G................................................. 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           ............................................................ 
00/180        ............................................................ 
02/014        ............................................................ 
AF027217      ............................................................ 
 
              601       611       621       631       641       651        
consensus     AAGTGGTGGGATGGTTACCATGGTGAAGAAGTGGTTGTTATTGATGACTTTTATGGCTGG 
00/186        ...............................................T............ 
00/182        ...............................................T............ 
00/194        ............................................................ 
99/032        ............................................................ 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           ............................................................ 
00/180        ............................................................ 
02/014        ............................................................ 
AF027217      ............................................................ 
  
              661       671       681       691       701       711        
consensus     CTGCCGTGGGATGATCTACTGAGACTGTGTGATCGGTATCCATTGACTGTAGAGACTAAA 
00/186        ............................................................ 
00/182        ............................................................ 
00/194        ............................................................ 
99/032        ............................................................ 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           ............................................................ 
00/180        ............................................................ 
02/014        ...................................A........................  
AF027217      ...................................A........................ 
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              721       731       741       751       761       771        
consensus     GGTGGAACTGTACCTTTTTTGGCCCGCAGTATTCTGATTACCAGCAATCAGACCCCGTTG 
00/186        ............................................................ 
00/182        ............................................................ 
00/194        ............................................................ 
99/032        ............................................................ 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           .........................................G.................. 
00/180        ............................................................ 
02/014        ............................................................ 
AF027217      ............................................................ 
 
              781       791       801       811       821       831        
consensus     GAATGGTACTCCTCGGCTGCTGTCCCAGCTGTAGAAGCTCTCTATCGGAGGATTACTTCC 
00/186        ............................................................ 
00/182        ..............A............................................. 
00/194        ............................................................ 
99/032        ............................................................ 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           ............................................................ 
00/180        ............................................................ 
02/014        ..............AA............................................ 
AF027217      ..............AA............................................ 
  
              841       851       861       871       881       891        
consensus     TTGGTATTTTGGAAGAATGCTACAGAACAGTCCACGGAGGAAGGGGGCCAGTTCGTCACC 
00/186        ............................................................ 
00/182        ............................................................ 
00/194        ............................CA.............................. 
99/032        ............................................................ 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           ............................................................ 
00/180        ............................................................ 
02/014        .............................A.............................. 
AF027217      .............................A.............................. 
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              901       911       921       931       941       951        
consensus     CTTTCCCCCCCATGCCCTGAATTTCCATATGAAATAAATTACTGAGTCTTTTTTATCACT 
00/186        ............................................................ 
00/182        ............................................................ 
00/194        ............................................................ 
99/032        ............................................................ 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           ............................................................ 
00/180        ............................................................ 
02/014        ............................................................ 
AF027217      ............................................................ 
 
              961       971       981       991       1001      1011       
consensus     TCGTAATGGTTTTTATTATTCATTTAGGGTTTAAGTGGGGGGTCTTTAAGATTAAATTCT 
00/186        ..........................T................................. 
00/182        ..........................T................................. 
00/194        ............................................................ 
99/032        ............................................................ 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           ............................................................ 
00/180        ............................................................ 
02/014        ...........................................................C 
AF027217      .................T.......................................... 
  
              1021      1031      1041      1051      1061      1071       
consensus     CTGAATTGTACATACATGGTTACACGGATATTGTAGTCCTGGTCGTATTTACTGTTTTCG 
00/186        ................................................A........... 
00/182        ................................................A........... 
00/194        ............................................................ 
99/032        ............................................................ 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           ............................................................ 
00/180        ............................................................ 
02/014        ............................................................ 
AF027217      ................................................A........... 
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              1081      1091      1101      1111      1121      1131       
consensus     AACGCAGTGCCGAGGCCTACATGGTCTACATTTCCAGTAGTTTGTAGTCTCAGCCAGAGT 
00/186        ............................................................ 
00/182        ............................................................ 
00/194        ..................................................G......... 
99/032        ...........C................................................ 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           ..T......................................................... 
00/180        ............................................................ 
02/014        ....................G.....C.......T..AG.......TC........A..C 
AF027217      ....................G.....C.......T..AG........C........A..C 
 
              1141      1151      1161      1171      1181      1191       
consensus     TGATTTCTTTTGTTATTGGGTTGGAAGTAATCGATTGTCCCATCAAGGACAGGTTTGGGG 
00/186        ............................................................ 
00/182        ............................................................ 
00/194        ................................T........................... 
99/032        ............................................................ 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           ............................................................ 
00/180        ............................................................ 
02/014        .....C...........T..............A..A..GGAG.....A...........T 
AF027217      ...G.C...........T..............A..A..GGAG.....A...........T 
  
              1201      1211      1221      1231      1241      1251       
consensus     GTGAAATAGCGGGAGTGGTAGGAGAAGGGCTGGGTTATGGTATGGCGGGAGGAGTAGTTT 
00/186        .............................T.............................. 
00/182        .............................T.............................. 
00/194        .....G...................................................... 
99/032        ...........A................................................ 
LW1998        ...........A................................................ 
1999a         ...........A................................................ 
1999b         ...........A................................................ 
FAC           ............................................................ 
00/180        .....G...................................................... 
02/014        .....G..A....................T....GG..T..................... 
AF027217      .....G..A....................T....GG..T..................... 
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              1261      1271      1281      1291      1301      1311       
consensus     ACATAGGGGTCATAGGTTAGGGCTGTGGCCTTTGTTACAAAGTTATCATCTAGAATAACA 
00/186        ............................................................ 
00/182        ............................................................ 
00/194        ............................................................ 
99/032        ..........................................................T. 
LW1998        ..........................................................T. 
1999a         ..........................................................T. 
1999b         .........................G................................T. 
FAC           ............................................................ 
00/180        ............................................................ 
02/014        .....T............T...............G......................... 
AF027217      .....T...................................................... 
 
              1321      1331      1341      1351      1361      1371       
consensus     GCACTGGATCCAACTCCCCTGTCACCCTGGGTGATTGGGGAGCAGGGCCAGAATTCAACC 
00/186        ............................................................ 
00/182        ............................................................ 
00/194        .............T.............................................. 
99/032        ............................................................ 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           ..........................T................................. 
00/180        ............................................................ 
02/014        ...G.......C.....T..A..............G........................ 
AF027217      ...G....G..C........A..............G........................ 
  
              1381      1391      1401      1411      1421      1431       
consensus     TTAACCTTTCTTATTCTGTAGTATTCAAAGGGTATAGAGATTTTGTTGGTCCCCCCTCCC 
00/186        ...............................................A............ 
00/182        ...............................................A............ 
00/194        ............................................................ 
99/032        ............................................................ 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           ...........................................................T 
00/180        ............................................................ 
02/014        ...............................................T.....T...... 
AF027217      ............................................................ 
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              1441      1451      1461      1471      1481      1491       
consensus     GGGGGAACAAAGTCGTCAATTTTAAATCTCAGCATGTCCACCGCCCAGGAGGGCGTTGTG 
00/186        .........................................................T.. 
00/182        .........................................................T.. 
00/194        ...................G........................................ 
99/032        ............................................................ 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           .........................................................C.. 
00/180        ............................................................ 
02/014        ....................A..........T............................ 
AF027217      ....................A..........T.........................C.. 
 
              1501      1511      1521      1531      1541      1551       
consensus     ACTGTGGTAGCCTTGACAGTATATCCGAAGGTGCGGGAGAGGCGGGTGTTGAAGATGCCA 
00/186        .........CG................................................. 
00/182        .........CG................................................. 
00/194        .........CG................................................. 
99/032        ............................................................ 
LW1998        ............................................................ 
1999a         .........CG................................................. 
1999b         ..........................C................................. 
FAC           ............................................................ 
00/180        ..A...........A............................................. 
02/014        ............................................................ 
AF027217      ............................................................ 
  
              1561      1571      1581      1591      1601      1611       
consensus     TTTTTCCTTCTCCAGCGGTAACGGTGGCGGGGGTGGACGAGCCAGGGGCGGCGGCGGAGG 
00/186        .....................................G...................... 
00/182        .....................................G...................... 
00/194        ............................................................ 
99/032        ......................................T..................... 
LW1998        .........T............................T..................... 
1999a         ......................................T..................... 
1999b         ......................................T..................... 
FAC           .......................C.................................... 
00/180        ............................................................ 
02/014        ..............A.....G....................................... 
AF027217      ..............A.....G....................................... 
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              1621      1631      1641      1651      1661      1671       
consensus     ATCTGGCCAAGATGGCTGCGGGGGCGGTGTCTTCGTCTGCGGTAACGCCTCCTTGGATAC 
00/186        ............................................................ 
00/182        ............................................................ 
00/194        ............................................................ 
99/032        .........................................................A.. 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ............................................................ 
FAC           ............................................................ 
00/180        .........................................................A.. 
02/014        ..................................T......................... 
AF027217      ..................................T......................... 
 
              1681      1691      1701      1711      1721      1731       
consensus     GTCATAGCTGAAAACGAAAGAAGTGCGCTGTAAGTATTACCAGCGCACTTCGGCAGCGGC 
00/186        ......T..................................................... 
00/182        ............................................................ 
00/194        ......T..................................................... 
99/032        ......T..................................................... 
LW1998        ............................................................ 
1999a         ............................................................ 
1999b         ...........................................T................ 
FAC           ......T..................................................... 
00/180        ............................................................ 
02/014        ...........................................T.........G...... 
AF027217      ............................................................ 
  
              1741      1751      1761       
consensus     AGCACCTCGGCAGCACCTCAGCAGCAAT 
00/186        ............................ 
00/182        ............................ 
00/194        ............................ 
99/032        ............................ 
LW1998        ............................ 
1999a         ............................ 
1999b         ............................ 
FAC           ...........................C 
00/180        ...........................C 
02/014        ...........................C 
AF027217      ...........................C 
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Table 3.7.  Summary of the major characteristics of Australian PCV strains sequenced.   
Isolate  Genome length (nt)  Type  Area, State of origin 
00/154 1760  PCV1  Cowra,  NSW 
02/015 1760  PCV1  Serpentine,  WA 
CT Bev  1759  PCV1  Beverley, WA 
00/180 1768  PCV2  Gingin,  WA 
00/182 1768  PCV2  Toowoomba,  QLD 
00/186 1768  PCV2  Toowoomba,  QLD 
00/194 1768  PCV2  Young,  NSW 
02/014 1768  PCV2  Serpentine,  WA 
LW1998 1768  PCV2  Dandalup,  WA 
1999a 1768  PCV2  Dandalup,  WA 
1999b 1768  PCV2  Dandalup,  WA 
99/032 1768  PCV2  Dandalup,  WA 
FAC 1768  PCV2 Cowra,  NSW 
 
Table 3.8.  A comparison (% nucleotide identity) of Australian PCV strains to PCV1 type strain (Accession 
No. PCU49186), a French PCV1 field isolate (AF012107) implicated in a PMWS-like syndrome and the initial 
PCV2 isolate sequenced (AF027217) and associated with PMWS. 
Percentage nucleotide identity to Genbank sequences 
Australian isolates 
PCU49186  AF012107 AF027217 Designated  PCV  type 
00/154  98.579  98.920 78.073 1 
02/015  98.636  98.465 77.912 1 
CTBEV  98.749  98.579 77.970 1 
00/180  77.438  77.919 96.380 2 
00/182  77.220  77.816 96.435 2 
00/186  77.278  77.874 96.378 2 
00/194  77.451  78.047 96.321 2 
02/014  77.393  77.932 98.869 2 
LW1998  77.220  77.759 96.208 2 
1999a  77.336  77.932 96.265 2 
1999b  77.220  77.759 96.208 2 
99/032  77.278  77.932 96.208 2 
FAC  77.220  77.759 96.380 2 
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control.  The emergence and application of quantitative PCR technology to diagnostics may, 
in the future, go some way to alleviating the problems outlined above with the application of 
current diagnostic PCR to endemic agents.   
The sensitivity and the specificity of the PCR used in the initial study was confirmed by other 
researchers (Larochelle et al., 1999a; Ouardani et al., 1999).  An investigation was carried out 
to establish the sensitivity and specificity of the technique in comparison with those of other 
routine diagnostic procedures that have been used for the detection of PCV, mainly virus 
isolation in cell culture, ISH, and immunohistochemical staining with hyperimmune serum 
(Allan et al., 1998b; Ellis et al., 1998; Kiupel et al., 1998; Morozov et al., 1998).  The data 
obtained confirmed the specificity of the PCR method as no PCR products could be obtained 
from DNA or RNA prepared from bacterial and viral pathogens commonly associated with 
respiratory disorders in pigs by using primer sets corresponding to different regions of the 
PCV1 and PCV2 genomes.  The sensitivity was comparable to those of PCR methods that 
have previously been reported for the detection of other small DNA viruses such as porcine 
parvoviruses (Molitor et al., 1991).  It was also demonstrated that amplification of the viral 
genome was not compromised by excessive amounts of cellular nucleic acids (Ouardani et 
al., 1999).   
PCR amplification of viral DNA in formalin-fixed, paraffin-embedded tissue is a simple and 
sensitive method but it is clear that the detection of PCV2 in tissues by the PCR does not 
necessarily indicate PMWS, as this virus is also detected in apparently healthy pigs with no 
history of PMWS (Allan and Ellis, 2000; Kim et al., 2001a).  PCR can only be of value as a 
diagnostic tool when it detects PCV2 in conjunction with characteristic histopathologic 
changes.   
The PCR assays used in this study confirmed the presence of PCV1 and PCV2 DNA in the 
Australian pig herd in a number of states.  It is assumed that these viruses would also occur 
in other states not represented in this survey, eg. Victoria, from which samples were not 
provided despite requests for them.  There was no evidence of any association with PMWS.  
This is consistent with reports in the literature where it has been shown that subclinical 
infections of pigs with PCV1 or PCV2 do not necessarily produce disease (Segales and 
Domingo, 2002; Todd et al., 2001a).   
PCV lesions are often associated with lymphoid organs as well as liver and lung, and PCV2 
antigen has been detected in a number of tissues but primarily in the spleen, thymus and lung 
(Allan et al., 1995; Clark, 1997; Morozov et al., 1998).  The choice of spleen tissue for the 
routine investigation of the presence of PCV in the Australian pig herd was based on these 
reports, and on results of experimental infection of pigs with the type strain of PCV1 that was 
undertaken in this laboratory (described in Chapter 4), which clearly indicated that spleen 
tissue was the tissue of choice for the detection of PCV genomic material in PCV1-infected 
pigs.     74
Most of the 367 submitted pigs were from post-weaning mortality cases.  Some of these were 
from herds where there was an ill-thrift problem in weaners but when tissues from these pigs 
were examined for histopathological changes it was not possible to detect any of the obvious 
characteristic microscopic lesions that have been ascribed to PMWS previously (Dr Ross 
Buddle, personal communication).   
As PCV had been implicated in CT (Choi et al., 2000: Stevenson et al., 1999a), samples from 
a CT outbreak in WA were examined for PCV. Two pigs initially presented were positive for 
both PCV1 and PCV2, but further submissions from the same outbreak were positive for 
PCV1 only.  There are only four reports of an association between PCV and congenital 
tremors (Choi et al., 2000; Stevenson et al., 1999a; Choi et al., 2002; and Kennedy et al., 
2003).  Choi, Chae and Clark (2000) and Stevenson et al. (1999a) associated PCV2 with 
congenital tremors and Choi et al. (2002) identified PCV1 from archival tissue material in a CT 
pig from the late 1960’s.  Kennedy et al. (2003), however, could not support any of these 
previous results but could not disprove them either.   
In this current study, the rate of detection of PCV1, relative to the rate of detection of PCV2, 
was higher than has been reported previously.  Although one study by Kim et al. (2003) found 
similar rates of detection of PCV1 and PCV2 of 18% and 20%, respectively, in tissues of pigs 
that had died post-weaning, most reports have described a higher rate of detection of PCV2 
than PCV1 in pig populations (Magar et al., 2000; Rodriguez-Arrioja et al., 2000).  In Canada, 
94.2% of 35 pigs were found by PCR to be infected with PCV2, compared with 5.7% infected 
with PCV1, and both PCV1-positive pigs were also infected with PCV2 (Ouardani et al., 
1999).  Another Canadian study used PCR to confirm the high infection rate with PCV2 
(97.6%) and lower (4.8%) rate of detection of PCV1 (Larochelle et al., 1999b) and examined 
tissue samples from pigs with clinical signs suggestive of PCV2 infection, including respiratory 
signs and weight loss (Ouardani et al., 1999), and pneumonia, tremors and PDNS (Larochelle 
et al., 1999b). In this current study, although nearly all the tissues examined were from pigs 
that had died post-weaning or were unthrifty, the lower prevalence of PCV2 infection detected 
in Australia, and the similar PCV1 and PCV2 infection rates in these tissues, may be 
associated with the absence of clinical PMWS in Australia.  Although PCV1 and PCV2 are 
present in Australia, the factors which predispose to the increased replication of PCV and the 
occurrence of PMWS, and perhaps enhanced transmission, do not appear to be present.   
The detection of antibody in approximately 30% of the 297 serum samples examined from 
WA pig herds confirms the widespread occurrence of infection in the WA pig herd.  PCV 
antibody was detected in pigs from 11 of the 14 farms with a minimum seroprevalence rate of 
25% and a maximum seroprevalence of 57% in these 11 farms.  This seroprevalence rate is 
within the range reported in Europe (Tischer et al., 1995b) and Canada (Dulac and Afshar, 
1989).  Why antibody was not detected in pigs from three farms is unknown.  It may have 
been due to the low number of samples that were tested from some of these herds but this   75
seems unlikely: Farm 11 was negative while Farm 2 had a seroprevalence rate of 43%, and in 
both cases 14 samples were tested.   
The serological results obtained with the IIF assay do not indicate which type of PCV was 
present; this assay did not discriminate antibody to the two types of PCV, and this is obviously 
desirable and the production of such a test is reported later in the thesis (Chapter 5).  Other 
studies have also utilised serological methods that do not differentiate antibody to the two 
types of PCV (Allan et al., 1994a; Dulac and Afshar, 1989; Tischer et al., 1995a), including an 
ELISA (Truong et al., 2001).  More recent reports have attempted to utilise PCV2-specific 
enzyme linked immunosorbent assays (ELISAs) where protein antigens were produced using 
recombinant DNA technology; with these assays seroprevalence rates of 82.4% have been 
reported in Canada (Liu et al., 2002), 14.6% in Costa Rica (Liu et al., 2002), 10% in the USA 
(Nawagitgul  et al., 2002) and 55-100% in Northern Ireland (Walker et al., 2000).  A 
seroprevalence rate of 72.7% in Spain was reported using a PCV2-specific 
immunoperoxidase monolayer assay (IPMA) (Rodriguez-Arrioja et al., 2003).  There are 
relatively few studies comparing the seroprevalence of PCV1 and PCV2, but from the 
available data it would appear that PCV2 is the more common type of PCV circulating in 
swine populations (Magar et al., 2000).  In a Spanish study based on the use of an IPMA, 
sera from 90 pigs from 37 farms were tested for the presence of PCV antibody and PCV1 
antibody was detected in 52.2% whereas PCV2 antibody was found in 97.8% of samples 
(Rodriguez-Arrioja et al., 2000).   
It must be stressed that the results of this initial study do not represent a comprehensive 
statistically valid serological survey.  The survey conditions were not stringent, as it was 
intended only to identify infected herds that could then be sampled in greater detail by PCR.  
The number of samples obtained per herd was based only on the number of pigs killed from 
that farm on the day of sampling, and therefore the sample numbers ranged widely from 6 to 
43 per herd.  The seroprevalence rates reported in this study do, however, provide a general 
indication of the situation in the Western Australian pig herd.  It is also likely that the results 
obtained with the IIF assay are an underestimate of the true seroprevalence rates; the assay 
is difficult to interpret and likely to be insensitive.  One reason for believing this is that studies 
by Allan et al. (1994c) utilising a more sensitive ELISA demonstrated that maternally derived 
antibodies persisted for eight to nine weeks after birth, longer than in the present study using 
the IIF technique.   
The importance of the survey was that it detected a number of farms that were infected with 
PCV, and enabled the selection of one farm (Farm 14) where there was a high 
seroprevalence, and a consequent study of when pigs were likely to be infected (during 
nursing, during weaning, or at the grower stage).  Published data by Segales et al. (2002) 
suggested that seroconversion to PCV2 occurred with the decline of maternal antibodies 
during the lactating and weaner periods, with the lowest levels at the end of the weaner 
period, and active seroconversion of almost all pigs during the grower period.  Larochelle,   76
Magar and D’Allaire (2003) found maternally-acquired PCV2-specific antibodies persisted up 
to 11 weeks of age, and was followed by seroconversion at 15 weeks of age.  The age-
associated prevalence study during this current investigation showed that 45% of two-week-
old pigs were PCV-antibody positive, presumably due to maternal immunity as older pigs four 
to eight-weeks of age were seronegative.  Seroconversion was detected at 10 to 12 weeks of 
age, which is reasonably consistent with these reports.  As it was determined that pigs 
experimentally infected with PCV1 present in PK15 cells developed IIF antibody about two 
weeks after infection (Chapter 5), it can be assumed that infection started to occur on this 
farm in pigs at eight to nine weeks of age.  Typical of what happens in many farms, in Farm 
14, pigs of certain age ranges were grouped together: pigs up to three weeks of age suckers 
were housed in the farrow shed, the four to eight week-old weaners were kept in the weaner 
shed and at nine weeks of age were transferred to the grower shed.  Each of these sheds 
was isolated and the pigs moved through the system without any contact with older or 
younger pigs.  The weaner shed was cleaned and sterilised when a group of pigs was moved 
from this shed to the grower shed.   
The 50% prevalence of antibody at two weeks of age suggests that a high percentage of 
sows may be antibody-positive, and that the adult sows (one to three years of age) on the 
farm were likely to have been infected some time during their life, would be antibody-positive, 
and possibly virus-free (as no transmission to piglets occurred during the nursing period).  
Antibody was not detected in pigs until they were ten weeks of age, so it is assumed that the 
four to eight-week-old pigs in the clean environment of the weaner shed were not exposed to 
infection.  Pigs were moved into the general population in the grower shed when they are 
eight to nine weeks of age, and were probably exposed then to PCV as antibody-positive pigs 
were detected at ten weeks of age, two weeks after they were moved into this population.  
Only 15% of the ten week-old pigs was antibody-positive, and 5% of the 12 week-old-pigs and 
it is hypothesised that all the pigs in the general grower population were exposed to infection 
but not all simultaneously.  It is probable that the degree of cross-infection that occurs 
depends on management conditions and perhaps on the pens where they are housed.   
However, by the time pigs reach 25 to 27 weeks of age (baconer weight) and are killed, most 
pigs on some farms may have been infected, evident from the seroprevalence rates of up to 
57% in some farms.   
The sequence data presented in this Chapter of the entire genomes of Australian PCV1 and 
PCV2 strains represent the first sequence data reported for any strains of PCV in Australia.  
Based on the similarity of these sequences with the reported sequence of PCV isolates in 
other countries it was concluded that the nucleotide sequences obtained in this study 
represented the encapsidated ss DNA strand of the virus.  The organisation of the genomes 
of Australian PCVs was highly similar to that reported for other PCV isolates: the ORF V1 in 
all isolates was situated in a similar position (nt 47-985) on the encapsidated strand as 
previously reported; the derived amino acid sequence of ORF V1 of the Australian PCV 
strains possessed three motifs characteristic of proteins involved in RCR, as well as a   77
nucleotide binding site (Koonin and Ilyina, 1993); they all contained a characteristic sequence 
upstream of ORF V1 which would be expected to form a stem-loop structure (nt 1751-12) with 
a nonanucleotide motif at its apex (nt 1762-2).   
A number of phylograms were constructed to visualise the relatedness of the Australian PCV 
strains when compared to previously published sequences submitted to GenBank.  Figure 3.5 
shows the three Australian PCV1 strains (02/015, CTBEV and 00/154) compared to all other 
PCV1 sequences available.  It can be seen that the three Australian strains form their own 
branch delineating from the tree and would appear to be highly related despite the fact that 
one of these strains (CTBEV) was isolated from a CT associated case.   
 
 
Figure 3.5.  A rooted phylogenetic tree comparing all available sequences of PCV1, and three characterised 
Australian strains: 02/015, CTBEV and 00/154.  The phylogram was generated by UPGMA method based on 
the distance matrix calculated by the Jukes-Cantor method.  The abbreviations used to note the Australian 
isolates are as described in Table 3.7; the remaining isolates are identified by their GenBank Accession 
numbers.   
 
A comparison of the ten Australian PCV2 strains with randomly selected PCV2 isolates from 
around the world is shown in Figure 3.6; all of the overseas PCV2 strains had been 
associated with PMWS.  Clearly, only strain 02/014 seems to be closely related to the PMWS 
associated PCV2s.  The remaining nine Australian strains grouped together on a separate 
branch and an outlying isolate (AF055393) grouped closer to the Australian PCV2 strains 
rather than the PMWS associated sequences.  The significance of this is unknown.   
A phylogenetic tree comparing the Australian PCV1 and PCV2 isolates that were sequenced 
is shown in Figure 3.7.  The divergence of the two types (PCV1 and PCV2) can be seen with 
the formation of two distinct branches and clustering of PCV2 strains on the upper branch and 
PCV1 strains on the lower branch.   
   78
 
Figure 3.6.  A rooted phylogenetic tree comparing selected overseas strains of PCV2 and the 10 Australian 
PCV2 strains sequenced.  The phylogram was generated by the UPGMA method based on the distance 
matrix calculated by the Jukes-Cantor method.  The abbreviations used to denote the Australian strains are 
as described in Table 3.7; the remaining isolates are identified by their GenBank Accession numbers.   
 
 
 
 
Figure 3.7. A rooted phylogenetic tree comparing the Australian PCV1 and PCV2 nucleotide sequences with 
the inclusion of PCV1 type strain (PCU49186) and the first sequenced isolate of PCV2 (AF027217)  The 
phylogram was generated by the UPGMA method based on the distance matrix calculated by the Jukes-
Cantor method.  The abbreviations used to denote the Australian strains are as described in Table 3.7; the 
remaining isolates are identified by their GenBank Accession numbers. 
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As expected, the Australian strains of PCV1 shared only 77-78% nucleotide identity with the 
overseas and Australian isolates of PCV2, but had approximately 98% nucleotide sequence 
identity with PCV1 type species and a French PCV1 field isolate implicated in a PMWS-like 
syndrome.  The Australian PCV2 strains had 96–98% identity with the overseas isolates of 
PCV2.  The significance of the 2-4% difference between Australian and overseas viruses of 
the same type is as yet unknown.  While there are a number of nucleotide substitutions in 
Australian strains of PCV, which can be readily observed in Figures 3.3 and 3.4; it was not 
possible to note any consistent or significant changes which may explain differences in 
pathogenicity and the lack of PMWS in Australia.  The only exception to this statement was 
the insertion of a ‘T’ residue at position 942 in the genomes of 00/154 and 02/015.   
Caution should be exercised in the interpretation of the significance of these groupings as 
several different approaches for the phylogenetic comparison of organisms are possible, and 
different results may be obtained using different methods.  Generally, the various algorithms 
for phylogenetic studies can be categorised into three categories: distance methods; 
maximum parsimony; maximum likelihood (Gaeta and K., 1997).  Among these categories, 
the methods based on distance are the simplest (Gaeta and K., 1997) and were utilised to 
construct the phylogenetic trees.  There are different strategies of clustering based on 
measured distances but generally the aligned sequences are examined and the number of 
exact matches, partial matches, and gaps are determined.  If the sequences are nucleic 
acids, transitions (purine-purine or pyrimidine-pyrimidine substitutions) or transversions 
(purine-pyrimidine substitutions) are tallied.  The counts are then used to compute a distance 
(Gaeta and K., 1997).  As the rate of divergence increases, the probability that more than one 
substitution occurred at a single site increases, so for all but closely related sequences the 
observed distance between the sequences underestimates the true distance.  In these cases, 
to construct a valid tree the observed distances must be corrected to account for multiple 
substitutions at a single site.   
Methods devised for phylogenetic analyses are each based on different assumptions about 
the substitution process.  The “uncorrected distance” method computes the distance between 
sequences without any correction for multiple substitutions; the method can be used for either 
nucleic acid or protein sequences (Swofford and Olsen, 1990).  The “Jukes-Cantor method” is 
based on two assumptions: that substitution occurs at any site along the sequence with equal 
probability, and that the probability of a change from one nt to any other or from one amino 
acid to any other is the same.  This method can be used for nt or amino acid sequences 
(Jukes and Cantor, 1969; Swofford and Olsen, 1990).  The “Tajima-Nei distance method” is 
applicable to nt sequences only and is based on 2 assumptions: that substitution occurs at 
any site along the sequence with equal probability, and that regardless of the original nt 
substitution, the rate of substitution to a given nucleotide is the same (Tajima and Nei, 1984).  
The “Kimura two-parameter distance method” is applicable to nt sequences only and it is 
based on the fact that transition substitutions (purine-purine or pyrimidine-pyrimidine) occur 
more frequently than transversion substitutions (purine-pyrimidine).  This method gives better   80
distance estimates than the Jukes-Cantor method when the rates of transitional and 
transversional substitutions are different (Kimura, 1980).  The “Jin-Nei gamma distance 
method” is applicable only to nt analysis and takes transitions and transversions into account.  
It is based on assumptions that the nt substitution rate varies from site to site according to the 
gamma distribution (Jin and M., 1990) for distance correction.  The “Kimura Protein Distance 
method” is applicable only for amino acids, and distances are calculated based on the 
relationship between observed amino acid substitutions and actual (corrected) substitutions 
(Kimura, 1983).   
The phylogenetic trees were constructed from the calculations of the distance matrices.  A 
range of methods, such as unweighted pair group method using arithmetic averages 
(UPGMA) (Sneath and Sokal, 1973) and Neighbour-Joining method (Saitou and Nei, 1987; 
Studier and J., 1988; Swofford and Olsen, 1990) were used.  Similar results were obtained 
with the different methods; the different methods were expected to provide similar results as 
the sequences under investigation were closely related (Sneath and Sokal, 1973).     81
Chapter 4.  Development and application of 
immunoassays for the detection of porcine circovirus 
infection 
 
Summary 
A recombinant PCV2 capsid protein was expressed in insect cells using a baculovirus 
expression system, purified and used to develop a PCV2-specific enzyme linked 
immunosorbent assay (ELISA) and a Western immunoblot assay.  The assays were then 
used to detect PCV2 antibody in the Australian pig herd.  The overall prevalence of PCV2 
antibody nationwide was approximately 33%.  Prevalences of 39.3%, 25.6%, 28.4%, 11.4%, 
23.9% and 51.3% were recorded for Queensland, New South Wales, South Australia, 
Western Australia, Tasmania and Victoria, respectively. 
A MAb specific to PCV2 was also produced and will have future application in the 
development of PCV2-specific immunocytochemical assays.     82
Introduction 
The availability of serological assays to determine the infection status of individuals or a 
population is a critical component of disease surveillance.  Consequently, the development of 
specific serological assays that can be used to detect antibody and therefore provide 
evidence of previous virus infection are essential.   
Initial serological tests for PCV were based on the use of PCV1 antigens (Tischer et al., 
1995b). Significant antigenic cross-reactivity between PCV1 and PCV2 has been 
demonstrated, so serological evaluation based on PCV1 alone probably underestimated the 
seroprevalence of PCV2 (Magar, Muller, and Larochelle, 2000; Rodriguez-Arrioja et al., 
2000), and vice-versa.  The IIF assay utilised in Chapter 3 to determine the prevalence of 
antibody in pigs in Western Australia was not specific and the assay, which utilised PCV1 in 
infected PK15 cells as an antigen, detected antibody to both PCV1 and PCV2.  Similarly, 
tests utilising indirect immunoperoxidase or immunofluorescence staining of PCV2-infected 
cell cultures (Balasch et al., 1999; Ellis et al., 1999) are also not specific because of the 
antigenic cross-reactivity between PCV1 and PCV2.  Other tests for PCV2 antibody with 
greater sensitivity have been developed that utilise PCV2-specific MAbs (Sala et al., 2000; 
Walker et al., 2000) and specific antigen preparations, but were not ideal as PCV2 is difficult 
to produce in cell culture (Blanchard et al., 2003b).  A peptide-ELISA test using an 
immunorelevant B-133 epitope of the ORF C2-encoded protein of PCV2 was developed 
(Mahe et al., 2000; Truong et al., 2001) and while this peptide proved specific for PCV2, the 
limited sensitivity of the ELISA developed meant it was unsuitable for individual serodiagnosis 
(Blanchard et al., 2003b).   
In the present study, a recombinant capsid protein, encoded by ORF C2 of PCV2, was 
produced to use in a specific ELISA for the detection of PCV2 antibody.  An ORF2-encoded 
histidine-tagged (HIS) protein was produced as an antigen using a baculovirus vector in 
insect cells.  The development of a reproducible and reliable method of producing PCV viral 
proteins was necessary as commercially available antigens were not available in Australia.   
The baculovirus expression system is the most widely used eukaryotic system; this system 
produces glycosylated protein products similar to those produced in mammalian cells.  The 
heterologous genes are placed under the transcriptional control of the strong polyhedrin 
promoter of the Autographa californica nuclear polyhedrosis virus (AcNPV) and are often 
abundantly expressed during the late stages of the recombinant virus infection of insect cells.  
In most cases, the recombinant proteins are processed, modified, and targeted to their 
appropriate cellular locations, where they are functionally similar to their authentic 
counterparts (Davies, 1994; King and Possee, 1992; Luckow, 1991; Luckow, 1993; Luckow, 
1995a; Luckow, 1995b; O'Reilly, Miller, and Luckow, 1992).   
AcNPV has a large (130 kb) circular double-stranded DNA genome with multiple recognition 
sites for many restriction endonucleases.  As a result, recombinant baculoviruses are   83
traditionally constructed in two steps.  The gene to be expressed is first cloned into a plasmid 
transfer vector downstream from a baculovirus promoter that is flanked by baculovirus DNA 
derived from a nonessential locus, usually the polyhedrin gene.  This plasmid is then 
introduced into insect cells along with circular wild-type genomic viral DNA.  Typically, 0.1-1% 
of the resulting progeny are recombinant, with the heterologous gene inserted into the 
genome of the parent virus by homologous recombination in vivo (Luckow, 1991).   
Recently, a rapid and efficient method to generate recombinant baculoviruses was developed 
by researchers at Monsanto (Luckow et al., 1993) and was used in the experiments reported 
in this Chapter.  The method is based on site-specific transposition of an expression cassette 
into a baculovirus shuttle vector (bacmid) propagated in Escherichia coli.  The bacmid 
(bMON14272) contains the low-copy-number mini-F replicon, a kanamycin resistance marker, 
and a segment of DNA encoding the lacZa peptide from a pUC-based cloning vector.   
Inserted into the N-terminus of the lacZa gene is a short segment containing the attachment 
site for the bacterial transposon Tn7 (mini-attTn7) that does not disrupt the reading frame of 
the lacZa peptide.  The bacmid propagates in E. coli DH10BAC™ as a large plasmid that 
confers resistance to kanamycin and can complement a lacZ deletion present on the 
chromosome to form colonies that are blue in the presence of a chromogenic substrate such 
as Bluo-gal or 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) and the inducer 
isopropyl-β-D-thiogalactopyranoside (IPTG).  Recombinant bacmids are constructed by 
transposing a mini-Tn7 element from a pFASTBAC™ donor plasmid to the mini-attTn7 
attachment site on the bacmid when the Tn7 transposition functions are provided in trans by a 
helper plasmid (pMON7124).  The helper plasmid confers resistance to tetracycline and 
encodes the transposase.  A series of pFASTBAC donor plasmids are available which share 
common features.  Each vector has a baculovirus-specific promoter (the polyhedrin or p10 
promoter from AcNPV) for expression of proteins in insect cells. The mini-Tn7 in a 
pFASTBAC donor plasmid contains an expression cassette consisting of a gentamycin 
resistance (Gm
r) gene, a baculovirus-specific promoter, a multiple cloning site, and an SV40 
poly(A) signal inserted between the left and right arms of Tn7.  The pFASTBAC HT (Polayes 
et al., 1996) series of vectors are used to express polyhistidine-tagged proteins which can be 
rapidly purified on metal affinity resins.  Genes to be expressed are inserted into the multiple 
cloning site of a pFASTBAC donor plasmid downstream from the baculovirus-specific 
promoter.  Insertions of the mini-Tn7 into the mini-attTn7 attachment site on the bacmid 
disrupts expression of the lacZa peptide, so colonies containing the recombinant bacmid are 
white in a background of blue colonies that harbour the unaltered bacmid.  Recombinant 
bacmid DNA can be rapidly isolated from small scale cultures and then used to transfect 
insect cells.  Viral stocks (>10
7 pfu/mL) harvested from the transfected cells can then be used 
to infect fresh insect cells for subsequent protein expression, purification, and analysis.  Using 
site-specific transposition to insert foreign genes into a bacmid propagated in E. coli has a 
number of advantages over the generation of recombinant baculoviruses in insect cells by 
homologous recombination.  Recombinant virus DNA isolated from selected colonies is not   84
mixed with parental, non-recombinant virus, eliminating the need for multiple rounds of plaque 
purification.  As a result, this greatly reduces the time it takes to identify and purify a 
recombinant virus from 4 to 6 weeks (typical for conventional methods) to within 7 to 10 days.  
Perhaps the greatest advantage of this method is that it permits the rapid and simultaneous 
isolation of multiple recombinant viruses, and is particularly suited for the expression of 
protein variants for structure/function studies.   
Materials and methods 
Primers and PCR  
An Australian PCV isolate (LW1998) that had previously been sequenced and characterised 
(Warfe, 1999) and found to be most similar to PCV2 associated with PMWS was used as a 
template in construction of recombinant plasmids, as was the type species PCV1 from PK15 
cells.   
Oligonucleotide primers were designed to amplify the entire coding sequence of ORF V1 (rep 
gene) in PCV1 or the entire ORF C1 (cap gene) in both PCV1 and PCV2 (Table 4.1).   
Engineered into the 5’ end of each primer was the recognition site for the restriction enzyme 
EcoRI.  This facilitated construction of the recombinant pFastBac
™ plasmid.  The primer pair 
PCV1ORF1Left and PCV1ORF1Right was used to amplify PCV1 rep, PCV1ORF2Left and 
PCV1ORF2Right for PCV1 cap, and PCV2ORF2For with PCV2ORF2Rev for amplification of 
PCV2 cap.   
 
Table 4.1.  Primers used for the amplification of genes of interest from PCV1 and PCV2 template DNA.  All 
primers contain the coding sequence for the restriction enzyme EcoRI at the 5’ end.   
Primer  Sequence (5’→3’)  Target genome (bp) 
Annealing 
temperature (°C) 
PCV1ORF1Left  GAATTCATGCCAAGCAAGAAAAGC  PCV1 (55 – 79)  55 
PCV1ORF1Right  GAATTCACACAGGCCTCGGCTATG  PCV1 (993 – 1017)  55 
PCV1ORF2Left  GAATTCAATAGTCAGCCTTACCACA  PCV1 (1730 – 1755)  60 
PCV1ORF2Right  GAATTCATGACGTGGCCAAG  PCV1 (1038 – 1058)  60 
PCV2ORF2For  GAATTCATGACGTWTCCAAGGAGGC  PCV2 (1034 – 1059)  60 
PCV2ORF2Rev  GAATTCTWAGGGTTYAAGTGGGGGGTC  PCV2 (1735 – 1762)  60 
 
PCR reactions were performed in 25 µL volumes containing 2 mM MgCl2, 2 mM of each 
deoxynucleotide triphosphate and 0.5 U of AmpliTaq DNA polymerase (Perkin Elmer) made 
up to volume with PCR buffer (Perkin Elmer).  The cycling conditions were a 7 min denaturing 
step at 94°C preceding a cycling program of 94°C for 45 s, 30 s at the appropriate annealing   85
temperature (Table 4.1) and extension for 2 min at 72°C for a total of 30 cycles.  This was 
followed by a final extension step at 72°C for 7 min to provide better efficiency of 3’ 
deoxyadenosine triphosphate addition to PCR products, useful in TA cloning.   
Escherichia coli strains  
E. coli TOP10 (F
- mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 ∆lacX74 recA1 deoR araD139 
∆(ara-leu)7697 galU galK rpsL (Str
R) endA1 nupG ) and E. coli TOP10F' (F' {lacI
q Tn10(Tet
R)} 
mcrA  ∆(mrr-hsdRMS-mcrBC)  φ80lacZ∆M15  ∆lacX74  recA1  deoR  araD139  ∆(ara-leu)7697 
galU galK rpsL( Str
R) endA1 nupG) were supplied in the TOPO TA Cloning
® kit (Invitrogen).  
E. coli DH10Bac
™ (F
-  mcrA  ∆(mrr-hsdRMS-mcrBC)  φ80dlacZ∆M15  ∆lacX74  endA1  recA1 
deoR  ∆(ara,  leu)7697  araD139  galU  galK  nupG  rpsL  λ
-/bMON14272/pMON7124) were 
supplied in the Bac-to-Bac
® Baculovirus Expression System (GibcoBRL/Invitrogen).  E. coli 
BL21 (B, F
-, dcm, ompT, hsdS(rB
-mB
-), gal) were kindly supplied by Meredith Stewart (this 
laboratory).  E. coli JM109 (F´ traD36 proA
+B
+ lacI
q ∆(lacZ)M15/ ∆(lac-proAB) glnV44 e14
- 
gyrA96 recA1 relA1 endA1 thi hsdR17) were obtained from New England Biolabs.   
Preparation of plasmid DNA 
Plasmids were purified using a plasmid DNA mini-prep procedure modified from Morelle 
(1991).  Briefly, a 10 mL volume of overnight culture in LB broth (10 g/L tryptone, 5 g/L yeast 
extract, 10 g/L NaCl) supplemented with 100 µg/mL ampicillin (Sigma), shaken at 250 rpm 
and incubated at 37°C.  Approximately 3 mL of culture broth was centrifuged (21,000 x g, 30 
s) to pellet the bacteria which were then resuspended in 200 µL of solution I (25 mM Tris-HCl, 
10 mM EDTA and 20 µg/mL RNAse A; pH 8.0) and an additional 200 µL of solution II (1% 
[w/v] SDS and 0.2 M NaOH) to lyse the bacterial cells.  The mixture was inverted several 
times for complete cell lysis before the addition of 200 µL solution III (3 M potassium acetate; 
pH 4.8) to neutralise the pH and precipitate proteins.  The precipitated protein was pelleted by 
centrifugation (21,000 x g, 20 min).  The supernatant was mixed with 600 µL of 100% 
isopropanol to precipitate all nucleic acids, and centrifuged (21,000 x g, 20 min).  The pellet 
was blotted onto paper towels to remove excess liquid and 500 µL of 70% (v/v) ethanol was 
added to wash salts away.  The tube was then centrifuged (21,000 x g, 10 min). The pellet 
was dried under a vacuum in a Savant Rotary SpeedVac for 10 min and subsequently 
resuspended in 50 µL dH2O.  Plasmid DNA preparations were subsequently used for 
restriction endonuclease digestion and PCR analysis.   
Restriction endonuclease digests of plasmids 
Restriction digests were performed in a total volume of 20 µL containing 2 µL 10X reaction 
buffer, 5 µL DNA template (approximately 800 ηg plasmid DNA), 1 µL restriction 
endonuclease (10 U) and 12 µL dH2O.  The digest reactions were incubated for at least 2 h at 
37°C.  Where incubations exceeded this time, 0.5 µL (5 U) of enzyme was used and the 
residual volume replaced by an appropriate amount of dH2O.     86
Ethanol precipitation of DNA 
To enable efficient precipitation of DNA, sodium acetate (pH 5.2) was added to the 
preparations to a final concentration of 1 M, then two volumes of 100% (v/v) ethanol.  After 
incubation at -20°C for at least 1 h, the sample was centrifuged (21,000 x g, 15 min, 4°C), the 
supernatant removed and the pellet washed with 500 µL of 70% (v/v) ethanol and further 
centrifuged (14,000 x g, 5 min, 4°C).  The supernatant was aspirated and excess supernatant 
removed by gentle tapping on a paper towel.  The DNA pellet was dried under vacuum in a 
Savant Speed Vac Concentrator for 5 min at room temperature and then resuspended in 
double-distilled deionised water (ddH2O).   
Agarose gel electrophoresis of DNA preparations 
Agarose gel electrophoresis was performed using either Bio-Rad Mini Sub™ DNA cells or 
Bio-Rad Wide Sub™ DNA cells (Bio-Rad).  Tank and gel buffers consisted of TAE (50X TAE: 
2 M Tris-Acetate, 0.05 M EDTA, pH 8.0) as described by Sambrook, Fritsch, and Maniatis 
(1989).  Agarose gels consisted of 0.8% (w/v) electrophoresis-grade agarose (Progen) and 10 
µg/mL ethidium bromide.  Electrophoresis was performed at 90 V for approximately 45 min 
and the gels viewed under ultraviolet light with a transilluminator.  Gels were photographed 
using the GelDoc system (Bio-Rad).   
Extraction of DNA from agarose gels 
The DNA band of interest was excised from the agarose gel and the volume estimated and 
the DNA recovered from the excised band using a Qiagen Gel Extraction kit (Qiagen) as 
described by the manufacturer.  Briefly, approximately three volumes of QX1 buffer 
(composition not supplied) were used to dissolve the agarose at 56°C for 10 min.  An 
equivalent volume of 100% isopropanol to the volume of the gel excised was then added to 
the solution and the mixture allowed to equilibrate.  The samples were then loaded onto a 
spin column (Qiagen) and centrifuged (21,000 x g, 1 min).  Following a wash with 500 µL of 
QX1 buffer, the column was washed with a PE buffered solution containing ethanol 
(composition not supplied).  The column was centrifuged and dried.  DNA was eluted from the 
column with 30 µL dH2O for 1 min and then centrifuged (21,000 x g, 1min).  The resulting 
DNA solution was stored at -20°C until used.   
Ligation of vector and insert DNA 
The formula below was used to accurately define the amount of insert needed to obtain 
desired molar ratios of insert to vector for efficient ligation.   
 
 
Ligation reactions were typically performed in a total volume of 10 µL containing ligation 
buffer (New England Biolabs), a determined amount of linearised plasmid (typically 25 ηg), an 
(ηg of vector) x (bp size of insert) x (molar ratio of insert to vector) 
 
(bp size of vector) 
= ηg insert needed   87
appropriate amount of insert and 4 Weiss units of T4 DNA ligase (New England Biolabs) in 
sterile dH2O.  The ligation reaction was incubated overnight (~15 h) at 14°C.  The reaction 
was stopped by heat inactivation of the enzyme at 70°C for 10 min and then the mixture was 
cooled to room temperature.  Ligation mixtures were stored at -20°C until used later for 
transformation.   
Cloning PCR products into pCR
®2.1-TOPO
®   
A TOPO TA Cloning
® kit (Invitrogen) was used as recommended by the manufacturer to 
clone PCR products into the plasmid vector.  Briefly, unpurified PCR products were quantified 
relative to molecular weight standards and added to a TOPO
® cloning reaction mixture with 
an insert:vector molar ratio of 3:1.  The 6 µL TOPO
® cloning reaction mix contained 1 ηg 
pCR
®2.1-TOPO
® plasmid DNA, an appropriate amount of PCR product, 1 µL salt solution and 
sterile water to make up the 6 µL reaction volume.  The TOPO
® cloning reaction was 
performed at 22°C for 5 min and then stored at -20°C until used for transformation.   
Cloning DNA fragments into pFastBac™ 
Approximately 500 ηg of pFastBac
™HT A (Invitrogen; Figure 4.1), a baculovirus expression 
vector containing an N-terminal hexahistidine (6xHIS) tag, was digested with the restriction 
endonuclease  EcoRI in a 20 µL reaction as described above, then dephosphorylated to 
reduce re-ligated plasmid background and increase the possibility of ligation of vector with the 
DNA fragment to be cloned.  Dephosphorylation of restriction endonuclease-digested vector 
was performed by treatment with 20 U calf intestinal alkaline phosphatase (CIAP; New 
England Biolabs) for 3 cycles of 15 min at 37°C followed by 15 min at 56°C.  The 
dephosphorylated plasmid was then recovered by ethanol precipitation and quantified using a 
Dynaquant DNA fluorometer (Hoefer).  Purified gel-extracted DNA to be cloned was 
quantified relative to DNA marker standards or by fluorometry.  Ligation was performed by 
standard procedures outlined above using a 5:1 insert:vector molar ratio.   
 
Figure 4.1.  Vector map of pFastBac
™HT A (from www.invitrogen.com/content/ 
sfs/vectors/pfastbacht_map.pdf; 27 July 2004).   
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Transformation of pCR
®2.1-TOPO
® 
Transformation of competent E. coli TOP10F’ cells with TOPO
® cloning reaction mixture by 
the heat-shock method was performed as recommended by the manufacturer.  Briefly, 2 µL of 
TOPO
® cloning reaction mixture was added to 50 µL of One Shot
® Chemically Competent 
TOP10F’ E. coli cells (Invitrogen).  Transformation reactions were incubated on ice for 30 min, 
heat shocked at 42°C for exactly 30 s and transferred back to ice.  A 250 µL volume of SOC 
medium (Invitrogen) at room temperature was added to the transformation mixture and the 
tube shaken at 200 rpm at 37°C for 1 h.  Fifty to 100 µL of the transformation mix was spread 
onto pre-warmed LB agar plates (10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl, 1.5% [w/v] 
agar supplemented with 100 µg/mL ampicillin and 50 µg/mL kanamycin) containing X-Gal and 
IPTG, and grown overnight at 37°C.  Resultant colonies were analysed by isolating the 
plasmid DNA, as described above, and digestion with appropriate restriction enzymes to 
ensure the plasmid contained the appropriately sized insert.   
Transformation of pFastBac
™HT A into E. coli TOP10 cells 
Transformation of competent E. coli TOP10 cells with pFastBac
™HT A was performed by a 
heat-shock method.  A 3 µL volume of the ligation reaction mix was added to a 1.5 mL 
microcentrifuge tube containing 25 µL of One Shot
® Chemically Competent TOP10 E. coli 
(Invitrogen).  Cells were incubated on ice for 30 min and then heat-shocked for 30 s at 42°C.  
The tubes were placed on ice and 250 µL of SOC medium at room temperature was added.  
Tubes were shaken at 200 rpm at 37°C for 1 h.  Fifty and 100 µL volumes of the transformed 
cells were spread on LB agar plates containing 100 µg/mL ampicillin.  Plates were incubated 
overnight at 37°C.  Resultant colonies were analysed by isolating the plasmid DNA, as 
described above, and digested with appropriate restriction endonucleases to ensure the 
plasmid contained the appropriate insert in the correct orientation for protein expression.   
Further characterisation of recombinant clones was performed by sequence analysis of the 
plasmid insert.  Once a recombinant clone in the correct orientation and frame was identified, 
transformation into DH10Bac competent cells was performed.   
Transformation of DH10Bac
™ E. coli  
Once the recombinant pFastBac
™ construct had been generated, it was necessary to 
transform the purified plasmid DNA into DH10Bac
™ E. coli.  The E. coli DH10Bac
™ strain 
contained a baculovirus shuttle vector (bacmid) with a mini-attTn7 target site and a helper 
plasmid.  Once the pFastBac
™ expression plasmid was transformed into the DH10Bac
™  cells, 
transposition occurred between the mini-Tn7 element on the pFastBac
™ vector and the mini-
attTn7 target site on the bacmid to generate a recombinant bacmid.  This transposition 
reaction occurred in the presence of transposition proteins supplied by the helper plasmid.  
Blue/white selection could then be used to identify colonies containing the recombinant 
bacmid.     89
For each transformation, 100 µL of MAX Efficiency
® DH10Bac
™ competent cells (GibcoBRL) 
was thawed on ice and transferred into a pre-chilled, 15 mL round-bottom polypropylene tube.  
Approximately 1 ηg of purified pFastBac
™HT A plasmid DNA containing the gene of interest 
was added to the cells and mixed gently.  The cells were incubated on ice for 30 min, then 
heat-shocked for 45 s at 42°C without shaking.  The tubes were then immediately transferred 
to ice and chilled for 2 min.  Following this, 900 µL of room temperature SOC medium was 
added and the tubes shaken (225 rpm) at 37°C for 4 hours.  For each pFastBac™ 
transformation, 10-fold serial dilutions of the cells were prepared with SOC medium and 100 
µL of each dilution was plated on an LB agar plate containing 50 µg/mL kanamycin, 7 µg/mL 
gentamicin, 10 µg/mL tetracycline, 100 µg/mL Bluo-gal (GibcoBRL), and 40 µg/mL IPTG.   
Plates were incubated for 48 h at 37°C and white colonies picked for analysis.   
Analysis of recombinant bacmid DNA by PCR 
Recombinant bacmid was recovered in the same way as plasmid DNA and then analysed by 
PCR for presence of the desired gene; the recombinant bacmid DNA was greater than 135 kb 
in size thereby making restriction endonuclease analysis difficult to perform.  The bacmid 
contained M13 Forward (-40) and M13 Reverse (Table 4.2) priming sites flanking the mini-
attTn7 site within the lacZα-complementation region to facilitate PCR analysis.   
 
Table 4.2.  Oligonucleotide primer sequences used in bacmid PCR analysis.   
Primer  Sequence (5’ → 3’) 
M13 Forward (-40)  GTTTTCCCAGTCACGAC 
M13 Reverse  CAGGAAACAGCTATGAC 
 
The recombinant bacmid DNA was amplified using the M13 Forward (-40) and M13 Reverse 
primers and Taq DNA polymerase.  Each PCR had a 50 µL reaction volume composed of 100 
ηg recombinant bacmid DNA, 5 µL 10X PCR Buffer, 1 µL 10 mM dNTP mix, 1.5 µL 50 mM 
MgCl2, PCR Primers (1.25 µL each, 10 µM stock), 0.5 µL Platinum
® Taq polymerase 
(Invitrogen) and sterile water to make up the 50 µL volume.  The thermal cycling profile 
parameters are outlined in Table 4.3.   
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Table 4.3.  PCR thermal cycling protocol for screening recombinant bacmid DNA. 
Temperature (°C)  Time (min : s)  Cycles 
93 3:00  1 
94 0:45   
55 0:45  35 
72 5:00   
72 7:00  1 
 
Transfection of insect cells 
Once it was confirmed that the recombinant bacmid contained the gene of interest, 
transfection of insect cells was performed to produce recombinant baculovirus.  In a 6-well or 
35 mm tissue culture plate, Sf9 cells (9 x 10
5 cells per well of a 6-well plate) were seeded in 2 
mL of Sf-900 II SFM (Invitrogen) containing antibiotics (50 units/mL penicillin and 50 µg/mL 
streptomycin).  Cells were allowed to attach at 27°C for at least 1 h.  For each transfection, 1 
µg of purified bacmid DNA was mixed with 100 µL of Sf-900 II SFM and 6 µL of Cellfectin
® 
Reagent (GibcoBRL).  The mixture was incubated for 45 min at room temperature.  While the 
DNA:lipid complexes were incubated, media was removed from the cells and they were 
washed once with 2 mL of Sf-900 II SFM.  To each tube containing the DNA:lipid complexes, 
0.8 mL of Sf-900 II SFM was added, mixed gently and added to one well of cells.  Cells were 
incubated at 28°C for 5 h before the DNA:lipid complexes were removed and 2 mL Sf-900 II 
SFM containing antibiotics was added.  Cells were incubated again at 28°C but this time in a 
humidified environment for 72 h or until a cytopathic effect (CPE) developed.  Once the 
transfected cells showed an advanced CPE, the medium (containing virus) from each well 
was collected and transferred to a sterile 15 mL tube.  The tubes were centrifuged (500 x g for 
5 min) to remove cells and large debris, and the clarified supernatant was transferred to fresh 
15 mL tubes.   
Amplification of recombinant baculovirus 
The viral stock recovered from the transfection was of low titre.  To increase the titre, Sf9 cells 
were infected at a multiplicity of infection (MOI) ranging from 0.5-2.  The MOI was defined as 
the number of infectious virus particles per cell, and the following formula used to calculate 
how much viral stock was required: 
 
Inoculum required =   MOI (pfu/cell) x number of cells 
   ----------------------------------------- 
      titre of viral stock (pfu/mL) 
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The infected cells were incubated with the inoculum at room temperature for 1 h to allow for 
attachment and the cells were then incubated for 48 h at 28ºC.  The cell culture medium was 
collected and transferred to sterile tubes, centrifuged (500 x g for 5 min) to remove cells and 
large debris, and the clarified supernatant pooled and stored at 4ºC, protected from light.   
Titration of recombinant baculovirus by plaque assay 
The titre of infectious virus in the baculovirus stocks was determined by plaque assay.   
Approximately 1 x 10
6 Sf9 cells were seeded into each 35 mm well of a 6-well plate, then 
incubated at room temperature for at least 1 h to ensure cell attachment, then the medium 
was aspirated.  Ten-fold serial dilutions of the virus preparation were prepared and 1 mL of 
each dilution added to wells and the monolayers incubated at room temperature for an 
additional 1 h.  The virus inoculum was then aspirated and replaced with 2 mL of a plaquing 
overlay consisting of Sf-900 1.3X (GibcoBRL) and sterile 4% (w/v) agarose at a ratio of 3:1.  
Plates were incubated at 28°C in a humidified incubator for 4 days, then the cells were 
stained by the addition of 2 mL of 0.03% (w/v) neutral red and incubated for 1 h at room 
temperature.  Excess stain was aspirated and the plates were inverted and placed in the dark 
at room temperature until the number of visible plaques did not change for two consecutive 
days.  To determine the titre of the viral inoculum, the plaques were counted in wells 
containing 3-20 plaques.   
Expression of baculovirus proteins in insect cells 
Once the pFastBac
™ baculovirus stock was generated with a titre of 1 x 10
8 pfu/mL or 
greater, it was possible to infect insect cells and assay for expression of recombinant 
protein(s).  Suspension cultures of Sf9 cells were grown in serum-free conditions in Sf-900 II 
SFM, and growth was monitored by counting cells in a haemocytometer using trypan blue 
exclusion.  Once cultures reached a density of 2 x 10
6 - 3 x 10
6 viable cells/mL and were in 
the mid-logarithmic phase of growth, they were infected with the recombinant baculovirus at 
an MOI of 10.  Infected cells were monitored at regular intervals and harvested 48 h post-
infection by centrifugation (500 x g for 10 min).   
Purification of baculovirus proteins 
All steps of the protein purification were carried out at 4°C.  The volume of the cell pellet was 
estimated and the cells then lysed by the addition of five volumes of Sf9 cell lysis buffer (50 
mM Tris-HCl [pH 8.5]; 5 mM β-mercaptoethanol; 100 mM KCl; 1 mM PMSF; 1% (v/v) Nonidet 
P-40) and gently mixed end-over-end for 5 min.  Suspensions were centrifuged (10,000 x g 
for 10 min) and the supernatant was transferred to a fresh tube.  An appropriate volume of Ni-
NTA agarose resin (Qiagen) was equilibrated with phosphate buffer 1 (50 mM potassium 
phosphate [pH 6.0]; 300 mM KCl; 5 mM β-mercaptoethanol; 10% (v/v) glycerol; 8 M urea) for 
10 min and loaded onto a chromatography column (BioRad), the resin was allowed to settle in 
the column before being washed again with ten volumes of phosphate buffer 1.  Supernatants    92
from the cell lysis step were loaded onto the column and allowed to flow through at 
approximately 1 mL/min.  The resin containing bound His-tagged protein was then washed 
with approximately 25 volumes of phosphate buffer 1.  Elution of the recombinant His-tagged 
protein was carried out by loading phosphate buffer 2 (50 mM potassium phosphate [pH 6.0]; 
300 mM KCl; 250 mM imidazole; 5 mM β-mercaptoethanol; 10% (v/v) glycerol and 8 M urea) 
onto the column and collecting 0.5 mL fractions for analysis by SDS-PAGE and WIB.   
Quantitation of purified protein 
Protein solutions were assayed in duplicate or triplicate using the BioRad Protein Assay Kit 
(BioRad).  Three to five dilutions of a bovine serum albumin (BSA) protein standard ranging 
from 8-80 µg/mL were prepared as standards.  A volume of 160 µL of each BSA standard, or 
a protein solution of unknown concentration was pipetted into a microtitre plate well.  A 40 µL 
volume of dye reagent concentrate (BioRad) was added to each well, the plates were shaken 
on a microplate mixer, incubated at room temperature for at least 5 min, and then the 
absorbance measured at 595 nm using a microplate reader.   
Taq dyedeoxy-terminator cycle sequencing 
Sequencing reaction mixtures were prepared that contained 4 µL fluorescent dye terminator 
premix (Applied Biosystems), 1.6 ρmoles of primer, and a specified amount of template to 
make up the final volume of 10 µL.  The quantity of DNA template for sequencing varied 
according to the type of DNA used but typically 50 ηg of PCR product or 300 ηg of plasmid 
DNA was added.  The thermal cycling protocol for sequencing reactions was as outlined in 
Table 4.4 and was performed on a Perkin Elmer Cetus 2400 Thermal Cycler.  Removal of 
unincorporated nucleotides and reactants in the sequencing reaction was performed using an 
ethanol precipitation method as described in the Prism™ Ready Reaction DyeDeoxy™ Cycle 
Sequencing manual (revision A, August 1995; Applied Biosystems, USA).   
 
Table 4.4.  PCR thermal cycling protocol for ABI Prism™ Ready Reaction DyeDeoxy™ Terminator Cycle 
Sequencing Kit.   
Temperature(°C)  Time(min : s)  Cycles 
96  3:00     1 
96 0:10   
50  0:05    25 
60 4:00   
4  ∞  
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Polyacrylamide gel electrophoresis  
Proteins were visualised by 0.1% (w/v) sodium dodecyl sulphate, 12.5% (v/v) polyacrylamide 
gel electrophoresis (SDS-PAGE) as described by Laemmli (1970).  The samples were then 
loaded onto a prepared mini-gel and electrophoresed at 200 V for 45 min.  Gels were stained 
with Coomassie blue and destained gels were stored by drying on a vacuum gel dryer 
(BioRad).   
ELISA 
Polycarbonate 96-well ELISA plates (NUNC) were coated with 100 µL of purified recombinant 
fusion protein that had been diluted to a concentration of 1.75 ηg/µL with carbonate buffer 
(350 mM NaHCO3, 150 mM Na2CO3; pH 9.6).  After incubation at 4°C overnight, plates were 
washed three times with 200 µL PBS with 0.1% (v/v) Tween-20 (PBST).  Test sera were 
diluted in PBS with 0.1% (v/v) Tween-20 and 5% (w/v) skim milk powder (PBSTM) to 1:40, 
and 100 µL applied to each well including one positive and one negative antiserum control 
well per plate.  Following incubation for 1 h at 37°C, wells were washed three times with 
PBST as before.  Secondary antibody conjugated to horseradish peroxidase (mouse anti-
porcine IgG-HrP conjugate; ICN) was used at a standard dilution of 1:5000 (100 µL/well) and 
incubated at 37°C for 30 min.  Residual conjugate antibody was removed by several washes 
with PBST as before.  A 100 µL volume of freshly prepared and warmed (37°C) 2,2’-azino-di-
(3-ethylbenzthiazoline-6-sulfonate) (ABST) substrate (BioRad) was then added to each well 
and incubated for 15 min at 37°C; the reaction was stopped by adding an equal amount of 1% 
(v/v) SDS.  All plates for each study were incubated with substrate for identical times.  The 
plates were read on an ELISA plate reader (BioRad) at 405 nm and raw absorbance values 
analysed by the equation below to attain cross-plate standardisation.   
x = 100    A
X – A
- 
               A
+ - A
- 
Where,  
X =   adjusted absorbance value 
A
X = absorbance value of sample 
A
- = absorbance value of control negative serum for plate 
A
+ = absorbance value of control positive serum for plate. 
 
Western immunoblotting 
Detection of recombinant antigens by WIB analysis was performed using the procedure 
originally developed by Towbin, Staehalin and Gordon (1979).  Unstained SDS-PAGE gels 
were transferred to 0.45 µm nitrocellulose membranes using a mini Trans-Blot apparatus   94
(BioRad) and ice-cold transfer buffer (25 mM Tris, 192 mM glycine, 20% [v/v] methanol).  
Transfer was performed at 100 V for approximately 1 h at 4°C.  The membrane was blocked 
overnight at 4°C with PBSTM and then washed in PBST.  Primary antibody was added to the 
membrane at a dilution of 1:10 for pig antisera, or 1:3,000 for mouse anti-HIS IgG, and the 
membrane incubated at 37°C for 2 h.  After 3 washes in PBST, a horseradish peroxidase 
(HrP) conjugated secondary antibody was added to the membrane at a dilution of 1:3,000 for 
anti-mouse (goat anti-mouse IgG-HrP conjugate; Sigma), or 1:2,500 for anti-pig (mouse anti-
porcine IgG-HrP conjugate; ICN) and incubated at 37°C for 1 h.  The membrane was then 
washed and allowed to react with 4-chloro-naphthol (4-CN) substrate (BioRad).  The reaction 
was stopped by rinsing the membrane under distilled and deionised water and allowed to dry.   
For assay of field serum samples, purified recombinant fusion protein was applied to an SDS-
PAGE gel with no wells, producing a continuous band of antigen across the gel.  All WIB 
assays were performed using reference positive antisera on one strip from each batch of 
strips obtained from one nitrocellulose membrane.   
Application of immunoassays to field serum samples 
Serum samples from six Australian states were obtained from a National Pig Serum Bank 
established at Murdoch University by Australian Pork Limited.  The samples for the serum 
bank were collected in the period 1999-2001.  Typically, each submission consisted of 30 
serum samples per herd.  There was also a set of sera (175 samples) obtained from feral pigs 
in Queensland.  Serum samples were tested in triplicate, always in parallel with a reference 
positive antiserum and a negative antiserum to enable standardisation of the assay.  For IIF, 
ELISA or WIB, sera were only considered positive if a positive result was obtained in at least 
two of the three replicate tests.   
IIF assays were analysed as described in Chapter 3, where the strength of reactivity was 
graded on a subjective scale (-, +, ++ or +++) relative to the negative and positive controls 
which were – and +++, respectively.   
Positive ELISA results were considered to be those where the absorbance values were equal 
to or greater than the mean absorbance plus 2 standard deviations (p > 0.05) of the reference 
positive serum.   
Positive WIB results were determined as those that had specific reactivity with the 
recombinant protein and a banding pattern similar to the positive control.  Strength of 
reactivity by WIB was graded on a subjective scale (-, +, ++, +++ and ++++) relative to the 
positive control which was ++++.   
Bacterial pGEX-6P-1 expression system 
Amplification of PCV1 rep and cap genes 
The entire ORF V1 and C1 from the PCV1 type strain was amplified by PCR from DNA 
extracted from persistently-infected PK15 cells using specific oligonucleotide primers  95
that incorporated EcoRI restriction sites.  The primers were as described above (Table 4.1) 
and incorporated a recognition site for the restriction enzyme EcoRI at the 5’ end of each 
primer.  This facilitated construction of the recombinant pGEX-6P-1 (Amersham Pharmacia 
Biotech) plasmid.  For amplification of PCV1 rep, the primer pair PCV1ORF1Left and 
PCV1ORF1Right were utilised in the PCR, whereas for amplification of PCV1 cap the primers 
PCV1ORF2Left and PCV1ORF2Right were used.  The PCR conditions for amplification were 
as described earlier (Chapter 4; Primers and PCR).   
Cloning amplified products into vector pCR
®2.1 
Amplified PCR products were cloned into plasmid pCR
®2.1 (Invitrogen) as a holding vector 
using TA Cloning
® technology as described earlier and this was used to transform E. coli 
TOP10F’ using a heat-shock method.  Recombinant colonies were screened by purifying the 
plasmid DNA and subjected to restriction endonuclease digestion with EcoRI as described 
earlier.  Inserts of the correct size were then excised from agarose gels and purified using a 
Qiagen Gel Extraction kit (Qiagen) in preparation for cloning into vector pGEX-6P-1.   
Subcloning genes into pGEX-6P-1 
The purified inserts corresponding to the amplified products of PCV1 V1 and PCV1 C1 were 
then subcloned into the pGEX-6P-1 bacterial expression vector containing an N-terminal 
glutathione-S-transferase (GST) tag.  The methodology used was the same as for cloning 
inserts into the pFastBac
™HT A vector, described elsewhere in this Chapter.  The only 
difference to the previously described methods was that multiple strains of E. coli were 
transformed with the plasmids.  This was done to investigate the variation of recombinant 
protein expression in various strains of E. coli, including BL21, JM109 and TOP10F’.   
Recombinant plasmids were screened for presence and orientation of the insert using PCR, 
restriction endonuclease digests and sequence analysis.  A number of recombinant plasmids 
containing the insert in the correct orientation were chosen for expression. 
Expression and purification of recombinant protein 
Protein synthesis from the recombinant plasmids in E. coli was induced using IPTG at a 
concentration of 100 mM.  Screening of pGEX recombinants for fusion protein expression 
was carried out using SDS-PAGE and WIB with the aid of an anti-GST antibody and pig 
serum samples.   
A number of variables were examined in the above expression protocol to maximise 
production of the recombinant protein including: the strain of E. coli, concentrations of the 
inducer (IPTG) from 10 mM to 1 M; incubation times with inducer ranging from 2-6 h; and 
incubation of cultures at 28°C and 37°C to facilitate correct folding of the protein.   
Two methods were used to purify recombinant proteins from the bacterial pellet: The first 
purified any soluble proteins while the second concentrated on purifying recombinant proteins 
from inclusion bodies.     96
Protein expression involved the inoculation of the bacterial clones containing the recombinant 
pGEX-6P-1 plasmid into 10 mL of LB broth supplemented with 100 µg/mL ampicillin (Sigma).  
The culture was grown overnight at 37°C on a horizontal shaking platform at 225 rpm.  The 
overnight culture was diluted 1:10 in fresh 2X YT-G (16 g/L tryptone, 10 g/L yeast extract, 5 
g/L NaCl, 2% [w/v] glucose) medium with 100 µg/mL ampicillin and incubated at 37°C for 4 h 
with shaking at 225 rpm until an OD600 0.7-0.9 was attained.  The inducer, IPTG, was added 
to a final concentration between 10-1000  mM.  Cultures were then incubated a further 4-6 h 
at 37°C with vigorous shaking (250 rpm) and then analysed for expression of protein by 
applying 10 µL of boiled cell suspension mixed 1:1 with sample loading buffer (6.25 mM Tris-
HCl [pH 6.8], 0.0125% [w/v] bromophenol blue, 5% [v/v] 2-β-mercaptoethanol, 2% [w/v] SDS, 
10% [v/v] glycerol) to SDS-PAGE.   
Preparation of large-scale cultures (0.5-2 L) for protein production involved a procedure 
similar to that used for the small-scale preparation.  An overnight 100 mL culture of 
recombinant bacteria was diluted 1:10 in fresh 2X YT medium and allowed to grow 1-2 h to an 
OD600 of 0.7-0.9.  Typically, 1 L large-scale protein production cultures were induced with 0.1-
100 mM IPTG for 4 h at 37°C with vigorous shaking (250 rpm).  Cells were harvested by 
centrifugation (7,700 x g, 10 min, 4°C).  The supernatant was discarded and the bacterial 
pellet resuspended in 50 mL ice-cold PBS.  Hen egg white lysozyme (Sigma) and DNase I 
(Sigma) were added to the cell suspensions at final concentrations of 250 µg/mL and 10 
ηg/mL, respectively, and incubated on ice for at least 1 h.  Aliquots of approximately 25 mL 
were subjected to 5 freeze-thaw cycles (snap frozen in liquid nitrogen and thawed at 42°C) or 
until the solution became viscous and grey in colour.  A non-ionic detergent, triton X-100, was 
added to a final concentration of 1% (v/v) to aid in the solubilisation of recombinant protein.  
The mixture was then incubated at room temperature for 30 min with gentle mixing.   
Centrifugation (12,000 x g, 10 min, 4°C) of the lysate resulted in a large pellet of insoluble 
material.  The supernatant was removed and used in the purification procedure.  If the pellet 
was stored, phenylmethylsulfonyl fluoride (PMSF) was added at a final concentration of 1 mM 
in order to reduce protein degradation and the pellet was then stored at -80°C.   
The recombinant proteins produced in E. coli were purified from the pellet using two methods, 
which purified the soluble and insoluble protein fractions.  The first method utilised the GST 
fusion tag and the second isolated the recombinant protein from inclusion bodies. 
Purification of recombinant protein tagged with GST was undertaken using a bulk matrix 
consisting of 50% (v/v) glutathione agarose (Sigma) equilibrated in PBS.  A 20 µL volume of 
the 50% suspension of the matrix was added to each 1 mL of lysate produced and incubated 
at room temperature for 1 h with gentle rotation.  The preparations were then centrifuged (500 
x g, 5 min, 4°C) to sediment the affinity matrix and the supernatant removed for further 
analysis.  The pelleted matrix was washed three times with PBS to remove contaminating 
proteins.     97
Previous optimisation experiments have shown elution by competitive binding with the GST 
affinity tag was the most efficient elution method.  Elution was performed using 20 mM free 
reduced glutathione in 50 mM Tris-HCl (pH 8.0).  For removal of the affinity tag from the 
protein of interest, ‘PreScission Protease’ (Pharmacia Biotech) cleavage was performed 
overnight (~16 h) following the manufacturer’s instructions and supernatants recovered by 
centrifugation (500 x g, 5 min, 4°C).  Samples at each step were retained for analysis by 
SDS-PAGE and WIB.   
Monoclonal antibody production 
Immunisation and testing of mice for antibody production 
Six week old Balb/c mice were subcutaneously injected with approximately 5 µg of purified 
recombinant PCV2 capsid protein expressed using the baculovirus system.  Mice were 
injected four times at weekly intervals with the antigen emulsified in an equal volume of 
incomplete Freund’s adjuvant.  After the fourth injection, tail snips were conducted to collect 
sera which was tested for antibody against the PCV2 capsid antigen by WIB as described 
above.  Mice that were PCV2 capsid antibody positive were given a booster shot of the pure 
protein with adjuvant three days prior to a fusion being conducted.   
Preparation of myeloma cells 
Myeloma cells (NSφ) were grown in Dulbecco’s modified essential medium (DMEM) 
supplemented with 10% (v/v) newborn calf serum (NBCS) and antibiotics at 37°C in a 7% 
CO2-in-air atmosphere.  To obtain healthy and actively multiplying NSφ cells, the cells were 
subcultured daily until fusions were performed.  On the day the fusion was conducted, the 
cells were centrifuged (250 x g, 5 min), the supernatant was discarded and the cells were 
suspended in 5 mL serum-free DMEM.  The viability of the cells was determined using trypan 
blue exclusion and a haemocytometer and the cells were used for fusion only if viability was 
greater than 95%.  Cells were held in ice prior to fusion.   
Preparation of spleen cells for fusion 
Three days after the final booster, an immunised and a non-immunised mouse were 
euthanased in a chamber filled with 80% CO2 and 20% O2.  The spleen of each mouse was 
removed aseptically, and placed in a sterile 60 mm Petri dish containing approximately 2 mL 
of serum-free DMEM.  The spleen cells were extracted from the spleen by teasing with two 
needles on the end of syringes.  An additional 3mL of serum-free DMEM was then added to 
the dish, and the viability of the cells was determined as described above.  The spleen 
suspension was kept at 4°C. 
Cells from immunised mice were fused to myeloma cells by standard methods.  About 2 x 10
7 
NSφ cells were added to 10
8 spleen cells in a round bottom sterile centrifuge tube, and then 
gently centrifuged (1,000 x g for 5 min).  The supernatant was discarded, the myeloma cells 
were gently mixed with the spleen cells by tapping the side of the tube, and 0.6 mL of 43%   98
polyethylene glycol (PEG, MW 1300-1600; Sigma) was slowly added over a period of 1 min 
with continuous gentle agitation of the cells.  The cells were again mixed by gentle swirling in 
a 37°C water bath for 2 min.  A 10 mL volume of serum-free DMEM was added, accompanied 
by the gentle shaking of the tube, and then centrifuged again (200 x g, 5 min).  The cells in 
the pellet were resuspended in 50 mL of DMEM-HAT (DMEM, 20% NBCS, 100 µM 
hypozanthine, 0.4 µM aminopterin, 16 µM thymidine, 0.58 mg/mL glutamine, 0.22 mg/mL 
sodium pyruvate, 200 IU/mL penicillin, µg/mL streptomycin) containing 10
6 normal spleen 
cells (from non-immunised mice) as feeder cells. The cells suspension was seeded in 50 µl 
volumes into wells of 96-well microtitre plates (NUNC), and the cells incubated for 4 days at 
37°C in a 7% CO2-in-air atmosphere.  Two drops of additional DMEM-HAT medium was then 
added to each well.  The culture trays were subsequently monitored each day for the 
presence of visible hybridomas.  On the eighth day following fusion, one drop of HT medium 
(DMEM-HAT medium without aminopterin) containing 2 x 10
6 feeder cells/mL was added to 
each well to stop the replication of non-fused cells. 
Screening hybridomas for anti-PCV2 capsid antibodies 
When large hybridomas were visible, approximately 10-12 days after fusion, the medium was 
tested for the presence of specific antibody by ELISA as described above.  ELISA-positive 
results were confirmed by WIB as described above, except that the hybridoma medium was 
diluted 1:1 in PBSTM and incubated with nitrocellulose strips pre-bound with recombinant 
PCV2 Capsid overnight at room temperature.   
Cloning and storage of hybridomas 
Hybridomas that secreted protein-specific antibody were continuously cultured in HT medium 
supplemented with feeder spleen cells at a concentration of 2 x 10
6 cells/mL.  After several 
passages, hybridomas that continued to secrete protein-specific antibody were cloned by 
limiting dilution in 96-well microtitre plates as described by  Astawa (1995) .  When single 
clones of the hybridomas developed in the plates, the supernatant medium was tested by 
WIB as described above to confirm the continued production of protein-specific antibody.   
Samples of such cloned antibody-secreting hybridomas were resuspended at a density 1 x 
10
6 cells/mL in NBCS containing 10% dimethylsulfoxide (DMSO; Sigma) and frozen in liquid 
nitrogen.   
Concentration and isotyping of monoclonal antibody 
The MAb produced was concentrated using 30K and 50K filter centrifuge tubes (Pall 
Gelman).  The process involved applying 10-15 mL of the hybridoma supernatant in the 
sample reservoir of the tube; followed by centrifugation (2,000 x g, 60 min or 3,000 x g, 40 
min).  The filtrate was discarded and the concentration cup attached to the bottom of the 
sample reservoir.  The concentrated MAb was collected by a further centrifugation step (3,000    99
x g, 3 min).  The MAb produced was isotyped using an EIA Grade Mouse Typer
® Mouse Sub-
Isotyping Panel (BioRad) according to the manufacturer’s instructions.   
Results 
Expression of PCV proteins by bacterial expression system 
PCV1 Rep, encoded by ORF V1, was expressed as shown in Figure 4.2.  Preparations from 
the cell lysate were used for WIB where the recombinant Rep was easily detected using an 
anti-GST antibody (Amersham Pharmacia Biotech) in the cell lysate; but when pig serum 
formerly identified as seropositive by the IIF assay was used as a primary antibody on the 
WIB, an incorrectly sized protein band was highlighted each time at approx 40 kDa.  The 
expected size of the GST fusion tag was 25 kDa, as shown in Figure 4.2, lane 3; and the 
expected size of the Rep-GST fusion protein was expected to be approximately 56 kDa as 
shown in Lane 5 (Figure 4.2).   
Further WIB experiments utilising many different serum samples found to be positive and 
negative for PCV antibody by IIF, showed that when pig serum was acting as the primary 
antibody that a number of different sized bands ranging from 25-80 kDa were detected (data 
not shown).   
The recombinant protein was insoluble and at the time, attempts to solubilise and purify the 
protein from the bacterial cell lysate, needed for ELISA and more definitive studies on the 
specificity of the protein, were unsuccessful.   
The cap gene from PCV1 and an Australian PCV2 (LW1998) was also cloned into pGEX-6P-
1.  It was not possible to express these proteins using this bacterial system.   
 
Figure 4.2.  Western immunoblot detecting recombinant PCV1 Rep-GST fusion protein from E. coli cell 
lysate.  Lane 1: Benchmark pre-stained protein ladder (GibcoBRL); 2: GST, 0 h induction; 3: GST 4 h 
induction; 4: PCV1 Rep-GST 0 h induction; Lanes 5-14: PCV1 Rep-GST 4 h induction.  The primary antibody 
applied to lanes 2-5 was anti-GST diluted 1:2000.  The primary antibody applied to lanes 6-12 was pig serum 
positive by IIF for PCV antibody, with lanes 13 and 14 negative by the IIF assay.  The secondary antibody 
used for detection in lanes 2-5 was anti-goat conjugated to HrP diluted 1:1500; for lanes 6-14, anti-swine HrP 
was used at a 1:2500 dilution.  The sizes of the protein bands of the pre-stained ladder are indicated in kDa. 
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Expression of PCV2 capsid protein by baculovirus expression system 
The PCV2 Cap protein was successfully expressed and purified using a eukaryotic 
baculovirus expression system, as shown in Figures 4.3, 4.4 and 4.5.  Optimal conditions for 
the expression of PCV2 Cap involved infecting an Sf9 cell culture in mid-logarithmic phase 
with the recombinant baculovirus at an MOI of 5 and allowing the culture to incubate at 28°C 
for 48 h after the Sf9 cells had ceased dividing.   
The expressed and purified PCV2 Cap was examined by mass spectrometry (MALDI-TOF).  
The protein was digested with trypsin and the spectra obtained from this digest were 
compared to a theoretical trypsin digest of PCV2 Cap proteins based on sequences located in 
GenBank.  The recombinant PCV2 Cap produced in the baculovirus system had a high 
correlation (>65%) to submitted sequences of putative PCV2 capsid proteins.  This MALDI-
TOF procedure and analysis was kindly carried out by Dr Richard Lipscombe from 
Proteomics International (Australia).   
Figures 4.3 (Coomassie blue stained) and 4.4 (WIB utilising a monoclonal anti-HIS antibody 
to detect the 6xHIS-tagged recombinant PCV2 Cap) show the various purification steps 
involved in isolating the recombinant protein with a nickel resin.  A number of wash steps 
were required to remove as much of the contaminating cellular proteins as possible, and the 
final two wash steps (Figures 4.3 and 4.4; Lanes 7 & 8) contained a low concentration of 
imidazole (50 mM) to assist in eluting any HIS-rich proteins from the nickel resin.  The 
recombinant protein was eluted from the resin using a buffer containing imidazole at a final 
concentration of 250 mM.  The concentration of imidazole was determined empirically after 
examining the effects of 0.1-1 M imidazole on elution of the protein.  As can be seen from 
Figures 4.3 and 4.4, protein was not eluted immediately in the first 0.5 mL fraction but was 
found subsequently in the second and third 0.5 mL fractions.   
 
 
Figure 4.3.  Coomassie blue stained gel showing purification steps of recombinant HIS-tagged PCV2 Cap.  
Lane 1: Precision Plus Protein Standards Unstained (BioRad); 2: uninfected Sf9 cell culture pellet; 3: 
recombinant baculovirus infected Sf9 cell culture pellet; 4: unbound protein fraction; 5: wash step 1; 6: wash 
step 2; 7: wash step 3 containing 50 mM imidazole; 8: wash step 4 containing 50 mM imidazole; 9: eluted 
protein fraction 1; 10: eluted protein fraction 2; 11: eluted protein fraction 3; 12: Precision Plus Protein 
Standards Unstained (BioRad). The sizes of the protein bands within the ladder are indicated in kDa. 
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Figure 4.4.  Western immunoblot of the protein purification steps using anti-HIS antibody as the primary 
antibody and anti-mouse HrP as the secondary antibody.  Lane 1: Precision Plus Protein Standards Dual 
Colour (BioRad); 2: uninfected Sf9 cell culture pellet; 3: recombinant baculovirus infected Sf9 cell culture 
pellet; 4: unbound protein fraction; 5: wash step 1; 6: wash step 2; 7: wash step 3 containing 50 mM 
imidazole; 8: wash step 4 containing 50 mM imidazole; 9: eluted protein fraction 1; 10: eluted protein fraction 
2; 11: eluted protein fraction 3.  The sizes of the protein bands within the pre-stained ladder are indicated in 
kDa.   
 
In order to verify specificity of the produced recombinant protein, it was also probed with the 
antisera obtained from a pig previously inoculated with PCV2 (LW1998).  Figure 4.5 shows 
the result of this experiment with a strong positive result.   
Prevalence of PCV2 antibody-positive pigs in samples from the 2001-2002 National Pig 
Serum Bank 
A total of 3993 samples were analysed by ELISA for antibody to the PCV2 capsid protein.  In 
order to maintain confidentiality, sera from each farm were allocated a unique producer 
number (Tables 4.6-4.11).  Where a result by ELISA was close to the cut-off range for a 
positive result, the samples were re-examined by WIB to confirm the result and then 
interpreted as positive or negative based on the result of the WIB.  The results are shown in 
Table 4.5 according to the state of origin of the samples.  Of the 3993 samples tested, the 
state of origin for 43 samples was unable to be determined, and consequently they were 
excluded from the results presented.  Antibody to the recombinant PCV2 capsid protein was 
detected in about 33% of all the serum samples.  The highest seroprevalence to the 
recombinant PCV2 capsid antigen was detected in the samples from Victoria where there was 
a 51.3% seroprevalence rate, and the lowest in Western Australia where there was a 11.4% 
seroprevalence rate.  
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Figure 4.5.  Western immunoblot demonstrating the results of the various purification steps, using antiserum 
from a pig previously identified as IIF positive (pig 485) as the primary and α-pig HRP as a secondary 
antibody, for the detection of the PCV2 capsid protein. Lane 1: Precision Plus Protein Standards Dual Colour 
(BioRad); 2: uninfected Sf9 cell culture pellet; 3: recombinant baculovirus infected Sf9 cell culture pellet; 4: 
unbound protein fraction; 5: wash step 1; 6: wash step 2; 7: wash step 3 containing 50 mM imidazole; 8: 
wash step 4 containing 50 mM imidazole; 9: eluted protein fraction 1; 10: eluted protein fraction 2; 11: eluted 
protein fraction 3.  The sizes of the protein bands within the pre-stained ladder are indicated in kDa. 
 
Table 4.5.  Results of the national serological survey to PCV2 Cap antibody, summarised by state.   
State  Number sampled (n)  Number positive  Percent positive 
QLD 1457  573  39.3 
NSW 927  237  25.6 
SA 444  126  28.4 
WA 411  47  11.4 
TAS 159  38  23.9 
VIC 552  283  51.3 
TOTAL 3950  1304  33.0 
 
 
Samples were tested from 26 farms in New South Wales (Table 4.6).  The samples from ten 
farms were seronegative and the seroprevalence in the other 16 farms ranged from 6.7-
100%. 
From Victoria, samples from 18 farms were tested (Table 4.7).  One farm was seronegative 
and the seroprevalence in the remaining farms ranged from 6.7-100%, similar to New South 
Wales.  The overall number of seropositive samples for Victoria was 283 indicative of 51.3% 
seroprevalence. 
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Table 4.6.  Summary of serology results for individual farms in New South Wales, identified by the unique 
producer numbers allocated. 
Producer  Samples submitted   Herd size (sows) Number positive  Percent positive 
67 30  25  2  6.7 
69 20  27  0  0 
76 30  38  0  0 
90 30  67  0  0 
96 60  85  22  36.7 
99 30 100 23  76.7 
108 30  199  0  0 
109 30  231  0  0 
116 30 1601  0  0 
477 30  16  16  53.3 
493 58  38  18  31.0 
508 30  68  5  16.7 
526 33  125  2  6.1 
527 60  130  6  10.0 
529 30  150  17  56.7 
531 30  160  28  93.3 
540 60  300  20  33.3 
542 30  309  25  83.3 
546 30  342  0  0 
550 30  450  30  100.0 
554 30  ?  0  0 
555 30  630  1  3.3 
556 36  700  2  5.6 
558 60  735  20  33.3 
565 30 4467  0  0 
992 30 1016  0  0 
 
? indicates that this information was not supplied or could not be obtained. 
 
Sera were examined from 40 farms, and from 175 feral pigs, in Queensland (Table 4.8).  
Antibody was not detected in samples from 2 farms, and the seroprevalence rates in the other 
farms ranged from 2.9-100%.  Antibody against the PCV2 capsid protein was detected in 
26.3% of the feral pigs examined from Queensland.   
Sera were examined from 17 farms in South Australia (Table 4.9).  Antibody was not detected 
in 3 farms and the seroprevalence rate in the remaining farms varied from 3.3-100% . 
Sera were examined from 15 farms in Western Australia (Table 4.10).  In samples from four 
farms, antibody was not detected and in the remaining farms the seroprevalence rate varied 
from 3.3-40%.  In no farm in Western Australia, unlike Victoria, New South Wales, 
Queensland and South Australia, was a seroprevalence rate of 100% detected.   
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Table 4.7.  Summary of serology results for individual farms in Victoria, identified by the unique producer 
numbers allocated. 
Producer  Samples submitted  Herd size (sows) Number positive  Percent positive 
310 33 17 3 9.1
332 35  100  13  37.1 
338 31  180  26  83.9 
342 30  285  2  6.7 
840 30  ?  18  60.0 
849 28  163  0  0 
850 29  190  12  41.4 
853 33  220  3  9.1 
854 30  220  15  50.0 
866 30  400  3  10.0 
872 30  560  19  63.3 
873 30  600  28  93.3 
875 30  627  28  93.3 
878 30  730  24  80.0 
880 30  814  30  100.0 
881 29  950  25  86.2 
882 33 1744  5  15.2 
885 30 4100 29  96.7 
 
? indicates that this information was not supplied or could not be obtained. 
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Table 4.8.  Summary of serology results for individual farms in Queensland, identified by the unique 
producer numbers allocated. 
Producer  Samples submitted   Herd size (sows)  Number positive  Percent positive 
120 30  ?  11  36.7 
168 30  61  13  43.3 
169 20  86  5  25.0 
174 20  ?  0  0.0 
176 30  95  20  66.7 
184 30  157  25  83.3 
186 30  191  0  0.0 
193 30  757  22  73.3 
194 25  1200  3  12.0 
576 30  0  2  6.7 
599 28  23  15  53.6 
607 30  45  29  96.7 
608 30  50  16  53.3 
615 30  65  24  80.0 
621 16  80  1  6.3 
626 30  90  19  63.3 
627 30  90  13  43.3 
628 12  90  1  8.3 
633 30  110  17  56.7 
635 60  120  28  46.7 
637 30  126  3  10.0 
640 30  135  4  13.3 
650 30  200  12  40.0 
654 33  285  3  9.1 
664 16  420  10  62.5 
666 30  430  22  73.3 
667 34  508  1  2.9 
669 60  531  7  11.7 
670 30  558  4  13.3 
673 30  637  28  93.3 
680 58  1677  37  63.8 
683 30  2785  8  26.7 
684 30  3125  10  33.3 
1009 30  ?  30  100.0 
1010 30  ?  14  46.7 
1011 30  ?  14  46.7 
1012 30  ?  23  76.7 
1013 30  ?  2  6.7 
1014 30  ?  3  10.0 
1015 30  ?  28  93.3 
Feral 175  ?  46  26.3 
 
? indicates that this information was not supplied or could not be obtained. 
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Table 4.9.  Summary of ELISA results for individual farms in South Australia, identified by the unique 
producer numbers allocated. 
 
Producer  Samples submitted   Herd size (sows)  Number positive Percent positive 
228 7  21  0  0 
265 30  0  8  26.7 
276 30  500  30 100.0 
277 30  558  10 33.3 
686 16  0  10 62.5 
709 30  12  1  3.3 
762 30  ?  1  3.3 
768 30  120  3  10.0 
778 1  300  0  0 
785 32  1700  4  12.5 
786 26  3750 20 76.9 
995 30  4400 24 80.0 
1000 30  ?  1  3.3 
1003 30  ?  11  36.7 
1007 30  ?  1  3.3 
1008 30  ?  0  0 
1016 31  ?  2  6.5 
 
? indicates that this information was not supplied or could not be obtained. 
 
 
 
Table 4.10.  Summary of ELISA results for individual farms in Western Australia, identified by the unique 
producer numbers allocated. 
 
Producer  Samples submitted   Herd size (sows)  Number positive  Percent positive 
352 30  0  0  0 
358 28  0  0  0 
370 13  10  3  23.1 
392 24  50  4  16.7 
393 26  52  3  11.5 
420 30  0  2  6.7 
912 11  14  1  9.1 
938 37  100  0  0 
948 30  260  1  3.3 
949 30  270  12  40.0 
951 32  340  1  3.1 
957 30  400  0  0 
961 30  682  10  33.3 
964 30  800  6  20.0 
997 30  ?  6  20.0 
 
? indicates that this information was not supplied or could not be obtained. 
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Sera were available from 5 farms in Tasmania (Table 4.11).  Antibody was not detected in 2 
of the 5 farms.  The seroprevalence rate on the other 3 farms ranged from 12.5%-59.4%. 
 
Table 4.11.  Summary of ELISA results for individual farms in Tasmania, identified by the unique producer 
numbers allocated. 
Producer  Samples submitted  Herd size (sows)  Number positive Percent positive 
289 32  192 4  12.5 
801 31  140  15  48.4 
803 33  445 0  0 
999 
 
31 
 
? 
 
0 
 
0 
 
Total 32  ?  19  59.4 
 
? indicates that this information was not supplied or could not be obtained. 
 
Comparison of the IIF, ELISA and WIB assays 
Recognising that IIF detected antibody to both PCV1 and PCV2, and that the ELISA/WIB 
assays used recombinant PCV2 antigen, ELISA and supporting WIBs were conducted on a 
separate set of samples from Western Australia that had been examined by IIF (Chapter 3).  
In the sera from the 14 Western Australian farms tested, positive results by IIF ranged from 
25-57.1%.  The positive results by ELISA varied from 16.7-50%.  Utilising both types of assay 
(IIF and ELISA) totally negative results were detected in only two farms: Farm 6 and Farm 11.  
Farms 1, 2, 4, and 10 contained a larger number of positives by ELISA than were detected by 
IIF but conversely, samples from Farms 3, 7 and 12 contained a lower number of ELISA 
positives than detected by IIF.  The results for the remaining farms (5, 6, 8, 9, 11, 13 and 14) 
were similar in both types of assay.   
 
Table 4.12.  Initial IIF serological results from 1998 compared with results using the PCV2 specific ELISA. 
Farm  Herd size (sows)  Number 
samples 
Number IIF 
positive 
Percent IIF 
positive 
Number ELISA 
positive 
Percent ELISA 
positive 
1 550  43 12  27.9  16  37.2 
2  20  6 0 0 1  16.7 
3  100  14 8  57.1  7 50 
4 50  39  10  25.6  15  38.5 
5 2500  23  8 34.8 8 34.8 
6  470  14  0 0 0 0 
7 1275  23  6 26.1 5 21.7 
8 60  12 3 25 3 25 
9 30  14 6  42.9  6  42.9 
10 140 40  16  40  19 47.5 
11  100  18  0 0 0 0 
12  45  15 7  46.7  6 40 
13 100 15  5 33.3 5 33.3 
14 110 21  8 38.1 8 38.1 
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Monoclonal antibody 
A MAb to the recombinant PCV2 capsid was produced, and as shown in Figure 4.6, the 
monoclonal antibody was specific for the PCV2 Cap protein.  It reacted with the purified 
recombinant HIS-tagged PCV2 capsid but not an 18 kDa recombinant HIS-tagged Jembrana 
disease virus (JDV) Tat protein in WIB.  The produced MAb was tested with a mouse typer 
sub-isotyping kit (BioRad) and was found to be an IgG1 type molecule.  
 
 
 
Figure 4.6.  Western immunoblot demonstrating the specificity of the MAb.  Lane 1: Precision Plus Protein 
Standards Dual Colour (BioRad); 2: purified recombinant PCV2 Cap probed with mouse α-HIS as a primary 
antibody and α-mouse HrP as a secondary antibody; 3: purified recombinant PCV2 Cap probed with MAb 
hybridoma supernatant as a primary antibody and α-mouse HrP as a secondary antibody; 4: purified 
recombinant PCV2 Cap probed with serum from a strong IIF positive pig as a primary antibody and α-pig HrP 
as a secondary antibody; 5: recombinant HIS-tagged Tat protein (18 kDa) probed with mouse α-HIS as a 
primary antibody and α-mouse HrP as a secondary antibody; 6: recombinant HIS-tagged Tat protein probed 
with MAb hybridoma supernatant as a primary antibody and α-mouse HrP as a secondary antibody; 7: 
recombinant HIS-tagged Tat protein probed with serum from a strong IIF positive pig as a primary antibody 
and α-pig HrP as a secondary antibody. The sizes of the protein bands within the pre-stained ladder are 
indicated in kDa.   
 
To verify the PCV2-specificity of the MAb, porcine kidney cell cultures were infected with 
PCV2 isolates, either LW1998, 00194 or 99/032, fixed to glass slides, and an IIF assay 
conducted using the MAb as the primary antibody and a fluorescein-conjugated α-mouse as 
the secondary antibody.  PCV1 persistently-infected PK15 cells were treated similarly.  As 
shown in Figure 4.7, a bright yellow-green positive signal was detected in the PCV2-infected 
cell cultures but not in the PCV1-infected PK15 cells.   
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Figure 4.7.  Use of the MAb in an IIF assay to determine specificity to PCV2.  The micrograph on the left 
shows a fluorescent signal in a cell culture infected with PCV2 strain LW1998; the micrograph on the right 
shows the fluorescent signal obtained when the MAb was applied to the PCV1 persistently infected PK-15 
cell culture. 200x magnification.   
 
Discussion 
In this study, the principle aim was to produce a PCV2 type-specific recombinant protein 
antigen for specific serological tests and to subsequently determine the prevalence of PCV2 
antibody in the Australian pig herd.  Two methods were tried in an attempt to produce an 
antigenically distinct serological antigen, both utilising recombinant DNA technology: A pGEX 
vector with expression in E. coli, and a baculovirus vector with expression in insect cells.   
Many systems are available for the production of recombinant proteins.  The selection of the 
most appropriate system is based on factors such as the yield required and the degree of 
post-translational modification required.  As a general rule with recombinant systems, the 
more complex the protein product desired, the smaller the yield of protein that can be 
expected.  Generally, prokaryotic recombinant protein expression systems are used for the 
production of high quantity, low quality gene products with no post-translational modification, 
ideal for serological antigens.  Alternatively, eukaryotic recombinant gene expressions are 
primarily used for the production of low quantity but high quality proteins where protein 
conformation and post-translational modifications are desired.  It is also common in 
recombinant protein production using prokaryotes that the proteins are stored in the cell as 
inclusion bodies.  Inclusion bodies are an aggregate of the recombinant proteins existing in an 
insoluble form (Luckow, 1995b).   
Upon commencement with the eukaryotic expression system, efforts were focused upon 
producing the viral capsid proteins as it was postulated that these would contain the most 
antigenic sites.  In the time frame of this project it was not possible to produce the 
recombinant PCV1 capsid protein.  However, a soluble recombinant PCV2 capsid protein was 
successfully expressed and purified using a baculovirus expression system.  The baculovirus 
system used allowed for a large quantity of recombinant protein to be produced, and it was 
easily purified by affinity chromatography from native cellular proteins due to the presence of 
an N-terminal HIS tag.  This protein appeared to be specific as it reacted strongly with the   110
serum of pigs that had been inoculated with Australian strains of PCV2 and the protein itself 
(Figures 4.4 and 4.5).   
The majority of reported serological studies have employed PCV whole virus particles for 
PCV serological tests (Blanchard et al., 2003b) and most commonly an indirect 
immunofluorescent or immunoperoxidase assay on PCV-infected cell cultures (Labarque, 
Nauwynck, and Pensaert, 2000; Magar, Muller, and Larochelle, 2000; Rodriguez-Arrioja et al., 
2000).  Such assays are not only time consuming, but lack PCV2 specificity, likely owing to 
antigenic cross reactivity between Rep proteins of the two PCV types.  More recently, PCV2 
viral particles in combination with specific PCV2 MAbs have been used to develop a 
competitive ELISA (c-ELISA) for specific detection of PCV2 antibodies (Sala et al., 2000; 
Walker et al., 2000).  However, this c-ELISA still requires the culture of PCV-infected cells.   
In the initial stages of this investigation, a prokaryotic system utilising recombinant pGEX-
PCV1 ORF V1 vector was tried for expression of the Rep protein of PCV1 in transformed E. 
coli.  It was thought this would be the simplest system with the greatest chance of success of 
producing suitable ELISA antigens.  Expression of the Rep protein was attempted first, as the 
Rep protein in PCV1 and PCV2 cross-reacts antigenically (Mahe et al., 2000) and it was 
thought this would be an appropriate antigen for primary screening of antibody to PCV1 and 
PVC2.  Even though it was possible to express the recombinant Rep protein with this system, 
it appeared the protein was stored as inclusion bodies and it was not possible to purify the 
protein from contaminating E. coli proteins.  Hence when the cell lysate was applied in a WIB, 
a number of bands were evident and it was not possible to identify if it was the specific protein 
of interest.  An explanation for this is that pigs contain a large microflora of E. coli, whose 
protein antibodies may be present in the serum samples.  It is likely that in the WIB assays 
that the E. coli antibody in the serum sample reacted with the E. coli proteins which were not 
able to be separated from the recombinant protein.  Attempts were also made to clone the 
ORF C1 from PCV1 and an Australian strain of PCV2 into pGEX; these genes encode the 
capsid proteins of PCV1 and PCV2, respectively.  Even though they appeared to be inserted 
into pGEX in the correct orientation, it was not possible to induce the E. coli to express the 
desired recombinant proteins.   
The baculovirus system was selected as this, whilst a more complex system, would allow 
correct folding of the recombinant proteins, easier purification, and overcome the problem of 
cross reactivity with the native cells and fusion tags employed in the bacterial system.  With 
this system, high levels of heterologous gene expression are often achieved compared to 
other eukaryotic expression systems, particularly for intracellular proteins. In many cases, the 
recombinant proteins are soluble and easily recovered from infected cells late in infection 
when host protein synthesis is diminished (Anderson et al., 1995; Luckow, 1995a).  An 
additional advantage is that baculoviruses have a restricted host range, limited to specific 
invertebrate species, and are safer to work with than most mammalian viruses since they are 
not infectious in vertebrates.  Most of the susceptible insect cell lines are not transformed with   111
pathogenic or infectious viruses and can be cared for under minimal containment conditions 
(Polayes  et al., 1996).  Helper cell lines or helper viruses are not needed since the 
baculovirus genome contains all the genetic information needed for propagation in a variety of 
cell lines or larvae from different insect species.  Prolific cell lines are available which grow 
well in suspension cultures, permitting the production of recombinant proteins in large-scale 
bioreactors (Davies, 1994).   
A soluble recombinant PCV2 capsid protein was successfully expressed using the 
baculovirus expression system, and it was possible to purify this protein.  The system enabled 
a large quantity of recombinant protein to be produced, and it was easily purified by affinity 
chromatography from cellular proteins due to the N-terminal His tag.   
This protein was used to develop an ELISA which appeared to be specific as it did not react 
with the serum of pigs that had been inoculated with the PCV1-infected PK15 cell line.  Such 
ELISAs have been shown to be as sensitive and specific as the indirect immunoperoxidase 
monolayer assay (IPMA) allowing possible serodiagnosis at an individual level (Blanchard et 
al., 2003b; Nawagitgul et al., 2002).  Although the use of a recombinant protein has been 
reported by others (Blanchard et al., 2003b; Nawagitgul et al., 2002; Walker et al., 2000) at 
the time of commencing these studies it had not been reported; in addition it would be a 
valuable reagent enabling PCV2-specific serological tests to be performed within Australia.  
Also, the availability of this test in Australia would lessen the dependence of Australia on 
reagents from elsewhere, and it would assist the detection of PCV2 infection and further 
investigation of the dynamics of PCV2 infection in the Australian pig herd.  In the time 
available it was not possible to produce the recombinant PCV1 capsid protein, although the 
system is now being used by others in this laboratory to do this.   
The national serological survey conducted in this current study showed that PCV2 infection in 
the Australian pig herd is widespread, with an overall seroprevalence of 33%, and showed 
that infection occurred in most farms in every state.  The immunofluorescence assay, that 
does not distinguish between PCV1 and PCV2, was conducted on small numbers of sera 
from Western Australia and resulted in higher seroprevalence rates but this was possibly due 
to a combined effect of antibody to PCV1 and PCV2.   
The occurrence of a small number of farms where the serological study was unable to detect 
antibody is interesting.  It is possible that these farms represent PCV-free properties but 
repeated examinations of such apparently PCV-free farms are needed to verify that this is not 
just a chance anomaly.  The negative result could be due to the low number of samples 
examined from each producer; repeated examination of the same farm might detect antibody 
and indicate a low prevalence of infection.  Although the relationship between seroprevalence 
rates and disease is poorly understood, such potentially seronegative farms in Australia could 
be of interest in the context of the future occurrence of PMWS.  Evidence suggests there is no 
relationship between a high seroprevalence of antibody to PCV and the occurrence of PMWS 
but PCV-naïve herds could be more susceptible.  Even in PMWS-endemic regions, a number   112
of studies have reported a high prevalence of PCV2 antibodies on farms with no known 
history of PMWS (Labarque, Nauwynck, and Pensaert, 2000; Magar, Muller, and Larochelle, 
2000; Rodriguez-Arrioja et al., 2000; Truong et al., 2001; Walker et al., 2000).  Antibodies to 
PCV2 have been detected several years before the onset of the disease (Magar, Muller, and 
Larochelle, 2000; Rodriguez-Arrioja et al., 2000; Walker et al., 2000).  Clearly, PCV2 infection 
does not necessarily result in PMWS or any other disease condition.   
Time constraints did not provide the opportunity to fully utilise the PCV2-specific monoclonal 
antibody that was produced.  Only its production and preliminary characterisation are 
documented in this thesis and the opportunity to utilise this monoclonal for the production of a 
specific immunohistochemical technique for the detection of virus antigen was not attempted.  
A major obstacle to doing this at the time was a lack of suitable PCV-infected cell cultures or 
tissues.  Such tissues were sought but were not provided by other research groups.   
However, studies utilising this antibody for the development of additional diagnostic methods 
for PCV2 infection, including an immunoperoxidase technique for the detection of virus 
antigen in cell culture and in animal tissues is currently under investigation by others in this 
laboratory.     113
Chapter 5.  Experimental infection of pigs with PCV1 
and PCV2 
 
Summary 
The high prevalence of PCV in the Australian pig herd and the absence of reports of PMWS 
suggested that the Australian strains of PCV2 detected may have been of low virulence.  To 
examine the pathogenicity of Australian strains, two animal experiments were conducted 
where the type species of PCV1 present in persistently-infected PK15 pig kidney cells and an 
Australian PCV2 strain were cultured in vitro in cell cultures and inoculated into weaner pigs.  
As expected, the PCV1 replicated well in pigs but did not result in the induction of clinical 
signs or lesions in the inoculated pigs.  The inoculation of cell-culture-replicated PCV2, with 
an apparent virus titre of 10
3 virus particles/mL, into weaner pigs resulted in infection of only 
some of the inoculated pigs and it was concluded that the PCV2 inoculum contained 
insufficient virus to infect all pigs into which it was inoculated.  The PCV2 did not induce any 
disease syndrome and could not be detected in tissue sections of infected pigs using 
immunohistochemical techniques.   
An in situ hybridisation (ISH) method was developed and using this it was possible to detect 
PCV1 and PCV2 DNA in cell culture, but it was not able to detect PCV in tissues of the 
inoculated pigs.     114
Introduction 
There was no information available on the pathogenesis of Australian strains of PCV.   Two 
animal experiments were conducted and are reported in this Chapter.  In one, the known non-
pathogenic PCV1 present in persistently-infected PK15 cells was inoculated into pigs to 
provide data on the optimum tissues to use for the detection of PCV in pigs by PCR, tissues 
to use in an attempt to provide PCV-positive tissues for the development of in situ 
hybridisation (ISH) techniques, and a source of known PCV1-specific antibody.  In a second 
experiment, an attempt was made to infect weaner pigs with an Australian strain of PCV2 to 
determine its pathogenicity. 
In Chapter 3, a multiplex PCR was described that was capable of differentiating PCV1 and 
PCV2 in DNA extracted from animal tissues but this technique does not allow for physical 
visualisation of the distribution of virus so a secondary objective of these animal experiments 
was to develop ISH techniques for the detection and differentiation of PCV1 and PCV2 in 
formalin-fixed paraffin-embedded tissue sections with digoxigenin (DIG) labelled probes.  In 
conjunction with the serological techniques described in Chapter 4, it was hoped that a 
clearer picture could be obtained regarding the effects of PCV infection on weaner pigs.   
It was hypothesised that a combination of PCR and ISH assays could be used for the 
detection of PCV and to determine the distribution of the virus in tissues.  It was also 
hypothesised that the multiplex PCR assay could also be applied to DNA extracted from 
archival tissue, in addition to fresh tissues as outlined in Chapter 3.  In this chapter, the 
application of PCR assays and development of ISH assays for the detection and 
differentiation of porcine circoviruses is described.  Various PCR primers depicted previously, 
and additional primers that were designed on the basis of the reported sequence of porcine 
circoviruses available in GenBank, were applied in the construction of specific probes for 
PCV1 and PCV2, and these probes were evaluated for their ability to detect porcine 
circoviruses.   
Besides examining the pathogenicity of the viruses, a by-product of the animal experiments 
would be the provision of valuable data and reagents for future studies on the viruses.   
Infection of pigs with PCV1 and PCV2 would provide antisera to the respective viruses that 
could be applied as positive and negative controls in various assays in the future.  This 
became a necessary focus of these experiments due to a lack of collaboration from overseas 
research groups, more advanced in their studies of PCV and associated disease syndromes.   
As little was known of the pathogenesis of PCV infections, cellular/tissue tropisms and 
methods of spread within a herd, it was essential that these initial animal experiments with 
Australian strains be conducted.  There was an urgent need to identify tissue tropisms, the 
extent and nature of lesions, and the patterns of viral persistence and shedding so that 
reliable diagnostic tools and control measures could be developed and applied in the event of 
an outbreak of PMWS or a related disease.  To this end, experimental challenge studies in   115
conventional pigs were conducted but it was not possible to conduct these studies on 
gnotobiotes.  Attempts to elucidate the natural history of the disease under field conditions 
were not possible due to the absence of disease in Australia.  Other research groups 
attempting this have been frustrated by the episodic nature of the wasting complex, the 
inconsistency of signs and lesions of PMWS within an infected herd or between infected 
herds, and the high incidence of asymptomatic infection with PCV2 in PMWS-negative herds 
(Krakowka et al., 2001).   
A number of overseas research groups have managed to replicate PMWS in pigs through 
animal experiments.  The first report of PMWS being reproduced in a laboratory was 
presented by Ellis et al. (1999), where gnotobiotic piglets were inoculated with tissue 
homogenates and low- and high-passage viruses in cell culture.  In their experiment, three-
day-old gnotobiotic piglets were inoculated intranasally with extracts from cell cultures, or 
homogenates of lymphoid tissue from PMWS-affected piglets, or control materials.  All piglets 
inoculated with the viral inocula developed lesions typical of PMWS, including generalised 
lymphadenopathy, hepatitis, nephritis, interstitial pneumonia, myocarditis and gastritis.   
Through re-isolation, immunohistochemistry (IHC) and PCR, PCV as well as a porcine 
parvovirus (PPV) contaminant, were detected in tissues and all infected piglets developed 
moderate to high titres of antibody to PCV and moderate titres to PPV.  No lesions, virus, or 
virus-specific antibodies were detected in sham-inoculated or non-inoculated control piglets.  
A similar experiment was carried out by Allan et al. (1999a) where PPV was knowingly 
included in the inoculation regimen.  Pigs were either inoculated with PCV2 alone, PPV alone 
or a combination of the viruses.  In this case, only the pigs inoculated with both viruses 
developed the characteristic lesions of PMWS, which at the time were likened to other field 
cases described in Europe and North America (Allan et al., 1999a).  Older pigs (seven weeks 
old) that were seronegative to PCV2 have been used in an experiment (Reynaud et al., 2000) 
where a cell culture isolate of PCV2 was used to produce a mild form of PMWS.  Typically, 
production of the syndrome has required gnotobiotic or specific-pathogen-free pigs being 
inoculated within the first week of life, and usually the inoculum has been derived from the 
homogenised tissues of PMWS affected pigs and has been introduced intranasally (Magar et 
al., 2000; Stevenson et al., 2000).  From these experiments, it was concluded that PCV2 
could induce PMWS lesions in weaned pigs in the absence of porcine parvovirus and other 
common swine pathogens.  However, in all these cases only mild forms of PMWS were 
produced, and only in some only of the infected, and never to the degree of severity that was 
observed in field cases.   
In 2001-2002, two research groups were able to fully reproduce severe forms of PMWS in 
experimentally-infected piglets (Krakowka et al., 2001; Ladekjaer-Mikkelsen et al., 2002).   
Once again gnotobiotic piglets were used, but they were infected subcutaneously with PCV2 
as well as intranasally.  In addition, the immune systems of certain pigs were stimulated using 
keyhole limpet haemocyanin (KLH) in incomplete Freund’s adjuvant (ICFA) and in the 
experiments of Krakowka et al. (2001) a thioglycollate broth was also used to stimulate   116
exudation of peritoneal macrophages.  Piglets whose immune systems where stimulated with 
various substances and infected with virus developed severe clinical signs of PMWS. 
Generally, the diagnosis of viral diseases in animals is based on detection of the virus by 
culture, PCR, immunohistochemistry (IHC) or ISH, and/or by detection of antibodies against 
the virus by serology.  The diagnosis of PMWS differs from this general approach because 
PCV2 can be detected in normal healthy pigs.  The detection of PCV2 alone does not 
necessarily confirm a diagnosis of PMWS.  In order to establish the aetiological diagnosis of 
PMWS, techniques are required that link virus and tissue lesions.  Thus, ISH has been 
employed.  However, the detection of PCV2 genetic material does not imply PMWS, only 
PCV2 infection.  In situ hybridisation allows for visualisation of the localisation of PCV2 in the 
infected tissues or cells.  In addition, this method provides cellular detail and highlights 
histological architecture so that the presence of PCV2 in lesions may be studied in formalin-
fixed paraffin-embedded tissue sections.   
Materials and methods 
Two animal experiments were conducted, one in which PCV1 derived from persistently-
infected PK15 cells was inoculated into weaner pigs, and a second where an Australian 
isolate of PCV2 (LW1998) was cultured in PCV-free PK15 cells and then inoculated, whilst 
attempts were made to simultaneously stimulate the immune system using procedures similar 
to those described previously by Allan et al. (2000b), Krakowka et al. (2001) and Ladekjaer-
Mikkelsen et al. (2002).   
Animals 
For the PCV1 experiment, 26 four-week-old piglets were derived from three litters purchased 
from a commercial pig farm, and housed in isolation units at Murdoch University.  The piglets 
were introduced to a proprietary creep feed from the first few days of life but did not consume 
significant amounts until their last week before weaning at 22-25 days of age.  Creep feed 
was phased out during the first week after weaning while weaner feed was phased in.  The 
creep feed was based on wheat, triticale, lupins, whey powder, fish meal and blood meal, and 
contained a minimum of 21.5% crude protein, 15.8 MJ DE/kg, and an available lysine:DE ratio 
of 0.87.  The weaner feed was based on wheat, triticale, lupins, canola meal, soya meal, fish 
meal, meat meal and blood meal, and contained a minimum of 20% crude protein, 14.5 MJ 
DE/kg, and an available lysine:DE ratio of 0.75.  Both rations contained a vitamin and trace 
mineral premix.  The weaned pigs were then infected at 35 days of age.  Uninfected control 
piglets were housed in a separate self-contained isolation unit.   
For the PCV2 experiment, pregnant sows that were seronegative for PCV antibody were 
sought.  Seventy five pregnant sows from a commercial pig farm were tested for PCV 
antibody by a combination of PCV2-specific ELISA (Chapter 4), Western immunoblot (WIB) 
(Chapter 4) and an indirect immunofluorescence (IIF) assay (Chapter 3).  Five of the seven 
seronegative sows were purchased, housed in farrowing pens in isolation rooms at Murdoch   117
University, and allowed to farrow.  Fifty two piglets were born and were weaned at 25-28 days 
of age.  At weaning, the pigs were randomly assigned to one of four groups of 10–12; three of 
these groups were located in one room, a fourth group was removed to another isolation unit 
and used as uninfected controls.   
Cell cultures 
PK15 cells (ATCC CCL-33) reported to be infected with PCV1, and PK15 cells free of PCV 
(obtained from the Australian Animal Health Laboratory, Geelong, Australia) were cultured in 
25 cm
2 cell culture flasks with Dulbecco’s modified essential medium (DMEM) supplemented 
with 10% newborn calf serum (NBCS) and antibiotics.  For routine maintenance and passage 
of cells the medium was aspirated, the cells were washed with phosphate buffered saline 
(PBS), trypsinised with ATV solution (1.4 M NaCl, 54 mM KCl, 55.5 mM glucose, 71.4 mM 
NaHCO3, 20 mg/mL trypsin [Sigma], 7 mM EDTA, 0.004% [w/v] phenol red indicator), then 
resuspended in growth medium in 25 cm
2 cell culture flasks to provide a split ratio of 1:3.   
Monolayers of cells in 25 cm
2 cell culture flasks were trypsinised and resuspended in 5 mL of 
growth medium, then centrifuged (1,000 x g, 5 min), the pelleted cells resuspended in 1.5 mL 
of a solution containing 300 mM D-(+)-glucosamine-HCl (ICN) in Hank’s salt solution (ICN) for 
45 min at 37°C.  The glucosamine-treated cells were then divided into two aliquots and 
centrifuged (1,000 x g, 5 min) and the supernatant discarded.  Each aliquot of cells was then 
resuspended in 1 mL of the virus-containing supernatant from the homogenised spleen tissue 
suspension and incubated for 1 h.  Growth medium was added to each aliquot of cells to a 
final volume of 7 mL and dispensed into 25 cm
2 flasks.   
Virus 
The strain of PCV1 used to infect animals was derived from the persistently-infected PK15 
cell line.  For preparation of virus for inoculation into pigs, monolayers of persistently-infected 
PK15 cells were prepared in 75 cm
2 tissue culture flasks with DMEM supplemented with 10% 
NBCS and antibiotics.  Confluent cultures were subjected to three cycles of freeze-thawing, 
then were treated with chloroform (10% for 1 h) and centrifuged (1,500 x g, 10 min) to pellet 
cellular debris, and the supernatant used to infect pigs.   
The strain of PCV2 (LW1998) used to infect pigs was isolated in PCV-free PK15 cells from 
the spleen of a pig in which the virus was detected by multiplex PCR as previously described 
(Chapter 3).  This spleen tissue was derived from a dead six-week-old pig that had 
succumbed to a condition with the hallmarks of PMWS, and the tissue was sent to Murdoch 
University for testing.  As described in Chapter 3, the virus identified in this tissue was 
sequenced and found to be 98% similar to overseas PCV2 isolates associated with PMWS.  
A 10% homogenate of the spleen tissue was prepared with an ice-cold mortar and pestle in 
DMEM, then centrifuged and inoculated onto PCV-free PK15 cells.  For isolation of the PCV2, 
monolayers of PCV-free PK15 cell cultures in 25 cm
2 tissue culture flasks were washed with 
PBS, trypsinised and suspended in 5 mL of DMEM.  Cells were centrifuged (1,000 x g, 5 min),   118
the medium aspirated and cells resuspended in 1.5 mL of 300 mM, D-(+)-glucosamine-HCl in 
Hank’s salt solution for 45 min at 37°C.  The glucosamine-treated cells were then divided into 
two aliquots and centrifuged (1,000 x g, 5 min).  The supernatant was removed and each 
aliquot of cells resuspended in 1 mL of the virus-containing supernatant from the 
homogenised spleen tissue suspension and incubated for 1 h.  Growth medium was added to 
each aliquot of cells to a final volume of 7 mL and dispensed into 25 cm
2 flasks.  Once cells 
had reached confluency, flasks were subject to three cycles of freeze–thawing in order to 
disrupt cells and release virus particles into the medium.  Cultures were then centrifuged 
(1,000 x g, 5 min, 4°C) and the supernatant used to infect other PCV-free PK15 cells as 
above.  Each passage of virus was checked by multiplex PCR for evidence of PCV2.  To 
determine the concentration of PCV2 DNA, each cell culture supernatant was serially diluted 
ten-fold and the presence of PCV2 in each dilution determined by PCR.  In the final inoculum 
used to infect piglets, PCV2 DNA was detected at a titre of approximately 2.5 x 10
3 50% cell 
culture infectious doses (CCID50) of virus per mL.   
Design of animal experiments 
In the PCV1 experiment, 26 weaned four-week-old piglets from three litters were divided into 
two groups.  One group (n = 2) of control pigs was not inoculated with PCV1, and each pig in 
the second group (n = 24) was inoculated intravenously (IV) with 1 mL PCV1 inoculum, 
prepared as described above.   
In the PCV2 experiment, the 52 piglets from five litters were divided into four groups at 28 
days of age.  Group A (n = 8) control pigs were sham inoculated (not injected with PCV2) and 
were maintained in isolation in a separate room.  The other three groups (2-4) were housed 
together in a room separated from Group A.  Group B pigs (n = 12) were injected at 35 days 
of age in four sites (both axillas and groins in each pig) with a total 2 mL volume consisting of 
1 mg keyhole limpet hemocyanin (KLH; Sigma) emulsified in incomplete Freund’s adjuvant 
(ICFA; Sigma).  This group was also given an intraperitoneal (IP) injection of 10 mL 
thioglycollate broth (Difco) to stimulate peritoneal macrophage exudation into the peritoneal 
cavity.  The parenteral injections with KLH/ICFA were repeated at 42 days of age, and pigs 
received additional IP injections of thioglycollate broth at 45 and 55 days of age.  Group C (n 
= 18) was given the same KLH/ICFA and thioglycollate injections over the same time interval 
as pigs in Group B but were also intranasally inoculated with 2 mL (1 mL/ side) and 
intravenously injected with 2 mL of PCV2 inoculum at 35 days of age.  Group D (n = 14) was 
also intranasally and intravenously inoculated with PCV2 as for group C but received no other 
injections.  
The pigs were humanely killed and tissues collected and examined at varying intervals after 
infection.  In the PCV1 experiment the tissues collected were mesenteric lymph node, iliac 
lymph node, bronchial lymph node, submandibular lymph node, lung, liver, spleen, thymus, 
ileum and serum.  In the PCV2 experiment tissues collected were axial lymph node, bronchial 
lymph node, iliac lymph node, mesenteric lymph node, liver, lung, spleen and serum.     119
Care was taken to avoid cross-contamination between tissues.  Tissue samples were divided 
into separate fragments for molecular and histopathological examination.  Tissue samples 
were processed for examination by multiplex PCR as described in Chapter 3.  Samples for 
histopathological examination were fixed in 10% buffered formaldehyde and processed for 
histopathological examination by standard techniques.  For serological analysis, blood was 
collected in Vacutainer
® tubes (Becton Dickinson) and left overnight at room temperature to 
clot.  Serum was then collected and stored at -20°C until required.   
Multiplex PCR  
The DNA extracted from tissue samples was subjected to multiplex PCR as described in 
Chapter 3 (Materials and methods – Multiplex PCR and thermal cycling conditions).   
ISH probes 
A number of probes were synthesised by PCR for use in the ISH reactions.  Previously 
described primers (Chapter 2) PCV3a, PCV3b and PCV3c were used in previously described 
combinations to produce 480 bp and 150 bp probes based on the ORF V1 sequence.  A 349 
bp region of ORF V1 was amplified using the primers PCV1ISHFor and PCV1ISHRev (Table 
5.1) and randomly labelled with DIG, to be employed as a PCV1-specific probe.  Similarly a 
481 bp PCV2-specific probe was constructed using primers PCV2ISHFor and PCV2ISHRev 
(Table 5.1), based on the ORF C1 sequence of PCV2.  These oligonucleotide primer 
sequences are based upon published sequences from Kim and Chae (2001).  The cycling 
protocol was carried out as previously described (Ellis et al., 1999; Larochelle et al., 1999a).  
An additional PCV2 specific 40-base oligonucleotide probe, complementary to nucleotides 
1085-1124 of ORF C1, (5’–CAGTAAATACGACCAGGACTACAATATCCGTGTAACCATG–3’) 
and end labelled with DIG was synthesised (Genset Oligos) and also used in ISH reactions.  
Apart from the 40-base oligonucleotide probe, all other DIG-labelled probes were synthesised 
by PCR using a PCR DIG Probe Synthesis Kit (Boehringer Mannheim) following the 
manufacturer’s protocols.  The PCR was performed in a total volume of 25 µL comprising 
PCR buffer (10 mM Tris-HCl, 50 mM KCl, pH 8.3), 2.5 mM MgCl2, PCR DIG Labelling Mix 
(0.2 mM each of dATP, dCTP and dGTP; 0.13 mM dTTP; 0.07 mM DIG-dUTP; pH 7.0), 1-100 
ηg DNA template, 16 ρmol of primers and 0.175 units of Taq DNA polymerase.  The reaction 
mix was made up to 25 µL with sterile distilled water.  The reactions were carried out on a 
GeneAmp
® PCR System 2400 thermal cycler (Applied Biosystems) with the thermal cycling 
profile outlined in Table 5.2.   
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Table 5.1.  Sequence of oligonucleotide primers used in PCR construction of ISH probes. 
Primer  Primer sequence (5’ → 3’)  Target ORF 
PCV3a CGACCTGTCTACTGCTGTG  V1 
PCV3b TAATCCTCCGATAGAGAGC  V1 
PCV3c CTGTCTTCCAATCACGCTC  V1 
PCV1ISHFor TTGCTGAGCCTAGCGACACC V1 
PCV1ISHRev TCCACTGCTTCAAATCGGCC  V1 
PCV2ISHFor CGGATATTGTAGTCCTGGTCG  C1 
PCV2ISHRev ACTGTCAAGGCTACCACAGTCA  C1 
 
Table 5.2. Thermal cycling protocol used for PCR synthesis of DIG-labelled probe using primers outlined in 
Table 5.1. 
Temperature (°C)  Time (min:s)  Cycles 
95 7:00  1 
95 00:45   
60 1:00  30 
72 2:00   
72 7:00  1 
 
ISH in cell culture controls 
To standardise the ISH technique and to provide controls, PCV1- and PCV2–infected PK15 
cell cultures were used.  Controls included non-infected PCV-free PK15 cells and equine 
kidney (EK) cells.  These cells were grown on eight-well chamber slides (BD Falcon) and 
used for confirmation of specificity of the three probes.  Cells were seeded onto slides at a 
density of 1.50 x 10
6 cells mL
-1 and incubated for 24–36 h at 37°C in an atmosphere of 7% 
CO2-in-air.  After incubation, the medium was discarded and the slides washed with PBS in a 
Coplin jar for 5 min.  Cells were fixed for 30 min in ice-cold 100% methanol at -20°C.  After 
fixation, the chambers were removed and slides washed twice in PBS for 5 min, each wash at 
room temperature, followed by dehydration through an ethanol series (70%, 80%, 100%; 5 
min at each concentration).  The dehydrated slides were stored at 4°C until required.  For 
use, fixed cultured cells were rehydrated through a decreasing ethanol series (90%, 70%, 
50%) and finally into PBS, then digested with proteinase K (5 µg mL
-1 [Roche] diluted in PBS) 
at 37°C for 5 min.  After rinsing twice with PBS, sections were dehydrated through a series of 
ethanol washes (50%, 70%, 90%, 100%; 1 min at each wash) and allowed to air dry.     121
For the hybridisation procedure, DIG-labelled probe (30 ηg) was diluted in 50 µL of 
hybridisation solution (TE8 buffer [10 mM Tris-HCl, 1 mM EDTA, pH 8.0] containing 2X SSC, 
50% [v/v] deionised formamide, 5% [w/v] dextran sulphate [Sigma] and 1 µg µL
-1 salmon 
sperm DNA [Invitrogen]).  Approximately 50 µL of the probe-hybridisation solution was 
layered over the section and the fluid held in place with a cover slip.  The slides were placed 
inside Terasaki plates moistened with 2X SSC and heated in an oven for 10 min at 95°C, 
quenched on ice, and then placed inside another oven for 2 h at 45°C for hybridisation.  After 
hybridisation, sections were thoroughly washed; twice in 4X SSC for 5 min at room 
temperature, twice in SSC for 5 min at room temperature, once in 0.1X SSC for 15 min at 
55°C, once in maleic acid buffer (100 mM maleic acid, 150 mM NaCl, pH 7.5) for 5 min at 
room temperature and once in blocking reagent (Boehringer Mannheim) for 30 min at room 
temperature in a humidified chamber.   
For detection of hybridised probe, sections were incubated for 30 min at room temperature in 
a humidified environment with either α-DIG antibody conjugated to alkaline phosphatase (AP) 
or α-DIG antibody conjugated to horseradish peroxidase (HrP).   
When α-DIG AP was used, the antibody solution was diluted 1:500 in blocking reagent.  After 
two washes in Buffer A (100 mM Tris-HCl, 150 mM NaCl, pH 7.5) of 5 min duration and 
equilibration in Buffer B (10 mM Tris-HCl pH 9.5, 10 mM NaCl, 50 mM MgCl2) for 5 min, 
substrate consisting of nitro blue tetrazolium chloride (NBT) and 5-bromo-4-chloro-3-indolyl 
phosphate toluidine salt (BCIP) was applied to the sections.  Colour was allowed to develop 
for approximately 1 h in the dark.  Substrate development was stopped by immersing the 
slides in TE8 buffer.  Sections were counterstained with 1% (w/v) neutral red for 2 min, and 
the slides then washed under running tap water and allowed to dry before being plunged into 
acetone for 20 s, followed by a wash in 100% ethanol and then dried completely.   
In order to detect probe hybridisation using α-DIG HrP, the blocking solution was tipped off 
the slides and replaced with the antibody solution at a concentration of 1.5 U mL
-1 and left in 
humidified boxes for 30 min at room temperature.  The slides were washed twice in Buffer A 
(5 min each wash) and then equilibrated in Buffer B for 2 min at room temperature.  Buffer B 
was tipped off the sections and replaced with approximately 200 µL of diaminobenzidine 
(DAB) solution (5 mg DAB, 10 mL PBS, 1 µL 30% H2O2).  Slides were developed in 
humidified boxes in darkness for 15 min and the reaction was stopped by washing the slides 
in distilled water.  Sections were counterstained with 1% (w/v) neutral red for 2 min, and the 
slides then washed under running tap water and allowed to dry before being plunged into 
acetone for 20 s, followed by a wash in 100% ethanol and then dried completely.   
Sections were scanned for a dark purple reaction product consistent with NBT/BCIP reacting 
with AP, or a brown reaction product when the HrP conjugated antibody and DAB was used.  
Sections were viewed by light microscopy at 40X, 100X and 200X magnification.  Digital 
images were obtained by using a confocal laser scanning microscope (BioRad) and a   122
transmission light detector with a 40X objective.  Images were analysed and optimised using 
Confocal Assistant version 4.02.   
ISH in formaldehyde-fixed paraffin-embedded tissues 
The ISH procedure for formalin-fixed paraffin-embedded tissues was a modified application of 
ISH on PCV1- and PCV2-infected cell cultures.   
To prepare the slides for cut sections they were soaked for 1 h in a 1-2% solution of a low 
toxicity laboratory detergent (Pyroneg).  The slides were then washed for 10 min under 
running tap water, 5 min in distilled water (dH2O), followed by 5 min in 100% ethanol, and 
dried in a warm oven at 37°C.  A 2% solution of 3-aminopropyltriethoxysilane in analytical 
grade acetone was made in a fume cupboard and the slides were immersed in this for 5 min.  
The slides were then washed for 2 min in acetone followed by two changes of distilled water.  
The slides were dried at 37°C and stored in boxes until required.   
Serial sections (4 µm thickness) were placed on treated slides and stored at room 
temperature.  Just before use, the sections were deparaffinised by washing twice in xylene (5 
min per wash) and rehydrated through an ethanol series (90%, 70%, 50%; 1 min each 
concentration).  Slides were then washed twice in PBS for 3 min each wash.  Tissue sections 
were digested with proteinase K solution for 20 min.  Following digestion, sections were 
rinsed twice with PBS and dehydrated through a series of ethanol washes (50%, 70%, 90%, 
100%; 1 min each wash).   
Hybridisation was carried out overnight at 45°C.  The DIG-labelled probe (30 ηg) was diluted 
in 50 µL of hybridisation buffer (see above) which was then layered over the section and the 
fluid held in place with a cover slip.  The slides were placed inside Terasaki plates moistened 
with 2X SSC and heated in an oven for 10 min at 95°C, quenched on ice, and then placed 
inside another oven at 45°C for overnight hybridisation.  After overnight hybridisation, 
sections were thoroughly washed, twice in 4X SSC for 5 min at room temperature, twice in 
SSC for 5 min at room temperature, once in 0.1X SSC for 15 min at 55°C, once in maleic acid 
buffer for 5 min at room temperature and once in blocking reagent for 30 min at room 
temperature in a humidified chamber.   
For detection of hybridised probe, sections were incubated with either α-DIG antibody 
conjugated to AP or HrP as described above, and the colour allowed to develop using the 
appropriate substrate for the enzyme conjugate used.  Sections were counterstained with 1% 
(w/v) neutral red for 2 min, and the slides then washed under running tap water and allowed 
to dry before being plunged into acetone for 20 s, followed by a wash in 100% ethanol and 
then dried completely.  Sections were scanned for reaction products as described above.   
Fluorescent ISH 
This procedure was essentially the same as the procedure described for cell culture 
preparations except that it utilised a fluorescein-labelled α-DIG antibody for the detection of   123
the DIG-labelled probe, and is referred to as a fluorescent ISH (FISH) procedure.  For the 
detection of the DIG-labelled ISH probe in methanol-fixed cells, the procedure was the same 
as described above except that after blocking, a fluorescein-conjugated α-DIG antibody (ICN) 
at a concentration of 15 µg mL
-1 was added to the slide.  The following steps were then 
carried out in darkness: the slides were left in humidified boxes for 30 min at room 
temperature; they were washed twice in Buffer A (5 min each wash) and equilibrated in Buffer 
B for 2 min at room temperature.   
Visualisation of the fluorescent signal generated by the FISH technique was with a confocal 
laser scanning microscope and LaserSharp software (BioRad).  The software was used under 
a setting specific for green FISH as recommended by the manufacturer.  Digital images were 
analysed and optimised with the use of Confocal Assistant version 4.02.  A fluorescent 
microscope was also used to visualise the FISH signal.  In order to obtain images, the 
Olympus automatic photomicrographic system (Model PM-10ADS) was utilised.   
Results 
ISH in cell culture controls 
All DIG-labelled probes were successfully synthesised by PCR, with the exception of the 40 nt 
oligonucleotide probe (see Materials and methods).  Figures 5.1 and 5.2 illustrate the 
difference in size between the unlabelled PCR products, and the DIG-labelled probes.  The 
DIG-labelled probes were slightly larger in size; this observation was more apparent with the 
larger 349 bp, 480 bp and 481 bp probes.   
 
 
 
 
Figure 5.1.  Agarose electrophoresis gel showing 480 bp and 150 bp DIG labelled DNA probes.  Lane 1 – 100 
bp molecular weight marker (Promega); lane 2 – DIG positive control; lane 3 – DIG labelled 150 bp probe; 
lane 4 – unlabelled 150 bp product; lane 5 – DIG labelled 480 bp probe; lane 6 – unlabelled 480 bp product; 
lane 7 – negative control (distilled water).   
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Figure 5.2.  Agarose electrophoresis gel showing 349 bp and 481 bp DIG labelled DNA probes. Lane 1 – 100 
bp molecular weight marker (Invitrogen); lane 2 – 349 bp DIG labelled probe; lane 3 – unlabelled 349 bp 
product; lane 4 – DIG labelled 481 bp probe; lane 5 – unlabelled 481 bp product; lane 6 – 100 bp molecular 
weight marker (Invitrogen). 
 
The ISH assays successfully detected PCV DNA in the PK15 cell line persistently infected 
with the non-pathogenic PCV1, and in PCV-free PK15 cells infected with an Australian strain 
of PCV2.  No reaction product was obtained with negative controls. Normal PSEK (equine 
kidney) cells and PK15 cells treated with the hybridisation mixture lacking the probe.   
A positive ISH signal was indicated by either brown, granular, intranuclear staining of the cells 
if α-DIG HrP was employed, or a deep purple reaction product if α-DIG AP was used, as 
shown in Figures 5.3 and 5.4 when the 349 bp and 481 bp probes were used.  Positive ISH 
results were also obtained with the 150 bp and 480 bp DIG-labelled probes but these probes 
were less specific and did not clearly discriminate between PCV1 and PCV2.  In PK15 cells 
persistently infected with PCV1, approximately 5% of cells showed reaction products, 
whereas only 1% of PCV2-infected cells were stained.  As expected there was no visible 
signal in the control PSEK cells or mock-treated PK15 cells.   
Optimal ISH conditions providing a strong signal with minimal background staining were 
determined with fixed cells where the following conditions were varied: fixative used to 
preserve cell morphology; concentration of proteinase K; hybridisation time; blocking time; 
concentration of antibody conjugate.  The optimal conditions determined were those 
described above in the material and methods section.  Despite variation in all these factors it 
was not possible to detect a positive signal when the 40-base oligonucleotide probe was used 
in the hybridisation reactions.   
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Figure 5.3. Photomicrograph of positively stained (brown reaction product) methanol-fixed PK-15 cells 
persistently infected with PCV1.  The PCV1 specific 349 bp DIG labelled probe was used in this ISH assay. 
Unstained nuclei are visible and represent the nuclei of PCV1-negative (uninfected) cells in the PK-15 cell 
monolayer.  200X magnification. 
 
 
 
 
Figure 5.4. Photomicrograph of positively stained methanol fixed PK-15 cells infected with PCV2 (purple 
reaction product) detected using a 481 bp PCV2 specific DIG-labelled probe.  400X magnification. 
 
FISH provided similar results in cell culture preparations to those obtained with the HrP 
reactions.  As with the α-DIG HrP system, the 349 bp and 481 bp probes generated a positive 
signal and were able to distinguish between the two types of PCV nucleic acid but the 150 bp 
and 480 bp probes, although they generated a positive signal, failed to differentiate between 
PCV1 and PCV2.  A positive signal was indicated by bright green granular staining localised 
to the nucleus and to a lesser extent, the cytoplasm.  No specific intranuclear staining was 
detected in the control methanol-fixed PSEK cell culture controls, or in the methanol-fixed 
PK15 cells treated with the hybridisation mix minus the DIG-labelled probe.  Similar to the 
initial ISH results, approximately 5% of the PCV1-infected PK15 cells exhibited a strong   126
fluorescent signal (Figure 5.5).  In the case of the PCV2-infected cultures, less than 1% of 
cells exhibited specific fluorescence (Figure 5.6).  There was some background fluorescence 
in all slides but this was characterised by a weak yellow fluorescence, as opposed to the 
positive results where there was an extremely strong bright green fluorescence within the 
nuclei of cells.   
 
 
 
Figure 5.5.  Fluorescent in situ hybridisation signals produced using the 349 bp PCV1 specific DIG labelled 
probe on methanol-fixed PK-15 cells.  100X magnification.   
 
 
 
Figure 5.6.  Fluorescent in situ hybridisation signal on PK-15 cells fixed in methanol utilising the 481 bp 
PCV2 specific DIG labelled probe.  400X magnification.   
 
 
Inoculation of PCV1 in pigs 
As shown in Table 5.3, tissues from pigs at the commencement of the experiment, before 
inoculation of PCV1, were all negative for the presence of circovirus DNA detectable using   127
the multiplex PCR.  Seven days post-inoculation (PI), PCV1 DNA was detected in four 
different tissue types: spleen, liver, lung and thymus.  Ten days PI, PCV1 DNA was also 
detected in the iliac and bronchial lymph nodes.  Seventeen days PI it was no longer possible 
to detect PCV1 in any of the tissue samples.   
 
Table 5.3.  Detection of  PCV1 in a range of formaldehyde-fixed paraffin-embedded tissues. The pigs were 
inoculated at Day 0 and subsequent tissue samples were taken at 3-4 day intervals.  Two pigs were killed at 
each time point and tissues removed from each.   
 
Tissue 
Days after inoculation with PCV1 
0           3            7          10          14          17 
Spleen -
  +
  + + + - 
Liver  - + + +  +/- - 
Iliac LN
*  - - -  +/-  +/-  - 
Bronchial LN
*  - - -  +/-  - - 
Mesenteric LN
*  - - - - - - 
Submandibular LN
* - - - - - - 
Lung  -  +/-  +/-  - - - 
Thymus  - +/- - +/- -  - 
Kidney  - - - - - - 
Tonsils  - - - - - - 
Ileum  - - - - - - 
 
- = individual samples from both pigs were negative 
+ = individual samples from both pigs were positive 
+/- = indicates a positive result from one pig and a negative result from the other pig tested at each occasion. 
 
Only tissues that were PCR positive for PCV1 were subjected to further analysis by ISH or 
FISH and the results of these tests are summarised in Table 5.4.  When formaldehyde-fixed 
paraffin-embedded PCR-positive tissues listed in Table 5.3 were examined by the ISH 
technique for the presence of PCV1 nucleic acid, tissues from uninfected animals were used 
as negative controls.  It was found that the 150, 349 bp and 480 bp probes did not provide a 
distinguishable positive signal in any cells.  High background levels of staining occurred when 
using HrP-conjugated α-DIG and was persistent despite the use of a pre-hybridisation 
blocking solution consisting of 0.6% hydrogen peroxide solution designed to block 
endogenous peroxidase activity.  When a post-hybridisation step involving treatment with the 
same 0.6% hydrogen peroxide solution was used in an effort to reduce the background, this 
had no effect; the background was visible on both test and positive control samples, but was 
stronger on the negative controls.  Minimal background staining occurred when the 
fluorescein-labelled anti-DIG was used. 
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Table 5.4. Detection by ISH of PCV1 in formaldehyde-fixed paraffin-embedded tissues utilising all probes. 
Tissue  ISH signal  Multiplex PCR result 
Spleen -  PCV1  positive 
Iliac LN
* -  PCV1  positive 
Bronchial LN
* -  PCV1  positive 
Liver +*  PCV1  positive 
Lung -  PCV1  positive 
Thymus -  PCV1  positive 
 
LN = lymph node 
+ = positive ISH signal 
-  = no detectable signal 
* The positive ISH signal seen in this tissue was visualised using a fluorescent antibody in conjunction with the PCV1 
specific 349 bp probe and also the 150 bp probe. 
 
When α-DIG conjugated to AP was employed in the same manner on the same tissues, it 
was also still not possible to visualise a positive signal.  In this case, however, there was only 
minimal background signal due to endogenous phosphatases.   
When FISH techniques were used, apparently positive results were obtained.  Of the 
formaldehyde-fixed paraffin-embedded tissues listed in Table 5.4, a positive signal was visible 
in one tissue type only.  Liver sections from four pigs (two pigs at 7 days PI and two pigs at 10 
days PI) showed a weak fluorescent signal when the 150 bp or 349 bp probes were used 
(Figure 5.7).  Background fluorescence on all of the tested slides was minimal (micrographs 
not shown) and comparable to the background that could be visualised on the slides 
containing fixed PK15 cells.   
 
 
 
Figure 5.7.  Formaldehyde-fixed paraffin-embedded liver tissue taken at 7 days PI, demonstrating positive 
fluorescent in situ hybridisation signals and low background using the 349 bp PCV1 specific probe.  100X 
magnification.   129
 
The positive signal that was detected on the liver section, indicated by bright green, granular 
fluorescence similar to what was detected in PK15 cells, and present primarily in the nucleus 
but also to a lesser extent in the cytoplasm of the affected cells, was detected in the liver that 
previously tested positive for PCV1 by multiplex PCR (Table 5.3).  Only a small number of 
cells had intense nuclear and cytoplasmic staining, and these cells were scattered throughout 
positive liver samples, and appeared to be Küppfer cells or hepatocytes (Dr. Amanda O’Hara, 
personal communication).  It was not possible to detect a positive signal in the other liver 
tissues that were PCR-positive for PCV1, or indeed for any of the other tissues which were 
PCR-positive.   
The optimal blocking procedure devised for liver tissue sections was treatment for 1.5 h with a 
blocking solution composed of Buffer A supplemented with 3% bovine serum albumin (BSA) 
(w/v) and 0.05% Triton X-100 (v/v), prior to treatment of the tissue section with the antibody 
conjugate.  When the blocking time was increased beyond 1.5 h, it was not possible to 
visualise either specific or non-specific fluorescence on the tissue sections.  A blocking time 
less than 1.5 h resulted in a high background, sometimes masking the weak positive signal.   
Serum samples were also tested using the various serological techniques described earlier 
(Chapters 2 & 3).  As the WIB and ELISA utilised PCV2 capsid as the antigen it was not 
expected that any of the serum samples would react.  However as the IIF assay was not 
specific for either PCV1 or PCV2, a positive result would be observed in a PCV-seropositive 
pig.  As can be seen in Table 5.5, it was apparent that antibodies to PCV could be detected at 
14, 17 and 38 days PI using the IIF assay.  Antibodies to the PCV2 capsid could not be 
detected except after 35 days PI, implying that the antibodies detected at 14, 17 and 38 days 
PI were antibodies to PCV1.  The positive ELISA result at 35 days PI is somewhat suspect as 
the adjusted absorbance reading was only just positive.   
 
Table 5.5.  Comparison of results of three serological tests using sera from  PCV1 animal experiment.   
Days PI  IIF  WIB  ELISA 
0 - -  - 
3 - -  - 
7 - -  - 
10 -  -  - 
14 +  -  - 
17 +  -  - 
21 -  -  - 
24 -  -  - 
28 -  -  - 
31 -  -  - 
35 -  -  + 
38 +  -  - 
42 -  -  - 
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Inoculation of pigs with PCV2 
Pigs in Group A, which were sham inoculated without any immunogenic boosters, remained 
PCR-negative throughout the course of the experiment (Table 5.6).   
 
Table 5.6. Multiplex PCR results from pigs in Group A of the PCV2 animal experiment, that were sham 
inoculated. Tissues tested were all harvested aseptically and stored frozen at -80°C before examination. 
Tissue 
Days after sham inoculation 
0            7          14          21          28         35 
Axial LN
*  - - - - - - 
Bronchial LN
*  - - - - - - 
Iliac LN
*  - - - - - - 
Mesenteric LN
*  - - - - - - 
Liver  - - - - - - 
Lung  - - - - - - 
Spleen  - - - - - - 
Serum  - - - - - - 
 
- = negative result 
 
Pigs in Group B, which were not inoculated with PCV2 but were inoculated with immune 
stimulants thioglycollate, KLH and ICFA, developed evidence of PCV1 and PCV2 infection as 
shown in Table 5.7.  At Day 0, virus was not detected by PCR in any tissues.  However, 
between 4 and 14 days PI both PCV1 and PCV2 were detected in a range of tissues but not 
in serum.  The multiplex PCR was carried out four times in order to verify the results and the 
positive samples consistently returned the same result.  Assays performed on samples 14 
days or more PI were consistently negative by PCR.   
Table 5.7.  Multiplex PCR results on tissues from pigs in Group B of the PCV2 experiment that were 
inoculated with thioglycollate, KLH and ICFA, but not inoculated with virus. 
Tissue 
Days after inoculation with thioglycollate, KLH and ICFA 
0              4              7            14            21           28           35 
Axial LN
*  - - - 1  - - - 
Bronchial LN
*  - 2  - 1  - - - 
Iliac LN
*  - 1,2  - 1,2  - - - 
Mesenteric LN
*  - 2  - 1,2  - - - 
Liver  -  1,2 2  1,2 -  -  - 
Lung  - - - 1  - - - 
Spleen  - - 1  1  - - - 
Serum  - - - - - - - 
 
- = negative result 
1 = PCV1 positive 
2 = PCV2 positive 
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Group C, inoculated with the substances to boost the immune response as in Group B and 
also inoculated with PCV2, contained no evidence of PCV infection at the time of inoculation.  
By seven days PI, PCV2 was detected in the liver, lung and mesenteric lymph node, and 
PCV1 was also detected in the spleen (Table 5.8).  Fourteen days PI, PCV2 was detected in 
all tissues examined except the serum.  Twenty one days PI, PCV2 was no longer detected 
by PCR.  As with the previous groups each tissue was tested four times to verify the positive 
or negative result.   
Group D, inoculated with PCV2 alone, also had evidence of virus infection after inoculation 
but not before inoculation (Table 5.9).  As in the other groups, at 0 days PI all pigs were PCR-
negative for both PCV types, and there was no evidence of PCV in serum over the course of 
the experiment, but between four and 21 days PI there was evidence of mixed PCV1 and 
PCV2 infection, although at 11 days PI all tissues tested by multiplex PCR were negative.   
All of the tissues that proved to be positive by PCR were subsequently tested by ISH and 
FISH once embedded in paraffin.  No evidence of virus infection was detected by either 
technique in any of the tissues examined.  Each tissue was tested several times with a variety 
of variables, including variation of the protease concentration, duration of treatment and 
temperature of incubation, variation in incubation times and temperature for probe 
hybridisation from 2-48 h and 45-58°C respectively, and variation in the length of incubation 
with α-DIG antibodies and substrate. 
 
Table 5.8.  Multiplex PCR results on tissues from pigs in Group C of the PCV2 experiment, inoculated with 
PCV2 and the immune stimulants thioglycollate, KLH and ICFA.   
Tissue 
Days after inoculation with PCV2, thioglycollate, KLH and ICFA 
0            7          14          21         25          29         32         35 
Axial LN
*  - - 2  - - - - - 
Bronchial LN
*  - - 2  - - - - - 
Iliac LN
*  - - 2  - - - - - 
Mesenteric LN
*  - 2  2  - - - - - 
Liver  - 2  2  - - - - - 
Lung  - 2  2  - - - - - 
Spleen  - 1  2  - - - - - 
Serum  - - - - - - - - 
 
- = negative result 
1 = PCV1 positive 
2 = PCV2 positive 
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Table 5.9.  Multiplex PCR results on tissues of pigs in Group D of PCV2 experiment that were inoculated with 
PCV2 and without any stimulation of the immune system.   
Tissue 
Days after inoculation with PCV2 only 
0         4          7         11       14        21        29        35 
Axial LN
*  -  1 1,2  -  2 2 -  - 
Bronchial LN
* - 1  - - 2  2  - - 
Iliac LN
*  -  2 1 -  2 2 -  - 
Mesenteric LN
*  - 2  - - 2  2  - - 
Liver  - 2  - - - 2  - - 
Lung  - 2  1,2  - - 2  - - 
Spleen  - 2  - - 2  2  - - 
Serum  - - - - - - - - 
 
- = negative result 
1 = PCV1 positive 
2 = PCV2 positive 
 
 
Histological examination of haematoxylin and eosin stained tissue sections revealed a 
number of lesions that were expected due to the nature of the experiment.  At the injection 
sites there was granulomatous panniculitis and nodules of inflammation which are typical of 
any injection site with the adjuvant (ICFA) used (Dr Shane Raidal, personal communication).  
In the lymph nodes that were examined, typically iliac and axial lymph nodes, there were 
varying degrees of histiocytic reaction, most commonly histiocytic lymphadenitis.  This is/was 
typical of PMWS, however there was a distinct lack of giant cells and inclusion bodies in any 
of the sections, which are the typical hallmarks of PMWS.   
Before inoculation, 80.8% of pigs were seropositive by ELISA and WIB utilising the 
recombinant PCV2 capsid as an antigen despite the fact that all sows used to derive piglets 
were seronegative for PCV2.  When DNA was extracted from the sera of these pigs and 
subsequently tested by the multiplex PCR all samples were negative for the presence of any 
PCV DNA.  The serology of two pigs from each group was monitored over the course of the 
experiment and the serum samples tested by the PCV2-specific WIB and ELISA (Table 5.10).  
A positive result in both assays is indicated by a +, a negative in both by – and a positive in 
one and negative in the other by +/-.   
In addition to the pigs that were sampled over the course of the animal experiment, serum 
was collected from every pig as it was killed.  Tables 5.11, 5.12, 5.13 and 5.14 outline the 
serological status of each pig at its time of death, using the recombinant PCV2 capsid as 
antigen.  Both the WIB and ELISA were used to assess each serum sample.   
Interestingly, antibody-positive pigs were present in every group of pigs including the sham 
inoculated controls (Table 5.11) in Group A.  In all groups except D, the serum samples from    133
pigs tested at 35 days PI were negative by both serological tests for presence of PCV2 
antibody. 
 
Table 5.10.  Serological results using PCV2-specific WIB and ELISA of the same 2 pigs from each group (A-D) 
that were repeatedly sampled over the course of the experiment. 
Group  Pig number.  Days PI 
    0  4  7  11 14 21 25 28 32 35 
A  336  +/-  N/T + N/T +  + N/T + N/T - 
A  14  - N/T + N/T -  - N/T - N/T - 
B  335  + + +  N/T  + +  N/T  +/-  N/T  - 
B  7  +  +  + N/T +  + N/T + N/T - 
C  478  +  N/T  +  N/T  + + + + + + 
C  18  +/-  N/T  +  N/T  + - - - - - 
D  350  +  -  +/-  -  -  -  N/T N/T N/T N/T 
D  25  +/-  -  +  +  +  - N/T - N/T - 
 
- = sample was negative in both tests 
+ = sample was positive in both tests 
+/- = indicates a positive result in one tests and  negative in the other test. 
N/T indicates that a sample was not taken or tested at that time. 
 
 
Table 5.11.  Detection of antibody to the recombinant PCV2 capsid in pigs in Group A that were sacrificed at 
intervals after infection.  
Pig number  Days PI  Serology 
12 7  - 
26 7  + 
30 14  + 
348 14  + 
14 35  - 
336 35  - 
 
- = sample was negative in both tests 
+ = sample was positive in both tests 
+/- = indicates a positive result in one test and negative in the other test. 
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Table 5.12.  Detection of antibody to the recombinant PCV2 Capsid in sacrificed pigs in Group B.  
Pig number  Days PI  Serology 
1 4  + 
31 4  + 
10 7  - 
338 7  + 
18 14  +/- 
9 14  + 
458 14  + 
334 21  + 
346 21  + 
340 28  - 
337 28  +/- 
335 35  - 
7 35  - 
 
- = sample was negative in both tests 
+ = sample was positive in both tests 
+/- = indicates a positive result in one test and negative in the other test. 
 
Table 5.13.  Detection of antibody to the recombinant PCV2 Capsid in sacrificed pigs in Group C.  
 
Pig number  Days PI  Serology 
477 7  + 
349 7  + 
21 14  +/- 
24 14  + 
13 21  - 
16 21  - 
32 21  +/- 
347 25  + 
19 25  - 
5 28  + 
11 28  - 
344 28  + 
456 28  +/- 
17 32  - 
409 32  + 
478 35  - 
32 35  + 
18 35  - 
22 35  - 
 
- = sample was negative in both tests 
+ = sample was positive in both tests 
+/- = indicates a positive result in one test and negative in the other test. 
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Table 5.14.  Detection of antibody to the recombinant PCV2 capsid in sacrificed pigs in Group D..  
Pig number  Days PI  Serology 
339 4  + 
20 4  - 
489 7  + 
4 7  + 
15 11  +/- 
2 11  + 
474 14  + 
342 14  + 
6 21  + 
350* 21  - 
332 21  + 
466 28  + 
8 28  + 
25 35  +/- 
 
*Pig 350 was euthanased at 21 days after inoculation due to ill health. 
- = sample was negative in both tests 
+ = sample was positive in both tests 
+/- = indicates a positive result in one test and a negative result in the other test. 
 
 
Discussion 
The current experiments were designed as preliminary experiments to examine the 
pathogenicity of Australian strains of PCV1 and PCV2.  The inoculation of the PCV1 present 
in the persistently-infected PK15 cell line was not expected to produce disease as the lack of 
pathogenicity of this strain has been well documented (Allan et al., 1995; Tischer and Buhk, 
1988; Tischer et al., 1986).  Rather, it was intended to provide baseline data on the 
pathogenicity of this virus and especially to provide reagents for the subsequent development 
of diagnostic procedures, including PCR, ISH and serological tests.  It did, however, provide 
some additional data on the tropism of PCV1 and information on the most appropriate tissues 
to examine for detection of PCV in virus-infected animals.  At the time these experiments 
were conducted, this was poorly understood.  It provided a series of serum samples from 
infected pigs that could be used for the development of serological tests.   
It was perhaps fortuitous that the pigs used for the inoculation of PCV1 were PCV1 antibody-
negative.  The test used to identify antibody was immunofluorescence, which is difficult to 
interpret and probably of low sensitivity.  It is unknown if these pigs were born antibody-
negative or if at 35 days of age (the age at when they were infected) they had lost maternally-
acquired immunity, but the absence of antibody, at least at the time of infection, was probably 
associated with the apparently classical response to the PCV1 in the inoculated pigs, typical 
of that in any acute virus infection in naive animals.  Infection was followed by a transient   136
period of virus replication with virus detected in a variety of tissues 4-14 days PI, followed by 
or coincident with the appearance of serum antibody.   
In contrast to the pigs inoculated with PCV1, the results in the pigs inoculated with PCV2 are 
less clear.  This was a deliberate attempt to try and determine if infection with a local strain of 
PCV2 might induce lesions typical of PMWS, using immuno-stimulation techniques as 
described by Krakowka et al. (2001) to enhance the pathogenicity of the PCV2 strain.  It was 
clear in this experiment that PCV2, with or without immuno-stimulation, did not result in the 
production of clinical signs or lesions of PMWS.  Analysis of the results of the PCV2 
experiment, however, suggest a number of possible problems that make interpretation of the 
results difficult and that need consideration prior to future attempts to repeat these 
experiments.   
The results in the four groups are hard to interpret, especially with regard to the detection of 
virus.  The five seronegative-sows farrowed in two rooms. At the time of inoculation, just after 
weaning at four weeks of age, neither PCV1 nor PCV2 were detected in any of their progeny. 
These weaners were then randomly allocated to four groups of pigs, and the sham-inoculated 
group A, housed separately from the others in the room in which two of the sows farrowed, 
remained PCV-negative throughout the experiment.  In the groups of pigs that were housed in 
the same room (Group B without virus but with immuno-enhancement, Group C with virus and 
immuno-enhancement, and Group D with virus only), seroconversion to both PCV1 and PCV2 
occurred in all three groups, but neither PCV type was consistently detected in all pigs in any 
group.  The conclusions are that (1) the PCV2 inoculum contained insufficient virus to infect 
all pigs, and (2) the piglets in Groups B-D acquired PCV1 from an extraneous source, 
presumably one or more of the sows.   
The PCV2 inoculum clearly contained insufficient virus to infect all pigs into which it was 
inoculated, although the detection of PCV2 in some of the pigs in Group B not inoculated with 
PCV2 but housed in a pen adjacent to Group D that was inoculated with PCV2 is presumed to 
indicate transmission from pig to pig of PCV2 within 7 days of introduction of the virus.  It is 
apparent that a higher titre virus inoculum is required to infect pigs and further attempts to 
better adapt the virus to replicate in cell culture are needed.  Virus DNA was detected by PCR 
in 10
-3 dilutions of the inoculum, suggesting a titre of the order of 10
3 virus particles/mL but 
this is obviously less than that required for consistent infection.   
One or more of the sows used to supply the pigs in Groups B, C and D must have been a 
source of PCV1.  The inability to detect PCV1 infection in the sows from which the piglets 
were sourced is a problem.  These sows were tested for PCV antibody by IIF assay and by a 
PCV2-specific ELISA and they were antibody-negative by both tests at the time of farrowing 
(although other sows in the donor herd were not).  Assuming one of the sows was the source 
of the PCV1 in the piglets in Groups B-D, the immunofluorescence assay was clearly 
insufficient to detect antibody that could indicate PCV1 infection.  It is interesting that PCV1 
was not detected at the time of inoculation or later than 14 days after the start of the   137
experiment, much the same as in the pigs experimentally infected with PCV1, suggesting the 
piglets acquired the infection from the sow(s) at about the same time as the attempts were 
made to infect the pigs with the PCV2 cell culture inoculum. Perhaps the age at inoculation 
coincided with the loss of an undetected low level of maternally-acquired immunity. 
It is apparent that these attempts to produce evidence or absence of evidence of the 
pathogenicity of the Australian strain of PCV2 do not provide any definitive results, and must 
be repeated.  Future experiments need to use antibody-negative sows, need to ensure 
freedom from endogenous virus infections.  In the absence of specific-pathogen-free pigs, 
ensuring freedom from endogenous PCV1 or PCV2 infection in sows will be a problem. A 
PCV1-specific ELISA to improve the sensitivity of the method of PCV1 antibody detection, as 
an index of possible PCV1 infection, would help.  Hysterectomy-derived piglets reared on an 
artificial diet are a possibility, although the isolation facilities required for this were not 
available.   
As a prerequisite for investigating the replication of virus in the experimentally-infected pigs, 
and for diagnosis of PMWS, ISH was developed as a method of detecting accumulations of 
PCV DNA in association with suspected lesions.  This technique, or the detection of viral 
antigen by immunoperoxidase staining, can be useful for the detection of virus in association 
with lesions in diseased pigs, and has been used by others for the detection of PCV in tissues 
from field cases of wasting disease (Choi and Chae, 1999; Ellis et al., 1998; Kiupel et al., 
1998; Morozov et al., 1998; Rosell et al., 1999) and reproductive disorders (West et al., 
1999).  Although immunohistochemistry has been reported to be more sensitive than ISH for 
the detection of PCV2 in archival formalin-fixed paraffin-embedded tissues from experimental 
and field disease (McNeilly et al., 1999), ISH was selected for the experiments described in 
this thesis because at the time of commencing the studies a monoclonal antibody directed 
against PCV2 was not available.   
There are issues that affect the ISH procedure and these need to be considered when 
analysing reports from different groups.  One issue is the significant genomic differences 
known to exist between PCV1 and PCV2, and probes for detection of PCV2 should not be 
modelled on the PCV1 genome; McNeilly et al. (1999) used hybridisation probes that were 
based on the PCV1 whole genomic sequence.  A second issue is the type of probe used; 
antisense probes have three to four times greater sensitivity for the detection of PCV2 nucleic 
acid than sense-strand probes (Morozov et al., 1998).   
In the present study it was demonstrated that ISH utilising DIG-labelled probes detected by α-
DIG antibody conjugated to either HrP or AP was able to detect PCV DNA in PK15 cells 
infected with PCV1 or PCV2.  A 3 h hybridisation time was determined to be optimal, as 
hybridisation times greater than this and up to 24 h resulted in a signal that was considerably 
weaker.  A possible explanation for this was that the hybridisation reaction was conducted at 
55°C, and exposure of cells to this temperature for long periods may have degraded nuclear    138
material, thereby resulting in a weaker signal.  However, while the ISH procedure worked 
satisfactorily in cell cultures infected with PCV1, application of the technique to tissues from 
PCV-infected pigs was less successful.  The 480 bp probe, which detected viral genetic 
material with low background levels in PK15 cells, was unable to detect virus in 
formaldehyde-fixed paraffin-embedded tissues.  Whether this lack of success in tissues was 
due to problems with the technique or to insufficient virus DNA in the tissues is unknown.  The 
probe size may have been a problem but much of the literature regarding optimal probe sizes 
provides contradictory information (Grunewald-Janho et al., 1996; Hoyland and Mee, 1996; 
Mikel, 1994; Nuovo, 1992).  It could be that the 480 bp probe was too large to apply to 
formaldehyde-fixed tissue sections, as two major problems can arise if an ISH probe is too 
large. Such large probes cannot penetrate the highly cross-linked tissue and hybridise to the 
target DNA, and stearic problems may be encountered between the probe and the target 
DNA (Mikel, 1994).  
Another problem with the ISH was high background signals detected when DIG-labelled 
probes were used and detected with α-DIG conjugated with HrP, and to a lesser extent with 
AP.  This became a major problem in visualising a positive signal in tissues.  There are many 
factors that might have caused high levels of background staining in the ISH protocols, 
including over-development of the antibody-conjugate complex, non-specific binding of the 
probe to tissues, and the presence of endogenous peroxidases.  Over-development of the 
peroxidase conjugate can be caused by an increased incubation temperature, an excessive 
incubation time of the HrP conjugate with DAB substrate, and incorrect preparation of the HrP 
conjugate and DAB substrate (Mikel, 1994).  It is believed that these factors were unlikely 
causes of the problem in the current study as the antibody conjugate and DAB substrate were 
prepared, utilised and stored according to the manufacturer’s instructions.  The presence of 
endogenous peroxidases can be a major problem preventing visualisation of a positive signal 
with HrP immunohistochemical systems, and in the current study while all tissues were 
treated with a hydrogen peroxide solution in order to decrease or block endogenous 
peroxidase activity, this seemed of limited value.  The use of α-DIG AP was used in an 
attempt to better visualise a positive signal and reduce the background, and compared to the 
HrP system, the background signal was reduced but it remained significant.  When sections 
were treated with a commercial blocking agent for endogenous phosphatases, this did not 
significantly reduce the background reaction.   
A fluorescent signal or FISH system provided better ISH results than the HrP and AP 
colorimetric detection systems and less background staining.  The FISH technique worked 
extremely well on methanol- and formaldehyde-fixed PK15 cells and there were only low 
levels of background fluorescence.  The majority of the signal was detected in the nucleus of 
cells, with only a minor component in the cytoplasm.  The location within the nucleus is 
consistent with observations that circovirus particles, at least with beak and feather disease 
virus (BFDV), occur within inclusion bodies wherein they form densely packed paracrystalline   139
arrays (Latimer et al., 1991; McOrist et al., 1984; Pass and Perry, 1984; Ritchie et al., 1990).  
The FISH procedure also detected PCV1 DNA in formaldehyde-fixed paraffin-embedded liver 
tissue. Labelled liver cells were most likely hepatocytes or Küpffer cells, based on their 
morphology and location within the tissue section (Dr Amanda O’Hara, personal 
communication).  The detection of PCV in the liver is consistent with recent reports of the 
detection of PCV1 and PCV2 in pigs utilising ISH technology by Allan et al. (1998b) and 
Rosell et al. (1999).  These authors also reported intense nuclear and sporadic cytoplasmic 
labelling of PCV2 nucleic acid in Küpffer cells and scattered hepatocytes throughout liver 
tissue.   
Little is known of the distribution of PCV1 in infected pigs as the majority of research on the 
tropism of PCV has been directed at the examination of PCV2.  Some indication of the tissue 
and cellular tropism was provided by the current study and there seem to be considerable 
analogies in the tropism of PCV1 and PCV2.  The PCR results obtained indicated the 
dominant tissues in which PCV1 could be detected by PCR were the liver and lymphoid 
tissues (spleen and lymph nodes).  A positive ISH signal for PCV1 was also seen in the liver 
of four pigs, suggesting this is a major location of the virus.  Although it was difficult to be 
sure, the liver cells in which PCV1 were detected seemed to be either Küpffer cells or 
hepatocytes.  Rosell et al. (1999) found that Küpffer cells and histiocytic infiltrates were the 
usual targets of PCV2 infection during PMWS.  Hepatocytes located near the periportal 
inflammatory infiltrates were sometimes labelled, mainly in the nucleus and sporadically in the 
cytoplasm (Rosell et al., 1999).   
In the current study the amount of viral nucleic acid detected was low, and the ISH technique 
was not a good indicator of the presence of virus.  Possibly this is associated with the low or 
negative pathogenicity of the viruses used in the study.  A strong correlation has been 
observed between the amount of PCV2 nucleic acid or antigen and the severity of 
microscopic lymphoid lesions, although it has also been possible to find PCV2 nucleic acid or 
antigen in tissues of clinically healthy pigs, but in these cases the amount of virus and the 
intensity of histopathological lesions are extremely low (Segales and Domingo, 2002).     140
Chapter 6.  General discussion 
 
Although porcine circovirus was first discovered in 1974 before the recognition of any 
associated disease syndromes, the appearance of PMWS in 1991 has greatly accelerated the 
research on this virus.  While this virus appears to be causing havoc, predominantly in Europe 
and North America, as a cause of PMWS it has raised questions about its distribution 
worldwide and whether it is functionally associated with a myriad of other disease syndromes 
such as PDNS, CT and porcine respiratory complex.   
At the time of commencing the studies reported in this thesis, there had been no reports of 
the occurrence of PCV in the Australian pig herd, and no evidence of PMWS in Australia 
despite its known occurrence in North America and Europe (McNeilly et al., 1999).  The aims 
of the project were therefore to determine whether the absence of PMWS was due to a lack of 
appropriate PCV strains, or whether PCV was present but PMWS was not manifest due to an 
absence of secondary factors acting in cohort with PCV to produce disease.  The studies 
undertaken and reported in this thesis have clearly, and for the first time, indicated the 
widespread occurrence of PCV in the Australian pig herd despite the fact that no cases of 
PMWS have been confirmed.   
A prerequisite for the studies undertaken was the need to develop techniques for the 
detection of PCV and PCV antibody.  Initial attempts to obtain reagents from overseas 
sources were unsuccessful and it was therefore deemed necessary to develop these so that 
they could be made freely available for use within Australia.   
The major technique developed for the detection of PCV was a multiplex PCR that could 
detect both PCV types in a single reaction.  It is realised that the cycling conditions for the 
multiplex PCR were not identical to those for the conventional PCR and this could affect the 
results obtained with the two techniques.  Although not reported in the thesis, parallel 
examinations were conducted with the conventional PCR assays (described in chapter 3) for 
the first 50 tissues examined and the results were always the same, and therefore reliance 
was later placed on the multiplex PCR for routine use throughout the remainder of the study.  
While a number of multiplex PCR methodologies that claimed to differentiate the 2 viruses 
had been published (Aguero, Arias, and Sanchez-Vizcaino, 2000; Kim et al., 2001b; 
Larochelle et al., 1999a; Ouardani et al., 1999), the method published by Larochelle et al. 
(1999a) seemed the most reliable and reproducible, and therefore was adopted for the 
duration of this study, and continues to be employed by researchers today.   
The tissues for PCR examination were nearly always obtained from unthrifty weaners in 
commercial herds with a case history that was PMWS-like. The tissues were submitted from 
several Australian States.  Importantly, in only three of 367 pigs from which tissues were 
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typical of PMWS were from the same herd in Queensland.  Subsequently formaldehyde-fixed 
paraffin-embedded lymph node tissues were analysed from these three pigs as well as a liver 
sample from one of the pigs.  Examination of haematoxylin and eosin stained sections of 
these tissues revealed lesions that at the time were thought to be suspicious of a circovirus 
infection in the lymph nodes of one pig only, but which are now considered inadequate to 
confirm a diagnosis of PMWS (Dr Shane Raidal, personal communication).   
The techniques devised in this project for detection of circovirus genetic material were 
conducted on the supplied tissue samples and negative results were obtained.  In no cases 
were the criteria described for the definition of PMWS met: the criteria used for the diagnosis 
of PMWS include the existence of compatible clinical signs, presence of characteristic 
microscopic lesions and detection of PCV2 within these lesions as described by Segales and 
Domingo (2002).   
The prevalence of PCV2 in the 367 pigs that were examined was 9.3% which clearly indicates 
that PCV infection was common in weaner pigs in Australia, despite the absence of PMWS.  
The pigs examined were, of course, not a random sample of pigs in weaner sheds as in most 
cases they were selected by veterinary practitioners because they were dead.  It is always 
possible that there were factors other than PCV that contributed to the disease and death of 
the pigs and which may have enhanced the replication of PCV2.  Whether the prevalence 
would be lower in pigs that were healthy in the same pig herds remains unknown.   
Unfortunately tissues from normal healthy pigs were rarely available for examination.   
It is difficult to compare the results of various PCV2 prevalence studies because the 
conditions vary.  However, some other studies have detected greater prevalence rates of 
PCV2 than were detected in this current study.  In one Canadian study, 94.2% of 35 pigs 
were found by PCR to be infected with PCV2 (Ouardani et al., 1999).  In another Canadian 
study, PCV2 was detected in 97.6% of pigs (Larochelle et al., 1999b).  However, in these 
studies tissue samples were from pigs with clinical signs suggestive of PCV2 infection, 
including respiratory signs and weight loss (Ouardani et al., 1999), pneumonia, tremors and 
PDNS (Larochelle et al., 1999b), which might explain the higher rate of infection with PCV2 
than detected in Australia.   
The rate of detection of PCV1 (12.5% in the 367 pigs, and concurrently with PCV2 in 3.8% of 
the 367 pigs), relative to the rate of detection of PCV2, was much greater than has been 
reported previously.  This was a surprising finding; most other reports have described a 
higher rate of detection of PCV2 than PCV1 in pig populations (Magar et al., 2000; Rodriguez-
Arrioja et al., 2000) although many studies have not attempted to detect PCV1 and have 
examined for PCV2 only.  In the Canadian study by Ouardani et al. (1999) where assays for 
both PCV1 and PCV2 were conducted, 94.2% of 35 pigs were infected with PCV2, compared 
with 5.7% infected with PCV1.  Larochelle et al. (1999b) in Canada also found a higher 
prevalence of PCV2 (97.6%) than PCV1 (4.8%).  The reasons for the higher detection rates of 
PCV1 in Australia than elsewhere are unknown.     142
A significant question that needed to be investigated was whether the strains detected in 
Australia were the same as those that had been detected in PMWS-endemic areas of North 
America and Europe.  Sequence analysis of the entire genomes of Australian PCV1 and 
PCV2 indicated the Australian strains of PCV1 shared only a 77–78% nucleotide identity with 
the overseas and Australian strains of PCV2, the overseas and three Australian strains of 
PCV1 all had approximately 98% nucleotide sequence identity, and the Australian PCV2 
strains had 96–98% identity with the overseas strains of PCV2.  The significance of the 2–4% 
difference between Australian and overseas viruses of the same type is unknown. While there 
were a number of nucleotide substitutions in Australian strains of PCV, there was no 
consistent change that might have contributed to the differences in pathogenicity and the lack 
of PMWS in Australia.  The only exception was the insertion of a ‘T’ residue at position 942 in 
the genomes of Australian PCV2 strains 00/154 and 02/015. 
The sequence data presented in Chapter 3 represent the first sequence data reported for any 
strains of PCV in Australia.  Based on the similarity of these sequences with the reported 
sequence of PCV isolates in other countries it was concluded that the nucleotide sequences 
obtained in this study represented the encapsidated single-stranded DNA strand of the virus.  
The organisation of the genome of the Australian PCV strains was very similar to that 
reported for other PCV isolates: the ORF V1 in all isolates was situated in a similar position 
(nt 47–985) on the encapsidated strand; the derived amino acid sequence of ORF V1 of the 
Australian PCV strains possessed 3 motifs characteristic of proteins involved in RCR, as well 
as a nucleotide binding site (Koonin and Ilyina, 1993); and they all contained a characteristic 
sequence upstream of ORF V1 that would be expected to form a stem-loop structure (nt 
position 1751-12) with a nonanucleotide motif at its apex (nt position 1762-2).   
The studies undertaken in this thesis will contribute to improved diagnostic capability for PCV 
in Australia.  An in situ hybridisation (ISH) technique for the detection of PCV in tissues of 
infected pigs was developed.  A monoclonal antibody against the capsid protein of PCV2 was 
also produced and this has future application for the development of an immunoperoxidase 
method for the detection of viral antigen in tissues.  Unfortunately, adequate analysis of the 
ISH and further development of an immunoperoxidase method were hindered by the lack of 
availability of suitable PCV-infected tissues.  Attempts to obtain these from other countries 
were unsuccessful, although they have been recently obtained and the monoclonal antibody 
produced in this study is now being applied to the development an immunoperoxidase 
method by others in this laboratory.   
At the time the studies reported in this thesis commenced, the only available serological test 
was an indirect immunofluorescence (IIF) assay that had been first described by Tischer et 
al., (1987).  It was deemed necessary to develop more sensitive assays that were type-
specific and easier to perform and interpret.  The use of recombinant virus proteins as 
antigens in serological tests seemed appropriate as these have significant potential 
advantages over whole virus antigens; they can be produced in large quantities, and are   143
generally easily purified and reproducible.  Increased specificity of the ELISA can be expected 
using the recombinant antigen rather than a whole virus antigen preparation as the viruses 
cross react antigenically.  It is also possible that the recombinant protein could have value as 
a potential vaccine for the control of PMWS although it is not currently a problem in Australia.  
Although vaccination was not a focus of the current study, such investigations may be 
warranted in the future; this could be a rewarding study, as vaccination against PMWS with a 
DNA and subunit vaccine has been demonstrated (Blanchard et al., 2003a), and subunit 
vaccines have completely inhibited PCV2 replication.  Future studies warrant the investigation 
of the protective effect of these DNA and subunit vaccines against PDNS, CT and PRC.   
Initial attempts to produce a suitable antigen were attempted with a bacterial expression 
system utilising the pGEX-6P-1 plasmid and based on the ORF V1 of PCV1 that encodes the 
Rep protein (Mankertz and Hillenbrand, 2001; Mankertz et al., 1998a) known to cross-react 
antigenically in the two PCV types (Meehan et al., 1998).  The protein was expressed in 
Escherichia coli but was insoluble and repeated attempts to solubilise it, in order to proceed 
with purification, using a variety of procedures, were unsuccessful.  Subsequent attempts to 
produce a recombinant protein utilised a baculovirus expression system, and expression of a 
soluble capsid protein of PCV2 was obtained (Chapter 4).  It was shown that the recombinant 
capsid protein of PCV2 was not recognised by sera from animals with experimentally induced 
PCV1 infection (Chapter 5).  This protein will provide an important reagent for subsequent 
serological studies within Australia as such PCV2-specific antigens are not commercially 
available within Australia. 
Time did not permit the production of a similar PCV1 capsid protein that would enable 
concurrent serological studies of this PCV type.  This is the subject of a subsequent study 
being undertaken by others in this laboratory but based on methods developed during this 
current study.  It would be possible to conduct a non-specific IIF assay in conjunction with a 
PCV2 specific Western immunoblot or ELISA on a serum sample to deduce the reactive 
antibody, or antibodies, present in the sample.   
The recombinant protein was used to develop an ELISA and Western immunoblotting 
procedure for the detection of PVC2.  Detection of PCV1 antibody was not possible except by 
extrapolation from the results of IIF assays (that detected both PCV1 and PCV2 antibody) and 
the specific PCV2 assays.  The results of the serological studies indicate an overall 
prevalence of antibody in pigs at slaughter, mainly pigs of baconer age collected during 
accumulation of a National Pig Serum bank, of 33% compared to the prevalence of PCV2 
detected by PCR of 9.3% (albeit in unthrifty or dead) pigs.   
Attempts were made to determine the pathogenicity of PCV isolates, and while the 
experiment to determine the pathogenicity of PCV1 worked well, provided valuable reagents 
for further study and confirmed the lack of pathogenicity of this virus in pigs, an experiment to 
determine the pathogenicity of an Australian strain of PCV2 (LW1998) was unsuccessful.   
The methodology used for the PCV2 experiment was based upon the animal experiments   144
described by Ladekjaer-Mikkelsen et al. (2002) and Kyriakis et al. (2002) which suggested 
that PCV2-induced PMWS was the result of increased virus replication in immuno-stimulated 
pigs, which might be associated with the occurrence of PMWS in pigs subjected to a multiple 
array of infectious agents and vaccines, greater than experienced in Australia.  The major 
problem encountered was that although PCV2 was inoculated into pigs, it was only detected 
in some of the inoculated pigs.  The reasons for this are not absolutely clear but it is likely that 
the cell-culture adapted PCV2 virus used was of insufficient titre to infect pigs.  The only 
available method of detecting virus infection in the cell cultures was by a semi-quantitative 
PCR.  Virus DNA was detected in 1:1,000 dilutions of the cell cultures and at the time it was 
thought this should provide a reasonable estimate of the titre of infectious virus but if this was 
correct, it was insufficient virus to infect 100% of inoculated pigs.  Another problem in the 
animal experiment in which pigs were infected with PCV2 was that PCV1 was also detected 
in the inoculated weaners, suggesting there had been transfer of the PCV1 from the sows to 
the pigs.  It is evident that future experimental infections should not be conducted until the 
titre of infectious virus in the inoculum can be increased, and this will require further 
examination of methods to improve virus replication in cell culture.  An additional problem is 
that a protective immunity to the PCV2 isolate may have been passed on through the sow’s 
colostrum, even though the sows had been screened by the PCV2-specific ELISA and 
Western immunoblots, and by IIF assay.  Ideally, it would have been desirable to utilise 
colostrum-deprived piglets, but raising and maintaining these piglets would have been beyond 
the capabilities of the facilities available.   
In conclusion, this project has resulted in the development of reagents and techniques for the 
detection of PCV and serological techniques for the detection of PCV antibody in tissues of 
pigs.  This capability was not previously available in Australia.  The techniques were used to 
identify a number of strains of both PCV1 and PCV2 and to show there was a high prevalence 
of both PCV types in unthrifty and dead weaner pigs in Australian pig herds.  The genetic 
characteristics of the Australian strains of PCV were determined. The results indicated that 
the Australian strains were very similar to overseas strains that have been associated with 
PMWS, including countries where PMWS is a problem and endemic in pig populations.   
Recombinant proteins were produced that enabled the development of specific serological 
techniques for the detection of PCV2 antibody, and these were subsequently used to verify 
that PCV2 infection is common in the Australian pig herd.  The overall results suggest the lack 
of PMWS in Australia is not due to an absence of PCV and that there are other factors in 
addition to PCV that are required to produce PMWS.     145
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